

**THE MOLECULAR ARCHITECTURE OF TRAINABILITY EXPLAINED BY  
GENETICS**

**Javier Alejandro Alvarez Romero**

**Thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy**

**Victoria University, Australia  
Institute for Health and Sports (IHeS)**

**February 2023**

## Abstract

### Introduction

There is a substantial interindividual variability in responses to exercise training, which is influenced by both environmental and genetic factors. However, the influence these genes is relatively unknown. Therefore, we have investigated the association between robust genetic variants, using the Exercise Polygenic Score (EPS), on mitochondrial and physiological response to four weeks of High-Intensity Interval Training (HIIT) in the Gene SMART (Skeletal Muscle Response to Training) study. Thus, **the overarching aim of this thesis is to evaluate the association of robust genetic variants using the Exercise Polygenic Score (EPS) in mitochondrial and physiological response to exercise phenotypes to four weeks of High Intensity Interval Training (HIIT).**

### Methods

116 adults from the Gene SMART cohort study completed four weeks of HIIT to measure physiological and mitochondrial responses. Maximal oxygen uptake ( $VO_{2max}$ ), lactate threshold (LT), and peak power output ( $W_{peak}$ ) were assessed before and after the exercise training. Muscle biopsies were collected before and after 4-weeks of HIIT to assess mitochondrial markers: citrate synthase (CS), cytochrome c oxidase (COX), succinate dehydrogenase (SDH), mitochondrial copy number (mtCN) and mitochondrial health index (MHI). DNA isolated from blood samples was genotyped using the Genome-Wide Genotyping Array, and genotype data was then used to derive exercise polygenic scores for each participant using exercise-related SNPs identified in **Chapter 3**.

### Results:

We found significant increases in mitochondrial markers CS and COX after the HIIT intervention ( $p < 0.05$ ), but no changes in mitochondrial health index (MHI). We also found that changes in LT were found to be positively correlated with changes in both CS ( $r = 0.2$ ,  $p$

= 0.014,) and COX ( $r = 0.19$ ,  $p = 0.019$ ). Also, significant correlations were found between changes in  $VO_{2max}$  and changes in two mitochondrial markers, CS ( $r = 0.24$ ,  $p = 0.0025$ ) and SDH ( $r = 0.20$ ,  $p = 0.011$ ). Finally, a significant correlation was found between changes in  $W_{peak}$  and changes in CS ( $r = 0.24$ ,  $p = 0.0024$ ). We did not observe significant associations between MHI changes and changes in physiological measurements.

We found no associations between EPSs and physiological and mitochondrial markers either before or after four weeks of HIIT. However, we found a significant association between baseline mtCN and the (*PPARGCIA*) rs8192678 SNP ( $p = 0.012$ ). We further showed several associations between SNPs and mitochondria factors i) baseline mtCN and rs8192678 ( $p = 0.021$ ), ii) 4-week change in mtCN and (*BIRC*) rs6090327 ( $p < 0.001$ ), iii) 4-week change in CS and (*AGT*) rs699 ( $p = 0.0381$ ), iv) 4-week change in SDH and rs609037 ( $p = 0.030$ ) and (*DAAMI*) rs12891759 ( $p = 0.035$ ) and v) baseline MHI and (*PPARA*) rs4253778 ( $p = 0.027$ ), (*RGS18*) rs10921078 ( $p = 0.029$ ), and (*ACTN3*) rs1815739 ( $p = 0.027$ ). We found no significant differences between SNP genotypes and least square means of  $VO_{2max}$ , LT, and  $W_{peak}$ .

## Summary

The experimental design of this study enables a better understanding of the roles of genes contributing to the complexity of exercise responses in humans. Future research should also integrate physiological molecular and omics (epigenomics, transcriptomics, metabolomics) to elucidate the mechanisms of exercise training in humans.

## **Student Declaration**

I, Javier Alejandro Alvarez Romero, declare that the PhD entitled “The molecular architecture of trainability explained by genetics” is not more than 100,000 words in length including quotes and exclusive of tables, figures, appendices, bibliography, references and footnotes. This thesis contains no material that has been submitted previously, in whole or in part, for the award of any academic degree or diploma. Except where otherwise indicated, this thesis is my own work.

I have conducted my research in alignment with the Australian code for Responsible Conduct of Research and Victoria University’s Higher Degree by Research Policy and procedures. This research was approved by the Human Ethics Committee at Victoria University (**HRE13-223 and HRE 21-122**).

**Signature:**

A solid black rectangular box redacting the signature of the student.

**Date: 17/02/2023**

## Acknowledgements

I would like to express my sincere gratitude to my principal supervisor Nir Eynon for his support, not only academically but in many other aspects. I always felt that I could count on you. Also, you put a fantastic team at my disposal to finish this project, which I am grateful for. Thanks also for teaching me through example that science is ultimately made by people with feelings and emotions, and the importance of being a good person. Without your example, it would not have been possible for me to finish a PhD, especially in the middle of a pandemic. To your question: Where is your thesis? Here it is! Thank you.

I was extremely lucky to have several co-supervisors and their input on this process. Particularly I want to thank Patrice Jones and Danielle Hiam, two great people who taught me how to get things done in a very supportive and positive manner. Thanks for teaching me how to pronounce English words, how to write them, and how to academically present in conferences and candidature milestones. Thank you.

To my supervisors Sarah Voisin and Gad Abraham, your valuable insights and contribution to this research made it possible. Thanks you both for your patience even in the most basic aspects of a PhD course. Sarah, you helped me immensely with my presentation skills, and Gad, you helped me with genetic knowledge in the middle of a pandemic. Thank you.

Thank to my colleagues Macsue Jacques, Shanie Landen, Andrew Palmer, Kirsten Seale, Mandhri Abeysooriya and Ethan Moreland. You all were always willing to help and share information. From all of you I have books, papers or documents you shared with me. Thanks. A special mention to Macsue Jacques: without your help in the lab, this project would

have not been possible. Also, you showed me that is possible to have a family while doing a PhD. I still have the tweezers you gave me to do my first mitochondrial respiration by myself, thank you. Andrew, thanks for bringing me food and medication when I got Covid being isolated at home. I still owe you a Colombian coffee.

To the technical staff, Samantha Cassar, Collene Steward and Suddina Hewakapuge, thank you for your help, patience and knowledge shared in the labs. You all were always willing to help and were aware of the issues we had in training-testing participants and running experiments in the biochemistry lab, especially in the pandemic, thanks. Thank you also to all my colleagues, masters and PhD students at VU.

To my family, for your support and encouragement across the PhD journey. To my parents Nasly Romero Ruiz and Javier Alfonso Alvarez Gonzalez, I miss you always and I am the person I am thanks to your values. To my uncle Omar Romero Ruiz, always willing to listen and open to discuss any topic. Thanks. To my siblings Andrea, Andres and Heidy, always cheering me on and making jokes about studying. To Omar Andres Romero Aguilar, your example of persistence and resilience is without compare, thanks.

To Paola Andrea Giraldo Forero, it is extremely difficult to express my feelings to you in words; it is not only gratitude, but the closest word that humanity has created so far is love. Denkenesh, this is ultimately for you, and also thanks to you.

## List of Publications

The following work has been accepted for publication at peer-reviewed journals in support of this thesis:

1. **Alvarez Romero J**, Voisin S, Eynon N, Hiam D. Mapping Robust Genetic Variants associated with Exercise Responses. *Int J Sports Med* 2020; 41: 1–15.
2. **Alvarez Romero J**, Jones P, Hiam D, Jacques M, Landen S, Garnham A, Abraham G, & Eynon N. Physiological and mitochondrial phenotypes in response to high intensity interval training in male and female skeletal muscle: The Gene SMART study. *Medicine & Science in Sports & Exercise* 2022. Under Review

During my candidature, the following work was published or submitted in a peer-reviewed journal and is outside the scope of this thesis:

1. Patrice R Jones, Sarah Voisin, Brendan J Nolan, Shanie Landen, Magsue Jacques, Beau Newell, Sav Zwickl, Teddy Cook, Alex Wong, Ariel Ginger, Andrew Palmer, Andrew Garnham, **Javier Alvarez-Romero**, Namitha Mohandas, Kirsten Seale, Ada Cheung, Nir Eynon. (2022). Uncovering the effects of gender affirming hormone therapy on skeletal muscle and epigenetics: protocol for a prospective matched cohort study in transgender individuals (the GAME study) *BMJ Open* 2022;**12**:e060869. doi: 10.1136/bmjopen-2022-060869.
2. **Alvarez-Romero, J.**, Seale, K., Laguette, MJ., Voisin, S., Fuku, N., Hiam, D., Jacques, M., Eri, M., Feller, JA., Tirosh, O., Collins, M., September, AV., Eynon, N. (2021). Collagen genetic variants within the *COL5A1* gene are associated with ligament injuries in Australian, South African, and Japanese Populations. *European Journal of Sport Science*
3. Jacques M, Landen S, **Alvarez-Romero J**, Yan X, Garnham A, Hiam D, Siegwald M, Mercier E, Voisin S, Eynon N (2021). Individual physiological and

mitochondrial responses during 12 weeks of intensified exercise. *Physiological Reports*.

4. Jacques, M., Kuang, J., Bishop, D. J., Yan, X., **Alvarez-Romero, J.**, Munson, F., Garnham, A., Papadimitriou, I., Voisin, S., & Eynon, N. (2020). Mitochondrial respiration variability and simulations in human skeletal muscle: The Gene SMART study. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 34(2), 2978–2986.
  
5. Hiam, D., Smith, C., Voisin, S., Denham, J., Yan, X., Landen, S., Jacques, M., **Alvarez-Romero, J.**, Garnham, A., Woessner, M. N., Herrmann, M., Duque, G., Levinger, I., & Eynon, N. (2020). Aerobic capacity and telomere length in human skeletal muscle and leukocytes across the lifespan. *Aging*, 12(1), 359–369.

## Conferences Presentations

- Exercise slows the ageing process in skeletal muscle. June 2019, **VU conference.**
- The molecular architecture of trainability explained by genetics. 2021 **IHeS Seminar.**
- The contribution of genetic variants to mitochondrial health and exercise in humans. 2021. **ESSA Poster**
- Collagen genetic variants within the *COL5A1* gene are associated with ligament injuries in Australian, South African, and Japanese Populations. **Sport Medicine Australia.**
- The molecular architecture of trainability explained by genetics. **IHeS Conference 2022.**

## **Funding, Grants and Awards**

- Student Advisory group **Victoria University** 2020 – 2021.
- HDR Strategy Working party **Victoria University** 2021.
- Academic Excellence **Victoria University** 2019.
- IHeS Conference 2022 (Long talk award) **Victoria University** 2022.
- Research Assistant VU. **Victoria University** 2019- 2023.
- Visual Scanning head movements and concussion. Healthy Brain and Mind research Centre. Dr Thomas Mc Guckian. **Australian Catholic University** 2022.



### DETAILS OF INCLUDED PAPERS: THESIS WITH PUBLICATION

Please list details of each scholarly publication and/or manuscript included in the thesis submission. Copies of published scholarly publications and/or manuscripts submitted and/or final draft manuscripts should also be included in the thesis submission.

This table must be incorporated in the thesis before the Table of Contents.

Chapter No.	Publication Title	Publication Status	Publication Details
3	Mapping Robust Genetic Variants with exercise responses	<ul style="list-style-type: none"> <li>Published</li> <li>Accepted for publication</li> <li>In revised and resubmit stage</li> <li>Under review</li> <li>Manuscript ready for submission</li> </ul>	<ul style="list-style-type: none"> <li>Citation, if published</li> <li>Title, Journal, Date of acceptance letter and Corresponding editor's email address</li> <li>Title, Journal, Date of submission</li> </ul>
4	Physiological and mitochondrial phenotypes in response to high intensity interval training in male and female skeletal muscle: The Gene SMART study	Manuscript ready for submission	N/A

Declaration by [candidate name]:

Javier Alejandro Alvarez Romero

Signature:

**javier** Digitally signed by javier  
Date: 2023.02.14 20:25:13 +11'00'

Date:

14-02-2023

Updated: September 2020

**PRIVACY STATEMENT** Victoria University (VU) values your privacy and is committed to handling your personal information in accordance with the Privacy and Data Protection Act 2014 (Vic) and other applicable privacy legislation. The personal information collected on this form will be used primarily for the purposes of assessing and processing this application. VU may also use and disclose your personal information to verify the information provided by you, to comply with government and other reporting requirements and/or to carry out associated activities connected with this application. Your personal information may also be disclosed to Commonwealth and State agencies such as the Department of Education and Training and the Department of Home Affairs in accordance with VU's obligations under the Education Services for Overseas Students Act 2000 (Cth) (ESOS Act), the National Code of Practice for Providers of Education and Training to Overseas Students 2018 (National Code) and other applicable legislation. Your personal information will not otherwise be used or disclosed without your consent, unless permitted by law. By completing and submitting this application, you agree to VU collecting, using and disclosing your personal information as described above and in accordance with VU's Privacy Policy and Student Information Privacy Collection Statement (which provides further detail about the types of personal information VU may collect from you and how it is managed) available on the Privacy page on our website [vu.edu.au/privacy](http://vu.edu.au/privacy). You have a right to access your personal information held by VU. If you have any questions regarding privacy, please refer to the Privacy page on our website, our frequently asked questions at ASKVU or phone us on 9919 6100 or 1300 VIC UNI (or 1300 842 864).

**PRIVACY INFORMATION:** We collect and protect your personal information in accordance with our Privacy Policy [vu.edu.au/privacy](http://vu.edu.au/privacy).  
Victoria University CRICOS Provider No. 00124K (Melbourne) and CRICOS Provider No. 02475D (Sydney). RTO Code: 3113. ABN: 83 776 954 731

<b>Table of Contents</b>	<b>Abstract</b>	<b>ii</b>
<b>Student Declaration</b>		<b>iv</b>
<b>Acknowledgements</b>		<b>v</b>
<b>List of Publications</b>		<b>vii</b>
<b>Conferences</b>		<b>ix</b>
<b>Funding, Grants and Awards</b>		<b>x</b>
<b>Table of Contents</b>		<b>xiii</b>
<b>List of Tables</b>		<b>xv</b>
<b>List of Figures</b>		<b>xvi</b>
<b>List of Abbreviations</b>		<b>xvii</b>
<b>Chapter 1: Introduction</b>		<b>1</b>
1.1 References	<b>Error! Bookmark not defined.</b>	
<b>Chapter 2: Review of the Literature</b>		<b>7</b>
2.1 The concept of trainability		7
2.2 Biological factors influencing trainability		7
2.3 Trainability between sexes		8
2.4 Methodological factors influencing trainability		9
2.5 Genetics and Exercise		9
2.5.1 Exercise Polygenic Score (EPS)		10
2.5.2 Genetic and molecular contribution to exercise responses		11
2.6 Mitochondria as a key organelle in exercise response to training		12
2.6.1 Mitochondrial markers		13
2.6.1.1 Mitochondrial DNA copy number		14
2.6.1.2 Cytochrome c Oxidase		14
2.6.1.3 Succinate dehydrogenase		15
2.6.1.4 Citrate synthase		15
2.6.1.5 Mitochondrial Health Index		15
2.7 Summary and study aims		16
2.7.1 Aims		16
2.8 References		18
<b>Chapter 3: Exercise Polygenic Score</b>		<b>23</b>
3.1 Genetics and Exercise		25
3.1.1 SNPs Selection criteria		26
3.1.2 Aerobic Trainability		36
3.1.3 Resistance Trainability		39
3.1.4 Functional Validation		41
3.2 References		44
<b>Chapter 4: Variability in physiological fitness and skeletal muscle mitochondria-related phenotypes in response to HIIT</b>		<b>50</b>
4.1 Introduction		52
4.2 Methods		53
4.2.1 Participants		53
4.2.2 Study design		54
4.2.3 Graded-Exercise Tests (GXT) tests		55
4.2.4 Muscle biopsies		56
4.2.5 Dietary control (48h prior to muscle biopsies)		56
4.2.6 Control period		56
4.2.7 Pre-HIIT baseline testing and HIIT intervention		56
4.2.8 Muscle derived mitochondrial health index (MHI)		57
4.2.9 Statistical analysis		58

4.3 Results-----	59
4.3.1 Changes in physiological and mitochondrial markers following a control period-----	59
4.3.2 Changes in physiological variables following HIIT-----	60
4.3.3 Changes in mitochondrial markers following HIIT-----	61
4.3.4 Associations between changes in physiological and mitochondrial markers-----	62
4.4 Discussion-----	64
4.5 Conclusion-----	67
4.6 References-----	69
<b>Chapter 5: Genetic Variants and its association with physiological and molecular phenotypes in skeletal muscle-----</b>	<b>72</b>
5.1 Introduction-----	72
5.2 Methods:-----	73
5.2.1 Participants and study design-----	73
5.2.2 Familiarization study visit-----	74
5.2.5 Mitochondrial measures-----	75
5.2.6 DNA extraction and genotyping-----	75
5.2.7 Exercise Polygenic Score-----	76
5.2.8 Statistical analysis-----	77
5.3 Results-----	78
5.3.1 Cohort phenotypes before and after HIIT.-----	78
5.3.2 Allele frequency distribution in the Gene SMART cohort-----	79
5.3.3 Associations between exercise polygenic scores and physiological and mitochondrial phenotypes.-----	80
5.3.4 Associations between individual SNPs and physiological variables-----	80
5.3.5 Associations between individual SNPs and mitochondrial variables-----	82
5.4 Discussion-----	86
5.5 Conclusion-----	90
5.6 References-----	91
<b>Chapter 6: General discussion, contribution to knowledge, limitations, and future research-----</b>	<b>94</b>
6.1 General discussion-----	94
6.2 Contribution to Knowledge-----	99
6.3 Strengths-----	99
6.4 Limitations-----	100
6.5 Future research-----	100
6.6 References-----	102
<b>Appendix: Supplementary figure and tables-----</b>	<b>104</b>

## List of Tables

<i>Table 3-1.</i> Gene Variants associated with aerobic trainability-----	28
<i>Table 3-2.</i> Gene variants associated with resistance trainability-----	32
<i>Table 3-3.</i> Robust SNPs associated with aerobic or resistance trainability-----	37
<i>Table 5.1</i> Lists of SNPs used to generate exercise polygenic scores-----	74
<i>Table 5.2</i> Cohort phenotypes before and after HIIT-----	75
<i>Table 5.3</i> Allele distribution in cohort-----	78
<i>Table 5.4</i> Associations between Exercise Polygenic Scores and physiological and mitochondrial phenotypes -----	80
<i>Table 5.5</i> Least square means estimates by genotype for physiological phenotypes before and following HIIT -----	81
<i>Table 5.6</i> Least square means estimates for mitochondria phenotypes before and after the HIIT intervention, by genotype (non-imputed data) -----	83

## List of Figures

<i>Figure 2.1. Mitochondrial diagram</i> -----	13
<i>Figure 2.2. Schematic representation of the study design</i> -----	17
<i>Figure 4.1. Study design</i> -----	54
<i>Figure 4.2. Changes in physiological variables over four weeks of control and HIIT exercise periods</i> -----	60
<i>Figure 4.3. Changes in mitochondrial markers over four weeks of control and four weeks of high intensity interval training (HIIT)</i> -----	61
<i>Figure 4.4. Correlations between changes in mitochondrial markers and changes in lactate threshold (LT) following four weeks of high intensity interval training (HIIT)</i> -----	62
<i>Figure 4.5. Correlations between changes in mitochondrial markers and changes in <math>VO_{2max}</math> following four weeks of high intensity interval training (HIIT)</i> -----	63
<i>Figure 4.6. Correlations between changes in mitochondrial markers and changes in peak power (<math>W_{peak}</math>) following four weeks of high intensity interval training (HIIT)</i> -----	64
<i>Figure 5.1. Study design</i> -----	74

## List of Abbreviations

1RM	1 repetition maximum
4WP	four weeks post (training)
ACE	angiotensin converting enzyme
ACSL1	acyl-coa synthetase long chain 1
ACTG1	actin gamma 1
ACTN3	alpha-actin-3
ADP	adenosine diphosphate
ATP	adenosine triphosphate
BMI	body mass index
CCL2	chemokine c-c motif ligand 2
CCR2	chemokine c-c motif ligand 2 receptor
CMJ	counter movement jumps
COX	cytochrome c oxidase
CON	control period
CRISPR	clustered regularly interspaced short palindromic repeats
CTNF	ciliary neurotrophic factor
CS	citrate synthase
DAAM1	dishevelled-associated activator of morphogenesis 1
DNA	deoxyribonucleic acid
ENDCON	end of control period
EPS	exercise polygenic score
ERR $\alpha$	estrogen-related receptor alpha
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GWAS	genome-wide association study

GXT	graded exercise test
HR	heart rate
HIIT	high intensity interval training
IL-15RA	interleukin 15 receptor subunit alpha
IL-6	interleukin 6
LEPR	leptin receptor
LT	lactate threshold
MCAD	medium chain acyl-coa dehydrogenase
MFF	mitochondrial fission factor
MFN1	mitofusin 1
MFN2	mitofusin 2
MHI	mitochondrial health index
mtDNA-cn	mitochondrial DNA copy number
MVC	maximal voluntary contraction
NADH	nicotinamide adenine dinucleotide + hydrogen
NAMPT	nicotinamide phosphoribosyltransferase
NHMRC	National Health and Medical Research Council of Australia
NR3C1	glucocorticoid receptor subfamily 3 group c
NRF2	nuclear factor erythroid 2
PARK2	parkin rbr e3 ubiquitin protein ligase
PDK4	pyruvate dehydrogenase lipoamide kinase isozyme 4
PGC1 $\alpha$	peroxisome proliferator activated receptor- $\gamma$ coactivator alpha
PPAR	peroxisome proliferator activated receptor
PPARD	peroxisome proliferator activated receptor delta
PPARG	peroxisome proliferator activated receptor gamma
PPARGC1A	peroxisome proliferator activated receptor gamma coactivator 1alpha
PPARGC1B	peroxisome proliferator activated receptor gamma coactivator 1beta

PTK2	protein tyrosine kinase 2
QTL	quantitative trait loci
SMART	skeletal muscle response to training
SDH	succinate dehydrogenase
SNP	single nucleotide polymorphism
RNA	ribonucleic acid
TFP $\alpha$	tri functional protein alpha
VLCAD	very long acyl-coa dehydrogenase
VO <sub>2</sub> max	velocity of maximal oxygen uptake
W <sub>peak</sub>	working peak rate

## Chapter 1: Introduction

Exercise training produces multiple adaptations on whole-body human phenotypes; however, these adaptations differ between individuals at both the physiological and molecular level (also called trainability) [1-3]. The molecular mechanisms underpinning the variance in exercise adaptations are largely unknown. Thus, to better understand trainability it is crucial to decipher the influencing components involved. Uncovering the drivers of trainability at physiological and molecular level will advance our understanding of adaptations to exercise training. Current evidence shows that the magnitude of exercise adaptations depends on the speed, force, duration and intensity of exercise interventions and related muscle contractions [4]. High intensity interval training (HIIT) has two general categories [5], one category is referred to as “aerobic HIIT” (the selected method for this thesis), and the other is “body weight HIIT” or “resistance HIIT”. HIIT can be diverse in duration, and studies has shown that as little as a few bouts of HIIT are sufficient to elicit physiological response [6]. Our chosen 4 weeks HIIT protocol was based on a balance between responses and feasibility. Our results show significant increase in physiological responses after 4 weeks. Previous research has suggested that HIIT induce greater responses than continuous moderate - intensity exercise and need less time spent [7] in markers of cardiovascular health, metabolic capacity and aerobic performance [8-12] Moreover, a growing body of literature suggests that biological determinants (i.e., genetics or baseline fitness) play a crucial role in regulating exercise adaptations [13]. Previous studies suggested that trainability is mediated by our genes [14-16]. However, it is also reported that regardless of the genetic component involved in trainability, no single gene has been shown to be absolutely responsible for a physiological phenotype due to the substantial amount of genes involved in exercise response [17]. This variation in response to exercise training is primarily characterized by aerobic capacity (VO<sub>2</sub>max) and by strength and muscle mass [18].

The large discrepancy among different training protocols (i.e., frequency, duration, intensity) increases the variability among the exercise field and is a limitation to be able to compare exercise responses between studies. However, the complexity of physiological and molecular responses to aerobic and resistance training emphasizes the relevance of collaborative efforts among investigators in the known phenotypic adaptations [18]. Despite many genes having been associated with exercise responses, the vast majority have not been replicated [19]. Replication is crucial to minimise number of false positives and increases the likelihood that results are true [20, 21]. Thus, **the aim of the first study (Chapter 3) was to identify robust genetic variants and create an exercise polygenic score (EPS) in exercise responses.**

Multiple sources of variability have been determined in exercise training studies [22]. This variability is minimized when a control period is included in the study design, suggesting that any physiological or molecular changes post-exercise are attributed to the intervention and not to day-to-day variability or technical error [22]. In addition to the physiological adaptations to exercise, mitochondrial changes are one of the most apparent adaptations responding to exercise [23], with even a single bout of exercise producing mitochondrial adaptations [24]. Also known as the “power house” of the cell, mitochondria are responsible for multiple regulations in skeletal muscle [23]. In addition, skeletal muscle mitochondria promote biogenesis and adaptation in function and, therefore, contribute to maintaining cellular and whole-body health [25]. There are two main aspects to evaluate mitochondrial adaptations in exercise responses: content and quality. Even though exercise training induces physiological and mitochondrial changes, these changes may not necessarily progress together [26]. Evaluating a composite mitochondrial measure is crucial to assess mitochondrial health, as previous studies showed that high mitochondrial content may exhibit a reduction in mitochondrial function, suggesting that mitochondrial content can be increased to compensate poor mitochondrial quality [27]. Also, it is suggested that single mitochondrial markers are bad

at predicting changes in the whole organelle [28]. The mitochondrial health index (MHI) combines key markers for mitochondrial content and function; it also integrates nuclear and mitochondrial encoded measurements, and mathematically outperformed individual markers in leucocytes [29]. However, it is unknown how MHI performs in other tissues. Therefore, **the aim in chapter 4 was to investigate physiological phenotypes adaptations and mitochondrial adaptations by exploring differences in mitochondrial content and function before and after exercise training preceded by a control period.**

Exercise response studies have reported a genetic contribution. However, a key limitation of these studies is that they assessed individual genes as a single variable, irrespectively of the gene's allelic composition [30]. Also, most of these studies looked at elite athletes but not at the general population, and not at robust muscle-related molecular phenotypes. In addition, previous exercise studies reported that no single gene is responsible for a specific phenotype [16, 17], with physiological and molecular phenotypes influenced by several genetic variants with small individual effect sizes [31-33]. Also, multiple genes interact to produce the phenotype's outcome [34]. Thus, the evaluation of combined multiple genes will play an important role to identify their association with physiological and molecular phenotypes. To evaluate the genetic influence on trainability, it was important to better understand such differences at baseline in physiological and molecular phenotypes. To our knowledge, no study to date has investigated the association between an exercise polygenic score with physiological and mitochondrial phenotypes before an exercise intervention. This is crucial as adaptations to exercise responses are also dependent on initial fitness levels, and baseline fitness levels reflect a long life of exercising. Therefore, **the aim of the third study (Chapter 5) was to assess the associations of the Exercise Polygenic Score derived from robust genetic variants with physiological and mitochondrial phenotypes before and after exercise.**

With a literature review (**Chapter 2**), this thesis further comprises three experimental chapters as described above:

- I. **Chapter 3**: Deciphering robust genetic variants in exercise responses in aerobic and resistance trainability.
- II. **Chapter 4**: Mitochondrial markers that explain physiological responses preceded by a control period (the Gene Study).
- III. **Chapter 5**: Associations between exercise polygenic score (EPS) and physiological and mitochondrial markers before and after exercise training.

The main findings of this thesis are summarised with a general discussion (**Chapter 6**), including the limitations of each study, the contribution to knowledge and recommendations for future studies

## References

1. Bouchard, C., *Human adaptability may have a genetic basis*. *Health Risk Estimation, Risk Reduction and Health Promotion.* , 1983: p. 463-476.
2. Bouchard, C., *DNA Sequence Variations Contribute to Variability in Fitness and Trainability*. *Med Sci Sports Exerc*, 2019. **51**(8): p. 1781-1785.
3. Jacques, M., et al., *Mitochondrial respiration variability and simulations in human skeletal muscle: The Gene SMART study*. *FASEB J*, 2020. **34**(2): p. 2978-2986.
4. Hawley, John A., et al., *Integrative Biology of Exercise*. *Cell*, 2014. **159**(4): p. 738-749.
5. Kilpatrick, M.W., M.E. Jung, and J.P. Little, *HIGH-INTENSITY INTERVAL TRAINING: A Review of Physiological and Psychological Responses*. *ACSM's Health & Fitness Journal*, 2014. **18**(5): p. 11-16.
6. Gibala, M.J. and M.J. MacInnis, *Physiological basis of brief, intense interval training to enhance maximal oxygen uptake: a mini-review*. *Am J Physiol Cell Physiol*, 2022. **323**(5): p. C1410-C1416.
7. Su, L., et al., *Effects of HIIT and MICT on cardiovascular risk factors in adults with overweight and/or obesity: A meta-analysis*. *PLOS ONE*, 2019. **14**(1): p. e0210644.
8. Gibala, M.J., et al., *Physiological adaptations to low-volume, high-intensity interval training in health and disease*. *The Journal of Physiology*, 2012. **590**(5): p. 1077-1084.
9. Guiraud, T., et al., *High-intensity interval training in cardiac rehabilitation*. *Sports Med*, 2012. **42**(7): p. 587-605.
10. Helgerud, J., et al., *Aerobic high-intensity intervals improve VO<sub>2</sub>max more than moderate training*. *Med Sci Sports Exerc*, 2007. **39**(4): p. 665-71.
11. Kessler, H.S., S.B. Sisson, and K.R. Short, *The potential for high-intensity interval training to reduce cardiometabolic disease risk*. *Sports Med*, 2012. **42**(6): p. 489-509.
12. Wisløff, U., Ø. Ellingsen, and O.J. Kemi, *High-intensity interval training to maximize cardiac benefits of exercise training?* *Exerc Sport Sci Rev*, 2009. **37**(3): p. 139-46.
13. Lightfoot, J.T., et al., *Biological/Genetic Regulation of Physical Activity Level: Consensus from GenBioPAC*. *Med Sci Sports Exerc*, 2018. **50**(4): p. 863-873.
14. Simoneau, J.A. and C. Bouchard, *Genetic determinism of fiber type proportion in human skeletal muscle*. *Faseb j*, 1995. **9**(11): p. 1091-5.
15. Simoneau, J.A., et al., *Inheritance of human skeletal muscle and anaerobic capacity adaptation to high-intensity intermittent training*. *Int J Sports Med*, 1986. **7**(3): p. 167-71.
16. Ahmetov, II, et al., *Genes and Athletic Performance: An Update*. *Med Sport Sci*, 2016. **61**: p. 41-54.
17. Williams, A.G. and J.P. Folland, *Similarity of polygenic profiles limits the potential for elite human physical performance*. *J Physiol*, 2008. **586**(1): p. 113-21.
18. Vellers, H.L., S.R. Kleeberger, and J.T. Lightfoot, *Inter-individual variation in adaptations to endurance and resistance exercise training: genetic approaches towards understanding a complex phenotype*. *Mammalian Genome*, 2018. **29**(1): p. 48-62.
19. Cagnin, S., F. Chemello, and I.I. Ahmetov, *Genes and response to aerobic training*, in *Sports, Exercise, and Nutritional Genomics*. 2019. p. 169-188.
20. Chanock, S.J., et al., *Replicating genotype–phenotype associations*. *Nature*, 2007. **447**: p. 655-660.

21. Huffman, J.E., *Examining the current standards for genetic discovery and replication in the era of mega-biobanks*. Nature Communications, 2018. **9**(1): p. 5054.
22. Voisin, S., et al., *Statistical Considerations for Exercise Protocols Aimed at Measuring Trainability*. Exerc Sport Sci Rev, 2019. **47**(1): p. 37-45.
23. Hood, D.A., et al., *Maintenance of Skeletal Muscle Mitochondria in Health, Exercise, and Aging*. Annual Review of Physiology, 2019. **81**(1): p. 19-41.
24. Picard, M., et al., *Acute exercise remodels mitochondrial membrane interactions in mouse skeletal muscle*. Journal of Applied Physiology, 2013. **115**(10): p. 1562-1571.
25. Russell, A.P., et al., *Skeletal muscle mitochondria: a major player in exercise, health and disease*. Biochim Biophys Acta, 2014. **1840**(4): p. 1276-84.
26. Meinild Lundby, A.-K., et al., *Exercise training increases skeletal muscle mitochondrial volume density by enlargement of existing mitochondria and not de novo biogenesis*. Acta Physiologica, 2018. **222**(1): p. e12905.
27. Giordano, C., et al., *Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy*. Brain, 2014. **137**(Pt 2): p. 335-53.
28. Groennebaek, T., et al., *Utilization of biomarkers as predictors of skeletal muscle mitochondrial content after physiological intervention and in clinical settings*. American Journal of Physiology-Endocrinology and Metabolism, 2020. **318**(6): p. E886-E889.
29. Picard, M., et al., *A Mitochondrial Health Index Sensitive to Mood and Caregiving Stress*. 2018(1873-2402 (Electronic)).
30. Chung, H.C., et al., *Do exercise-associated genes explain phenotypic variance in the three components of fitness? a systematic review & meta-analysis*. PLOS ONE, 2021. **16**(10): p. e0249501.
31. Bouchard, C., *Genomic predictors of trainability*. Exp Physiol, 2012. **97**(3): p. 347-52.
32. Moreira, J.D., et al., *Gaining Insight into Mitochondrial Genetic Variation and Downstream Pathophysiology: What Can iPSCs Do?* Genes, 2021. **12**(11): p. 1668.
33. Drake, J.C., R.J. Wilson, and Z. Yan, *Molecular mechanisms for mitochondrial adaptation to exercise training in skeletal muscle*. FASEB J, 2016. **30**(1): p. 13-22.
34. Williams, C.J., et al., *Genes to predict VO<sub>2</sub>max trainability: a systematic review*. BMC genomics, 2017. **18**(8): p. 81-110.

## **Chapter 2: Review of the Literature**

### **2.1 The concept of trainability**

Exercise alters a vast amount of whole-body human physiological and molecular phenotypes including oxygen capacity, muscle power, muscle strength, lactate threshold and mitochondrial biogenesis. These adaptations between individuals differ in both physiological and molecular responses to any given exercise training (also called “trainability”) [1-3]. One of the key aspects to quantifying trainability is understanding the components of the variations involved. Uncovering the molecular drivers of trainability has the potential to advance our understanding of exercise adaptations to regular exercise. This generated knowledge may in turn be used to develop biomarkers that predict the ability of an individual to improve physiological markers in response to exercise training [4].

Differences in human exercise phenotypes are influenced by the individual and combined effects of our genes and environment [5]. However, the molecular mechanisms by which genetic and environmental factors interact to impact individual responses to exercises phenotypes, such as cardio-respiratory fitness, are poorly understood [6]. Previous research has indicated that the variability between individuals on response to exercise is mediated by both genetic and environmental factors [7]. However, the influence of environmental conditions on individual trainability is gaining relevance as the variability in physiological adaptation enables the study of the association between molecular responses to exercise and the magnitude of physiological change in humans [8, 9].

### **2.2 Biological factors influencing trainability**

A large variability has been observed in many physiological parameters [10], including maximal oxygen uptake ( $VO_2\text{max}$ ) [11, 12], resting heart rate [12], exercise heart rate [12], aerobic threshold [13], anaerobic threshold [12], muscle mass and strength [14, 15]. In addition to this, molecular phenotypes such as resting muscle glycogen content, muscle enzyme activity

[16], and in mitochondrial function have also shown large variability [17]. There are several potential biological contributors to this, including sex, genetics, and molecular markers such as mitochondrial markers [18].

### **2.3 Trainability between sexes**

It is widely known that males and females respond significantly different to exercise. Not only anatomical, but physiological differences between males and females determine the variation in human performance between sexes [19], with a large variability shown in several physiological phenotypes between them [20]. For example, females have an increased lifespan compared to males [21], and have also shown higher increase in  $VO_{2max}$ , as well as higher lipolysis rate to an intervention in endurance training [22]. There are several examples showing that males hold greater absolute muscle strength and produce greater power output than females in multiple exercise conditions [23]. In contrast, females also have a higher heart rate (HR) response than males for similar workloads, showing a significant variability in physiological phenotypes between sexes [24].

In addition to physiological markers, sex differences also exist in molecular markers associated with skeletal muscle health and functioning. Skeletal muscle fibre-type distribution differs between sexes, with females having more type I fibres compared to males [25, 26]. In contrast, females have moderately lower mitochondrial ADP sensitivity than males [27]. Major enzymes involved in fat oxidation vary between sexes. For example, the tri-functional protein alpha ( $TFP\alpha$ ), the very long acyl-CoA dehydrogenase (VLCAD), and medium chain acyl-CoA dehydrogenase (MCAD) were found to be higher in content in females [28]. In addition to sex, biological factors that may significantly impact trainability are genetics and mitochondrial functioning.

## **2.4 Methodological factors influencing trainability**

In addition to the biological factors influencing trainability, there are several methodological factors affecting variability in response to exercise. These include type of exercise, volume and intensity of training, and method of prescription [18], which need to be considered when attempting to untangle and characterise the effects of biological factors on exercise responses. Further, differing statistical methods must be employed to properly isolate individual biological responses from random error [29]. Common approaches to evaluate the mean response of a sample have failed to recognize the inter-individual differences in response to any exercise program [30]. Also, tissue samples and laboratory variability techniques are to be considered when quantifying the relevance of genetic variations using human muscle tissue [31]; for example, it is reported that technical error and sample variability in the same biopsy area account for about 15% of the variance on the reported results [32, 33]. Approaches to classify individuals as “responders” or “non-responders” dichotomy are not a sensible way to investigate personal response [34]. A more useful approach is to study dimensions rather than categories. Thus, trainability is not a qualitative variable; it should be considered as a quantitative one, as it is a matter of more or less [35].

## **2.5 Genetics and Exercise**

Humans are considerably different across populations in exercise traits [36] and the human variability in exercise traits is a representation of the substrate of human genetics [37]. There is compelling evidence that genetics is a significant component in the human variation in exercise responses [1, 38]. Genes explain around 50% of the heritable aspect of exercise responses [39]. In the HERITAGE study, it was shown that exercise traits at baseline as well as exercise responses were more similar within families than between them [40]. Thus, the recognition of genetic variants has become essential to identify human variation in complex traits such as exercise responses [38].

The ultimate goal of genomic research is to identify DNA differences causing diseases or predicting the potential adaptability on a particular trait [31]. This goal has been investigated by two different approaches: candidate genes and genome-wide association (GWAS) study. A candidate gene is a gene that theoretically has relationship with a physiological or molecular trait of interest [31, 41]. Although this approach was the origin of several exercise response studies, it is also known that candidate gene studies often have small sample sizes and lack statistical power [42, 43]. In contrast to candidate genes is the GWAS approach. This method scans up to 5 million genetic variants and reported that trainability is influenced by many genes (i.e., it is polygenic) [44]. From the first GWAS study performed in 2007 [45], the exercise field developed interest in the combined influence of genetic variants in exercise responses. To date, 2339 genetic variants are associated with exercise; the catalogue of these studies and their results can be examined at <http://www.genome.gov/gwastudies>. Thus, GWAS have become essential to identify SNPs contributing to the variation in exercise responses studies [31].

### **2.5.1 Exercise Polygenic Score (EPS)**

The genetic architecture of trainability is a polygenic trait. This means that many parameters such as number, frequency, relationship between and magnitude of effect of genetic variants contribute to it [46]. Despite the initial potential of GWAS to interrogate for polygenic traits, enthusiasm quickly faded due to the small effect sizes on individual alleles. This has led to the idea of testing multiple genetic loci simultaneously (“genomic profiling”), which collectively may provide superior prediction [47]. These predictions are based on whether the genetic variants overcome an arbitrary P value threshold, or the estimation of their effects in a particular sample followed by validation in an independent sample for a given phenotype [48]. Prior to undertaking a polygenic analysis a power calculation is needed to establish the boundaries of what can be achieved [49]. It was initially hoped that once the genetic architecture of a trait was identified, the observed effects of the associated alleles could be used

to construct a combined score and to predict individuals at the tail ends of the distribution [50]. In addition, new methodologies that aggregate data from a larger fraction of the genotyped variants that scored below the genome-wide significance threshold were formulated to account for undiscovered loci [47].

The use of the Exercise Polygenic Score is becoming more frequent in the field of exercise genomics. EPS can be used to gain insight into the aetiology of physiological phenotypes in exercise responses studies [51] as well as in elite athletes [52]. Although several genetic variants have been associated with trainability [51] and athletic performance [41], the results of these studies have not been replicated to date. In association analysis, the aim is to identify specific associated variants. A stringent threshold for declaring significance of individual SNPs is important, providing confidence that the identified variants are true positives.

### **2.5.2 Genetic and molecular contribution to exercise responses**

To date, there is very little literature ascribed to understanding the interplay between genes and other molecular factors and the development of physiological traits. Much work remains to identify causal variants and functional relevance of genes associated with molecular phenotypes related to exercise responses, and how these associations link to physiological phenotypes in aerobic and resistance trainability (Figure 2.1). Few studies have investigated links between the mitochondrial genome and training adaptations; therefore, conclusive findings from such studies are limited and only focus on particular sections of the mitochondria [53]. Key molecular phenotypes explored in this project are mitochondrial markers, which have important roles in responses to exercise. For example, it has been shown that with exercise there is an increase in the mitochondria electron transport chain [54] and in mitochondrial enzymes [55]. Exercise also upregulates mitochondrial content in humans [56, 57].


## 2.6 Mitochondria as a key organelle in exercise response to training

Structurally, mitochondria consist of four compartments: the inner membrane, the outer membrane, the intermembrane space and the matrix (located inside the inner membrane). Mitochondria perform numerous tasks such as pyruvate oxidation, the Krebs cycle, and metabolism of amino acids, fatty acids, and steroids. However, the most crucial function is the generation of energy as adenosine triphosphate (ATP) by means of the electron-transport chain and the oxidative-phosphorylation system (the “respiratory chain”) [58].

The respiratory chain consist of five multimeric protein complexes that are vital for maintaining health through their regulation of substrate metabolism and energy production [59], and are also involved in influencing skeletal muscle size and function [60]. As a result of exercise, several mechanisms have been identified such as mitochondrial biogenesis [61], gene expression [62], mitochondrial remodelling [63], mitochondrial quality increase through mitophagy [64] and more recently mitochondrial cristae density [65]. Exercise training also influences the expression of nuclear encoded mitochondrial biogenesis markers such as PGC1 $\alpha$ , PPAR $\delta$ , PDK4, NFR-2, GAPDH, NAMPT [66, 67] as well as fusion markers such as MFN1, MFN2, ERR $\alpha$ , MFF and PARK2 [68]. During exercise there is an increase in several molecular signals in skeletal muscle that are in part responsible for the initial activation of mitochondrial biogenesis [69]. Thus, exercise can diminish mitochondrial skeletal muscle diseases induced by defects of the respiratory chain due to enzyme deficiencies, structural alterations [69] or induced by defects in any of the mitochondrial pathways [58].

Mitochondrial proteins are encoded both by nuclear and mitochondrial genomes, and changes in either the nuclear DNA or mitochondrial DNA can potentially alter mitochondrial biogenesis and result in individual variation in mitochondrial content or function [70]. Human mitochondrial DNA (mtDNA) is a circular multicopy genome coding for 13 peptides involved

in the electron chain transport with an estimated mtDNA copy number in muscle cells of ~ 3700 [71] (Figure 2.1).



**Figure 2.1** Mitochondrial diagram of the key components involved in this study.

The increase of mitochondrial protein content and subsequent expansion of the mitochondrial reticulum (mitochondrial biogenesis) [72] is a recognized marker for adaptive function response to training [73, 74]. Although the markers to evaluate the function or the content of the mitochondria are well known [75, 76], the measurement of their content or quality maybe insufficient to evaluate mitochondrial function as changes in their content, volume or enzyme activities may not necessarily progress together [77]. For instance, elevated mitochondrial content may cause a reduction in mitochondrial quality, and as a result, mitochondrial DNA copy number per cell can be increased as a compensatory mechanism [78].

### 2.6.1 Mitochondrial markers

Multiple markers have been used to evaluate mitochondrial biogenesis and dynamics in skeletal muscle [79], as it is well known that exercise training induce an increase in enzyme

activities [73]. For this thesis, we will evaluate four functional parameters, which represent nuclear and mitochondrial genomes.

There are two main known aspects in measuring mitochondrial adaptations to changes in oxidative demand induced by exercise:

1. mitochondrial content within cells: Mitochondrial DNA copy number (mtDNA-cn) is a measure of the number of mitochondrial genomes per cell [75].

2. Mitochondrial function: The main function of mitochondria is to generate ATP. Thus, the most direct way to measure mitochondrial function in the context of bioenergetics is to assess ATP synthesis rates [76]. Alternatively, mitochondrial function can be measured by the activity of 13 different enzymes normalized by mitochondrial protein content [76].

#### **2.6.1.1 Mitochondrial DNA copy number**

Mitochondrial DNA copy number (mtDNA-cn) is a measure of the number of mitochondrial genomes per cell [75] and therefore mtDNA content is often used as a marker of mitochondrial content in skeletal muscle [80]. It also reflects the net results of gene-environmental interactions between unknown hereditary factors and the level of oxidative stress [81]. In contrast, mitochondrial content decreases in skeletal muscle in disuse [82].

#### **2.6.1.2 Cytochrome c Oxidase**

Cytochrome c Oxidase (COX) is the terminal component of the mitochondrial respiratory chain complex that catalyses the conversion of redox energy to ATP. The largest COX subunits I, II and III, represent the catalytic core of the enzyme. These subunits are encoded by the mitochondrial DNA and synthesized within the mitochondria, while the rest of the smaller subunits implicated in the mitochondrial function are encoded in the nuclear DNA [83]. The proton gradient complexes consist of three proteins known as complex I (NADH/ubiquinone oxidoreductase), III (*cytochrome c reductase*), and IV (*cytochrome c oxidase*). Complex IV transfers the electrons from cytochrome c to molecular oxygen and

contributes to the proton gradient by using up to four protons per consumed oxygen molecule of water [84]. COX is used as marker of complex IV as well as the mitochondria membrane marker [85].

### **2.6.1.3 Succinate dehydrogenase**

Succinate dehydrogenase (SDH) is the enzyme which catalyses the oxidation of succinate to fumarate in the Krebs cycle and transfers electrons to the ubiquinone pool (complex II of the mitochondrial respiratory chain). SDH represents one of the reliable marker of the mitochondrial ATP synthesis [86]. It also plays an important role at high respiration rates, as its activity is considered a good indicator of mitochondrial metabolic capacity [87, 88]. SDH activity differs from other mitochondrial dehydrogenases [87], thanks to its unique redox properties, and represents a crucial antioxidant enzyme in the mitochondria which controls superoxides' scavenging activity of the respiratory chain [89]. In addition, SDH plays an important role at high respiration rates and its activity has been considered a good indicator of the mitochondrial oxidative metabolic capacity [89].

### **2.6.1.4 Citrate synthase**

Citrate synthase is one of the most common markers of mitochondrial content [90]. It is the first enzyme involved in the citric acid cycle, where it performs the irreversible condensation of acetyl-COA with oxaloacetate to form citrate, which in turn determines the whole tricarboxylic acid cycle rate [91]. Citrate synthase is significantly elevated by acute exercise in human skeletal muscle in both exercise-trained and untrained muscle [92]. Multiple studies have reported that the training effect on citrate synthase ranges between 0 to 100% [55, 93].

### **2.6.1.5 Mitochondrial Health Index**

Mitochondrial health is emerging as the major determinant of healthy physiological regulation [94]. In relation to disease, mitochondria also play a determinant role in cellular life

and death [95]. The mitochondrial health index (MHI) integrates four functional markers in a simple equation with two numerators and two denominators, which equally represent the nuclear and the mitochondrial genomes. In the MHI, respiratory chain activity (SDH and COX) are mean-centred and added as numerator, and markers of mitochondrial content (CS and mtDNA copy number) are also mean-centred and added as the denominator. The quotient of both terms therefore yields a scalar index, the MHI, which reflects respiratory chain capacity per unit of mitochondrial content. This MHI measure has been previously shown to outperform individual mitochondrial functions measures in leucocytes [17]. In addition, it was demonstrated that activities of SDH and COX enzymes are likely regulated through independent mechanisms, which is consistent with the fact that SDH is entirely encoded by the nucleus whereas COX is partially encoded by the mtDNA. Thus, SDH and COX must contribute independently to mitochondrial health. However, this index has not been examined in skeletal muscle in the context of exercise responses.


## **2.7 Summary and study aims**

Exercise response is a polygenic trait. Thus, it should be evaluated using robust genetic variants and tight-controlled study designs to minimize variability from internal (biological) or methodological (statistics, or untrained controlled period) factors. Understanding the genetic component and the mitochondrial component in exercise responses in skeletal muscle will enable a more systemic picture.

### **2.7.1 Aims**

The overarching aim of this thesis is to determine the influence of robust genetic variants using the Exercise Polygenic Score (EPS) in mitochondrial and physiological response to exercise phenotypes to four weeks of High Intensity Interval Training (HIIT) in the gene SMART study (Figure 2.2). The specific aims are as follow:

1. To identify mitochondrial skeletal muscle markers that explain exercise physiological fitness responses.
2. To test whether exercise polygenic score (EPS) is associated with physiological and mitochondrial phenotypes at baseline (pre-exercise).
3. To test EPS association with changes in physiological and molecular phenotypes after 4 weeks of HIIT.



**Figure 2.2** Schematic representation of the study design.

## References

1. Bouchard, C., *Human adaptability may have a genetic basis*. ealth Risk Estimation, Risk Reduction and Health Promotion. , 1983: p. 463-476.
2. Bouchard, C., *DNA Sequence Variations Contribute to Variability in Fitness and Trainability*. Med Sci Sports Exerc, 2019. **51**(8): p. 1781-1785.
3. Jacques, M., et al., *Mitochondrial respiration variability and simulations in human skeletal muscle: The Gene SMART study*. FASEB J, 2020. **34**(2): p. 2978-2986.
4. Sarzynski, M.A., S. Ghosh, and C. Bouchard, *Genomic and transcriptomic predictors of response levels to endurance exercise training*. The Journal of Physiology, 2017. **595**(9): p. 2931-2939.
5. Denham, J., et al., *Exercise: Putting Action into Our Epigenome*. Sports Medicine, 2014. **44**(2): p. 189-209.
6. Chapman, M.A., et al., *Skeletal Muscle Transcriptomic Comparison between Long-Term Trained and Untrained Men and Women*. Cell Rep, 2020. **31**(12): p. 107808.
7. Bouchard, C., et al., *Familial aggregation of V<sub>o</sub> 2 max response to exercise training: results from the HERITAGE Family Study*. Journal of Applied Physiology, 1999. **87**(3): p. 1003-1008.
8. Timmons, J.A., et al., *Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans*. Journal of Applied Physiology, 2010. **108**(6): p. 1487-1496.
9. Timmons, J.A., et al., *Modulation of extracellular matrix genes reflects the magnitude of physiological adaptation to aerobic exercise training in humans*. BMC Biol, 2005. **3**: p. 19.
10. Mann, T.N., R.P. Lamberts, and M.I. Lambert, *High responders and low responders: factors associated with individual variation in response to standardized training*. Sports Med, 2014. **44**(8): p. 1113-24.
11. Kohrt, W.M., et al., *Effects of gender, age, and fitness level on response of VO<sub>2</sub>max to training in 60-71 yr olds*. J Appl Physiol (1985), 1991. **71**(5): p. 2004-11.
12. Scharhag-Rosenberger, F., et al., *Differences in adaptations to 1 year of aerobic endurance training: individual patterns of nonresponse*. Scand J Med Sci Sports, 2012. **22**(1): p. 113-8.
13. McPhee, J.S., et al., *Inter-individual variability in adaptation of the leg muscles following a standardised endurance training programme in young women*. Eur J Appl Physiol, 2010. **109**(6): p. 1111-8.
14. Ahtiainen, J.P., et al., *Heterogeneity in resistance training-induced muscle strength and mass responses in men and women of different ages*. Age (Dordr), 2016. **38**(1): p. 10.
15. Jones, N., et al., *A genetic-based algorithm for personalized resistance training*. Biol Sport, 2016. **33**(2): p. 117-26.
16. McPhee, J.S., et al., *Variability in the magnitude of response of metabolic enzymes reveals patterns of co-ordinated expression following endurance training in women*. Exp Physiol, 2011. **96**(7): p. 699-707.
17. Picard, M., et al., *A Mitochondrial Health Index Sensitive to Mood and Caregiving Stress*. 2018(1873-2402 (Electronic)).

18. Meyler, S., L. Bottoms, and D. Muniz-Pumares, *Biological and methodological factors affecting  $\dot{V}O_{2max}$  response variability to endurance training and the influence of exercise intensity prescription*. *Exp Physiol*, 2021. **106**(7): p. 1410-1424.
19. Ansdell, P., et al., *Physiological sex differences affect the integrative response to exercise: acute and chronic implications*. *Experimental Physiology*, 2020. **105**(12): p. 2007-2021.
20. Ansdell, P., et al., *Physiological sex differences affect the integrative response to exercise: acute and chronic implications*. *Exp Physiol*, 2020. **105**(12): p. 2007-2021.
21. Alberts SC, et al., *The male-female health-survival paradox: a comparative perspective on sex differences in aging and mortality*. In: *Sociality, Hierarchy, Health: Comparative Biodemography*. DC: National Academies Press., 2014.
22. Carter, S., C. C. Rennie, and M. Tarnopolsky, *Substrate utilization during endurance exercise in men and women after endurance training*. *Am J Physiol Endocrinol Metab*, 2001. **280**: p. 898 - 907.
23. Billaut, F. and D. Bishop, *Muscle Fatigue in Males and Females during Multiple-Sprint Exercise*. *Sports Medicine*, 2009. **39**(4): p. 257-278.
24. Rascon, J., et al., *Differences between Males and Females in Determining Exercise Intensity*. *International Journal of Exercise Science*, 2020. **13**(4): p. 1305-1316.
25. Esbjörnsson-Liljedahl, M., et al., *Metabolic response in type I and type II muscle fibers during a 30-s cycle sprint in men and women*. *J Appl Physiol (1985)*, 1999. **87**(4): p. 1326-32.
26. Haizlip, K.M., B.C. Harrison, and L.A. Leinwand, *Sex-based differences in skeletal muscle kinetics and fiber-type composition*. *Physiology (Bethesda)*, 2015. **30**(1): p. 30-9.
27. Miotto, P.M., et al., *Sex differences in mitochondrial respiratory function in human skeletal muscle*. *Am J Physiol Regul Integr Comp Physiol*, 2018. **314**(6): p. R909-R915.
28. Maher, A.C., et al., *Women have higher protein content of beta-oxidation enzymes in skeletal muscle than men*. *PLoS One*, 2010. **5**(8): p. e12025.
29. Voisin, S., et al., *Statistical Considerations for Exercise Protocols Aimed at Measuring Trainability*. *Exerc Sport Sci Rev*, 2019. **47**(1): p. 37-45.
30. Bonafiglia, J.T., N. Preobrazenski, and B.J. Gurd, *A Systematic Review Examining the Approaches Used to Estimate Interindividual Differences in Trainability and Classify Individual Responses to Exercise Training*. *Frontiers in Physiology*, 2021. **12**.
31. Bouchard, C., T. Rankinen, and J.A. Timmons, *Genomics and genetics in the biology of adaptation to exercise*. *Compr Physiol*, 2011. **1**(3): p. 1603-48.
32. Simoneau, J.A., et al., *Repeatability of fibre type and enzyme activity measurements in human skeletal muscle*. *Clin Physiol*, 1986. **6**(4): p. 347-56.
33. Simoneau, J.A. and C. Bouchard, *Genetic determinism of fiber type proportion in human skeletal muscle*. *Faseb j*, 1995. **9**(11): p. 1091-5.
34. Senn, S., *Mastering variation: variance components and personalised medicine*. *Stat Med*, 2016. **35**(7): p. 966-77.
35. Plomin, R., *Blueprint*. 2018, United Kingdom: Penguin Books 280.
36. Roth, S.M., *Chapter 10 - The current and future state of sports genomics, in Epigenetics of Exercise and Sports*, S.M. Raleigh, Editor. 2021, Academic Press. p. 217-233.
37. Bouchard, C., R.M. Malina, and L. Pérusse, *Genetics of fitness and physical performance*. 1997: Human Kinetics.

38. Bouchard, C., T. Rankinen, and J.A. Timmons, *Genomics and Genetics in the Biology of Adaptation to Exercise*. 2011.
39. Zempo, H., et al., *Heritability estimates of muscle strength-related phenotypes: A systematic review and meta-analysis*. *Scand J Med Sci Sports*, 2017. **27**(12): p. 1537-1546.
40. Bouchard, C., et al., *The HERITAGE family study. Aims, design, and measurement protocol*. *Med Sci Sports Exerc*, 1995. **27**(5): p. 721-9.
41. Ahmetov, I., et al., *Genome-wide association study identifies three novel genetic markers associated with elite endurance performance*. *Biol Sport*, 2015. **32**(1): p. 3-9.
42. Bray, M.S., et al., *The human gene map for performance and health-related fitness phenotypes: the 2006-2007 update*. *Med Sci Sports Exerc*, 2009. **41**(1): p. 35-73.
43. Rankinen, T., et al., *Advances in exercise, fitness, and performance genomics*. *Med Sci Sports Exerc*, 2010. **42**(5): p. 835-46.
44. Cagnin, S., F. Chemello, and I.I. Ahmetov, *Genes and response to aerobic training, in Sports, Exercise, and Nutritional Genomics*. 2019. p. 169-188.
45. Vasan, R.S., et al., *Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study*. *BMC Med Genet*, 2007. **8 Suppl 1**(Suppl 1): p. S2.
46. Torkamani, A., N.E. Wineinger, and E.J. Topol, *The personal and clinical utility of polygenic risk scores*. *Nat Rev Genet*, 2018. **19**(9): p. 581-590.
47. Evans, D.M., P.M. Visscher, and N.R. Wray, *Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk*. *Hum Mol Genet*, 2009. **18**(18): p. 3525-31.
48. Wray, N.R., et al., *Pitfalls of predicting complex traits from SNPs*. *Nat Rev Genet*, 2013. **14**(7): p. 507-15.
49. Wray, N.R., et al., *Research review: Polygenic methods and their application to psychiatric traits*. *J Child Psychol Psychiatry*, 2014. **55**(10): p. 1068-87.
50. De La Vega, F.M. and C.D. Bustamante, *Polygenic risk scores: a biased prediction?* *Genome Med*, 2018. **10**(1): p. 100.
51. Bouchard, C., *Genomic predictors of trainability*. *Exp Physiol*, 2012. **97**(3): p. 347-52.
52. Eynon, N., et al., *Mitochondrial biogenesis related endurance genotype score and sports performance in athletes*. *Mitochondrion*, 2011. **11**(1): p. 64-9.
53. Vellers, H.L., S.R. Kleeberger, and J.T. Lightfoot, *Inter-individual variation in adaptations to endurance and resistance exercise training: genetic approaches towards understanding a complex phenotype*. *Mammalian Genome*, 2018. **29**(1): p. 48-62.
54. Menshikova, E.V., et al., *Effects of exercise on mitochondrial content and function in aging human skeletal muscle*. *The journals of gerontology. Series A, Biological sciences and medical sciences*, 2006. **61**(6): p. 534-540.
55. Holloszy, J.O., et al., *Mitochondrial citric acid cycle and related enzymes: Adaptive response to exercise*. *Biochemical and Biophysical Research Communications*, 1970. **40**(6): p. 1368-1373.
56. Wyckelsma, V.L., et al., *Preservation of skeletal muscle mitochondrial content in older adults: relationship between mitochondria, fibre type and high-intensity exercise training*. *J Physiol*, 2017. **595**(11): p. 3345-3359.

57. MacInnis, M.J., et al., *Superior mitochondrial adaptations in human skeletal muscle after interval compared to continuous single-leg cycling matched for total work*. The Journal of Physiology, 2017. **595**(9): p. 2955-2968.
58. DiMauro, S. and E.A. Schon, *Mitochondrial Respiratory-Chain Diseases*. New England Journal of Medicine, 2003. **348**(26): p. 2656-2668.
59. Fritzen, A.M., et al., *Adaptations in Mitochondrial Enzymatic Activity Occurs Independent of Genomic Dosage in Response to Aerobic Exercise Training and Deconditioning in Human Skeletal Muscle*. Cells, 2019. **8**(3).
60. Malik, A.N. and A. Czajka, *Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction?* Mitochondrion, 2013. **13**(5): p. 481-92.
61. Holloszy, J., *Biochemical Adaptations in Muscle*. J. Biol. Chem, 1967: p. 2278-82.
62. Pilegaard, H., B. Saltin, and P.D. Neuffer, *Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle*. J Physiol, 2003. **546**(Pt 3): p. 851-8.
63. Axelrod, C.L., et al., *Exercise training remodels human skeletal muscle mitochondrial fission and fusion machinery towards a pro-elongation phenotype*. Acta Physiol (Oxf), 2019. **225**(4): p. e13216.
64. Pagano, A.F., et al., *Autophagy and protein turnover signaling in slow-twitch muscle during exercise*. Med Sci Sports Exerc, 2014. **46**(7): p. 1314-25.
65. Nielsen, J., et al., *Plasticity in mitochondrial cristae density allows metabolic capacity modulation in human skeletal muscle*. J Physiol, 2017. **595**(9): p. 2839-2847.
66. Niklas, P., et al., *Mitochondrial gene expression in elite cyclists: effects of high-intensity interval exercise*. European Journal of Applied Physiology, 2010. **110**(3): p. 597-606.
67. Costford, S.R., et al., *Skeletal muscle NAMPT is induced by exercise in humans*. American Journal of Physiology-Endocrinology and Metabolism, 2010. **298**(1): p. E117-E126.
68. Huertas, J.R., et al., *Human muscular mitochondrial fusion in athletes during exercise*. The FASEB Journal, 2019. **33**(11): p. 12087-12098.
69. Russell, A.P., et al., *Skeletal muscle mitochondria: a major player in exercise, health and disease*. Biochim Biophys Acta, 2014. **1840**(4): p. 1276-84.
70. Chacko, B.K., et al., *The Bioenergetic Health Index: a new concept in mitochondrial translational research*. Clin Sci (Lond), 2014. **127**(6): p. 367-73.
71. Miller, F.J., et al., *Precise determination of mitochondrial DNA copy number in human skeletal and cardiac muscle by a PCR-based assay: lack of change of copy number with age*. Nucleic Acids Res, 2003. **31**(11): p. e61.
72. Freyssenet, D., P. Berthon, and C. Denis, *Mitochondrial biogenesis in skeletal muscle in response to endurance exercises*. Arch Physiol Biochem, 1996. **104**(2): p. 129-41.
73. Holloszy, J.O., *Biochemical adaptations in muscle. Effects of exercise on mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle*. 1967(0021-9258 (Print)).
74. Hood, D.A., et al., *Unravelling the mechanisms regulating muscle mitochondrial biogenesis*. Biochem J, 2016. **473**(15): p. 2295-314.
75. Longchamps, R.J., et al., *Evaluation of mitochondrial DNA copy number estimation techniques*. PLOS ONE, 2020. **15**(1): p. e0228166.
76. Lanza, I.R. and K. Sreekumaran Nair, *Regulation of skeletal muscle mitochondrial function: genes to proteins*. Acta Physiologica, 2010. **199**(4): p. 529-547.

77. Meinild Lundby, A.-K., et al., *Exercise training increases skeletal muscle mitochondrial volume density by enlargement of existing mitochondria and not de novo biogenesis*. *Acta Physiologica*, 2018. **222**(1): p. e12905.
78. Giordano, C., et al., *Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy*. *Brain*, 2014. **137**(Pt 2): p. 335-53.
79. Konopka, A.R., et al., *Markers of Human Skeletal Muscle Mitochondrial Biogenesis and Quality Control: Effects of Age and Aerobic Exercise Training*. *The Journals of Gerontology: Series A*, 2013. **69**(4): p. 371-378.
80. Menshikova, E.V., et al., *Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity*. *Am J Physiol Endocrinol Metab*, 2005. **288**(4): p. E818-25.
81. Shen, J., et al., *Mitochondrial copy number and risk of breast cancer: a pilot study*. *Mitochondrion*, 2010. **10**(1): p. 62-8.
82. Booth, F.W. and J.R. Kelso, *Cytochrome oxidase of skeletal muscle: adaptive response to chronic disuse*. *Can J Physiol Pharmacol*, 1973. **51**(9): p. 679-81.
83. Lenka, N., et al., *Structural Organization and Transcription Regulation of Nuclear Genes Encoding the Mammalian Cytochrome c Oxidase Complex*. 1998. p. 309-344.
84. Kuhlbrandt, W., *Structure and function of mitochondrial membrane protein complexes*. *BMC Biol*, 2015. **13**: p. 89.
85. Meinild Lundby, A.K., et al., *Exercise training increases skeletal muscle mitochondrial volume density by enlargement of existing mitochondria and not de novo biogenesis*. *Acta Physiol (Oxf)*, 2018. **222**(1).
86. Baliotti, M., et al., *The effect of chronic physical exercise on succinic dehydrogenase activity in the heart muscle of old rats*. *Biogerontology*, 2005. **6**(2): p. 95-100.
87. Chalmers, G.R., R.R. Roy, and V.R. Edgerton, *Adaptability of the oxidative capacity of motoneurons*. *Brain Res*, 1992. **570**(1-2): p. 1-10.
88. Beal, M.F., B.T. Hyman, and W. Koroshetz, *Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?* *Trends Neurosci*, 1993. **16**(4): p. 125-31.
89. Rustin, P., A. Munnich, and A. Rotig, *Succinate dehydrogenase and human diseases: new insights into a well-known enzyme*. *Eur J Hum Genet*, 2002. **10**(5): p. 289-91.
90. Larsen, S., et al., *Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects*. *The Journal of physiology*, 2012. **590**(14): p. 3349-3360.
91. Morrison, H., *Chapter 10 - Citrate synthase*, in *Enzyme Active Sites and their Reaction Mechanisms*, H. Morrison, Editor. 2021, Academic Press. p. 45-49.
92. Leek, B.T., et al., *Effect of acute exercise on citrate synthase activity in untrained and trained human skeletal muscle*. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, 2001. **280**(2): p. R441-R447.
93. Green, H.J., et al., *Metabolic adaptations to training precede changes in muscle mitochondrial capacity*. *Journal of Applied Physiology*, 1992. **72**(2): p. 484-491.
94. Juster RP, et al., *Social inequalities and the road to allostatic load: From vulnerability to resilience*. . 3rd ed, ed. C. D. 2016, Developmental Psychopathology: Cambridge Press.
95. Kasahara, A. and L. Scorrano, *Mitochondria: from cell death executioners to regulators of cell differentiation*. *Trends Cell Biol*, 2014. **24**(12): p. 761-70.

## Chapter 3: Exercise Polygenic Score

The following section is based on the following publication:

**Alvarez Romero J, Voisin S, Eynon N, Hiam D.** Mapping Robust Genetic Variants associated with Exercise Responses. *Int J Sports Med* 2020; 41: 1–15.



THE NEW WAY TO DO UNI

### OFFICE FOR RESEARCH TRAINING, QUALITY AND INTEGRITY

#### DECLARATION OF CO-AUTHORSHIP AND CO-CONTRIBUTION: PAPERS INCORPORATED IN THESIS

*This declaration is to be completed for each conjointly authored publication and placed at the beginning of the thesis chapter in which the publication appears.*

##### 1. PUBLICATION DETAILS (to be completed by the candidate)

Title of Paper/Journal/Book:	Mapping Robust Genetic Variants associated with Exercise Responses		
Surname:	Alvarez Romero	First name:	Javier
Institute:	Institute for Health and Sport	Candidate's Contribution (%):	45
Status:		Date:	
Accepted and in press:	<input type="checkbox"/>	Date:	
Published:	<input checked="" type="checkbox"/>	Date:	2020

##### 2. CANDIDATE DECLARATION

I declare that the publication above meets the requirements to be included in the thesis as outlined in the HDR Policy and related Procedures – [policy.vu.edu.au](https://policy.vu.edu.au).

 Digitally signed by javier Date: 2023.01.09 18:04:20 +11'00'	<a href="https://policy.vu.edu.au">https://policy.vu.edu.au/</a> 1/10/2023
Signature	Date

##### 3. CO-AUTHOR(S) DECLARATION

In the case of the above publication, the following authors contributed to the work as follows:

The undersigned certify that:

1. They meet criteria for authorship in that they have participated in the conception, execution or interpretation of at least that part of the publication in their field of expertise;
2. They take public responsibility for their part of the publication, except for the responsible author who accepts overall responsibility for the publication;

PO Box 14428, Melbourne,  
Vic 8001, Australia  
+61 3 9919 6100

Victoria University ABN 83776954731  
CRICOS Provider No. 00124K (Melbourne),  
02475D (Sydney), RTO 3113

3. There are no other authors of the publication according to these criteria;
4. Potential conflicts of interest have been disclosed to a) granting bodies, b) the editor or publisher of journals or other publications, and c) the head of the responsible academic unit; and
5. The original data will be held for at least five years from the date indicated below and is stored at the following location(s):

Name(s) of Co-Author(s)	Contribution (%)	Nature of Contribution	Signature	Date
Danielle Hiam	35	Writing and editing the manuscript		10/01/2023
Sarah Voisin	5	Editing the manuscript		09/01/2023
Nir Eynon	15	Writing and editing the manuscript		

**Updated: September 2019**

### **3.1 Genetics and Exercise**

The heritable component of trainability is large, with genetics explaining 47% of the variance in VO<sub>2</sub> peak trainability, and around 52% in resistance variability (1). The contribution of familial factors (genetics and environment) to trainability was demonstrated in the seminal HERITAGE family study (2). This study indicated that VO<sub>2</sub>max was more variable between families than within families at baseline (3) and in response to exercise training (4), thus suggesting that DNA sequence variations could modulate exercise responses (5, 6). Pinpointing the responsible gene variants could illuminate the fundamental mechanisms driving this heterogeneity in response to exercise training (6).

The genetic contribution to trainability has been investigated by two different approaches: candidate genes and genome-wide association (GWAS) study. The GWAS approach involves scanning several hundred thousand (currently up to 5 million) DNA markers across the human genome to find genetic variations associated with a particular trait. One of the advantages of the GWAS approach is that it is unbiased and hypothesis-free. In contrast, candidate gene studies require knowledge of the trait of interest and are particularly useful to validate the functional impact of gene loci such as those identified by GWAS (7). GWAS have demonstrated that trainability is polygenic (i.e., influenced by many genetic variants), and that people harbouring the same genotypes in specific gene variants respond more similarly to exercise training than people harbouring different genotypes (8-11). These variants may modulate gene expression that is essential to the molecular adaptation to exercise training, since molecular processes mediate metabolism,

angiogenesis, cardiac and skeletal myofiber hypertrophy, and other processes that lead to better fitness (12).

While many SNPs have been associated with exercise response and trainability, the vast majority of the genes previously identified have not been replicated (13). Replication in an independent cohort is important as it increases the likelihood that results are true and reduces the number of false positives (14, 15). In this chapter we summarised SNPs associated with both resistance and aerobic trainability which have been replicated in two independent cohorts. In addition, we have screened these SNPs with the goal of identifying SNPs at trainability-associated loci that may have functional relevance. Further, we discussed future directions of performing large-scale exercise studies to elucidate the functional relevance of the discovered genomic markers. This approach will allow more rigour and reproducible research in the field of exercise genomics.

### **3.1.1 SNPs Selection criteria**

To provide a robust and comprehensive narrative review, a semi-structured search was performed (July 2019) to identify all studies relating to genetic variants and exercise trainability. Three electronic databases (PUBMED, MEDLINE and SCOPUS) were used to identify relevant articles using the following keywords “genes”, “genome”, “exercise”, “physical activity”, “aerobic capacity”, “resistance”, “strength”, “power”. We excluded studies where the sole focus was on populations with a diagnosed medical condition such type 2 diabetes mellitus, any inflammatory conditions, and cardiovascular disease. Articles were separated in two categories: genetic variants associated with either aerobic or resistance trainability (Table 2.1 and 2.2).

Finally, we selected SNPs that were classified as robust and separated them according to whether they were related to the aerobic trainability or resistance trainability. We chose this criterion as it reflects the reliability of the findings and increases the likelihood that there is true association of the SNP with trainability (15). It also allows us to identify and summarise SNPs with biological relevance, which is useful for researchers to ‘select’ candidate SNPs to identify causality and purpose of gene (16).

SNPs were considered robust if:

- 1) They showed consistent association with a given phenotype in at least *two independent* cohorts, and/or;

- 2) SNPs were shown to have functional relevance in an animal model or cell culture, with gene expression/DNA methylation Quantitative Trait Loci (QTLs) analysis or network, and enrichment analysis.

**Table 3.4. Gene Variants associated with aerobic trainability**

Author, Date	Sample Size	Sex (% Males)	Age	Ancestry/ Country / ethnicity	Chromosome	Annotated gene	Variant	Genotype and training response (+/-/0)	Intervention (if any)/ exercise	Duration	Type of study
<b>Alves (2009) (1)</b>	N= 83	100%	20-35yrs	Brazil	17 1	<i>ACE</i> <i>ATG</i>	rs4340 rs699	ACE (2) VO <sub>2max</sub> TT (+) LVM	Moderate intensity endurance training	3 days/week 16 weeks	Candidate Gene
<b>Bouchard 2011 (3)</b>	N= 742	Males and Females	17-65yrs	HERITAGE study Caucasian and African-American USA	4 6 9 3 9 3 1 1 20 11 14 15 11 14 2 4 11 3 22 11 6	<i>ACSL1</i> <i>PRDM1</i> <i>GRIN3A</i> <i>KCNH8</i> <i>C9orf27</i> <i>ZIC4</i> <i>CAMTA1</i> <i>RGS18</i> <i>BIRC7</i> <i>DBX1</i> <i>DAAM1</i> <i>NDN</i> <i>CXCR5</i> <i>TTC6</i> <i>LOC400950</i> <i>LOC100289626</i> <i>LOC100130460</i> <i>NLGN1</i> <i>MN1</i> <i>CD44</i> <i>ENPP3</i>	rs6552828 rs10499043 rs1535628 rs4973706 rs12115454 rs11715829 rs884736 rs10921078 rs6090314 rs10500872 rs1956197 rs824205 rs7933007 rs12896790 rs4952535 rs2053896 rs2198009 rs2030398 rs738353 rs353625 rs10452621	(+) VO <sub>2max</sub>	Endurance training Moderate: at 55% HR first two weeks and intense: last 6 weeks 75% HR	20 weeks	GWAS
<b>Dionne (1991)(4)</b>	Males N=46	Males 100%	17-29yrs	Canada, USA	Mitochondria	<i>MTND2</i> <i>MTND5</i>		MTN2 (-) VO <sub>2max</sub> MTND5 (+) VO <sub>2max</sub>	Endurance training at 85% of HRR	3-5 days/week 20 weeks	Candidate gene
<b>Hautala et al. 2007 (5)</b>	N= 478	Males=48.3% Females	17-65yrs	HERITAGE study Caucasian and African-American Canada, USA	22	<i>PPARD</i>	rs2016520 rs2076167	African American only rs2016520 CC (-) VO <sub>2max</sub> , PPO rs2076167 (2)	Endurance training moderate 55% of VO <sub>2</sub> and absolute 75% of VO <sub>2</sub> intensity	20 weeks	Candidate gene
<b>He et al. 2008 (6)</b>	N= 181	Males 100%	19± 1	Han Chinese	7	<i>NRF-1</i>	rs2402970	rs2402970 CC (+) VT, RE	Endurance training	18 weeks	Candidate gene

					15	<i>NRF-1</i> <i>NRF-2</i>	rs6949152 rs6949152	rs6949152 AA (+) VT, RE rs6949152 AA (+) VO2max	95% to 105% ventilatory threshold		
<b>He et al. 2006 (7)</b>	N= 181	100%	19± 1	Han Chinese	11	<i>HBB</i>	rs10768683	C (+) RE	Endurance training 95% to 105% ventilatory threshold	18 weeks	Candidate gene
<b>He et al. 2007 (8)</b>	N= 181	Males= 100%	19± 1	Han Chinese	15	<i>NRF-2</i> <i>NRF-2</i> <i>NRF-2</i>	rs12594956 rs8031031 rs7181866	ATG haplotype (+) RE	Endurance training 95% to 105% ventilatory threshold	18 weeks	Candidate gene
<b>He et al. 2008 (9)</b>	N= 181	100%	19± 1	Han Chinese	4 4 4	<i>PPARGC1A</i> <i>PPARGC1A</i> <i>PPARGC1A</i>	rs17847357 rs8192678 rs6821591	rs17847357, rs8192678 (2) VO2max rs6821591 G (+) VO2max	Endurance training High intensity 95% to 105% HR	18 weeks	Candidate gene
<b>He et al. 2010 (10)</b>	N= 181	100%	19± 1	Han Chinese	4 4 4 2 9	<i>PPP3CA</i> <i>PPP3CA</i> <i>PPP3CA</i> <i>PPP3R1</i> <i>PPP3R2</i>	rs2850965 rs3804423 rs3804358 rs4671887 rs3739723	G (+) VO2max G (+) VO2max G (+) VO2max A (+) VO2max A (+) RE	Aerobic endurance 95% to 105% of ventilatory threshold	18 weeks	Candidate gene
<b>He et al. 2010 (11)</b>	N= 181	100%	19± 1	Han Chinese	8 8 8 8 8	<i>PPP3CC</i> <i>PPP3CC</i> <i>PPP3CC</i> <i>PPP3CC</i> <i>PPP3CC</i>	rs1879793 rs1075534 rs7430 rs2461483 rs10108011	CC (+) SV AA (+) SV, CO GG (+) SV CC (+) SV GG (+) SV	Aerobic endurance 95% to 105% of ventilatory threshold	18 weeks	Candidate gene
<b>Leon et al. 2004 (12)</b>	N= 766	Males (43%) and Females	17-65yrs	HERITAGE study Caucasian and African-American USA	19	<i>APOE</i>	E2, E3, E4	(2)VO2max	Endurance training Moderate: at 55% HR first two weeks and intense: last 6 weeks 75% HR	20 weeks	Candidate Gene
<b>McKenzie 2011 (13)</b>	N= 109	46.7% Males	50-75yrs	Caucasian USA	14	<i>AKT1</i>	rs1130214	Men: GG (+) VO2max Females: (2)	Aerobic training moderate 50- 70%	24 weeks	Candidate gene
<b>McPhee et al 2011 (14)</b>	N=58	Females only	Age 18- 37yrs	Caucasian UK	14	<i>HIF1A</i>	rs11549465	T (+) VO2max	Aerobic 75-90% of HRmax	6 weeks	Candidate gene

<b>Pickering et al 2018 (15)</b>	N=42	Males only	16-19 yrs	European (UK)	4	<i>PPARGCIA</i> <i>VEGF</i> <i>ADBR2</i> <i>ADBR2</i> <i>CRP</i>	rs8192678 rs2010963 rs1042713 rs1042714 rs1205	Endurance genotype (+) Yo-Yo Test	Aerobic training moderate to intense	8 weeks	Candidate gene
<b>Prior et al. 2003 (16)</b>	N=233	Males 39.3% and Females	50-75 yrs	Caucasian and African-American USA	14	<i>HIF1A</i>	rs28708675 rs11549465	African American cohort: rs28708675 AA (+) VO2max  Caucasian cohort: rs11549465 CC (+) VO2max	Aerobic training moderate 50-70%	24 weeks	Candidate gene
<b>Prior et al. 2006 (17)</b>	N=146	Males (42%) and Females (58%)	50-75 yrs	Caucasian and African-American USA	6	<i>VEGF</i>	rs699947 rs1570360 rs2010963	AAG & CGC haplotypes (+) VO2max	Aerobic training moderate 50-70%	24 weeks	Candidate gene
<b>Rankinen et al 2000 (18)</b>	N= 472	Males and Females	Age 17-65yrs	HERITAGE study Caucasian USA	1	<i>ATPIA2</i>	Polymorphisms at exon 1 and 21-22	2α haplotype (+) VO2max and PP	Endurance training Moderate: at 55% HR first two weeks and intense: last 6 weeks 75% HR	20 weeks	Candidate Gene
<b>Rankinen et al 2000 (19)</b>	N= 472	Males (48.7%) and females	Age 17-65yrs	HERITAGE study Caucasian USA	17 1	<i>ACE</i> <i>ATG</i>	rs4340 rs699	Males: ACE I/D (2) ATG M (+) reduced diastolic blood pressure.  Females: ACE I/D (2) ATG M/T (2)	Endurance training Moderate: at 55% HR first two weeks and intense: last 6 weeks 75% HR	20 weeks	Candidate Gene
<b>Rico-Sanz et al 2003(20)</b>	N= 779	Males and Females	Age 17-65yrs	HERITAGE study Caucasian and African-American USA	1	<i>AMPD1</i>	rs17602729	TT (-) VO2max	Endurance training Moderate: at 55% HR first two weeks and intense: last 6 weeks 75% HR	20 weeks	Candidate Gene

<b>Ring-Dimiriou et al 2014 (21)</b>	N=24	Males	45-65yrs	Austria	4	<i>PPARGCIA</i>	rs8192678	GG (+) VO <sub>2peak</sub>	70-90% of Vo <sub>2peak</sub>	3 days/week 10 weeks	Candidate Gene
<b>Rivera et al 1997 (22)</b>	N= 240	Males and Females	17-65yrs	HERITAGE study Caucasian and African-American USA	19	<i>CKMM</i>	rs8111989	CC (-) VO <sub>2max</sub>	Endurance training Moderate: at 55% HR first two weeks and intense: last 6 weeks 75% HR	20 weeks	Candidate Gene
<b>Sonna et al 2001 (23)</b>	N=147	Males (42.2%) and Female	Age 21.7 ± 3.6yrs	USA: 57% Caucasians, 25% African-Americans, 14% Hispanics, 3% Asians, and 1% Native American	17	<i>ACE</i>	rs1799752	ACE I/D (2) VO <sub>2max</sub>	2 aerobic days and 2 strength training days per week	8 weeks	Candidate Gene
<b>Stefan et al (2007) (24)</b>	N= 136	Males and Females	Age 19-67 yrs	Germany	22 22 22 22 4	<i>PPARD</i> <i>PPARD</i> <i>PPARD</i> <i>PPARD</i> <i>PPARGCIA</i>	rs2267668 rs6902123 rs2076167 rs1053049 rs8192678	rs2267668 G (-) AT, VO <sub>2peak</sub> rs6902123 (2) rs2076167 (2) rs1053049 (2) rs8192678 A (-) AT	Unsupervised: 3h of moderate sports per week	9 months	Candidate Gene
<b>Steinbacher et al. 2015 (25)</b>	N=28	Males Only	50-69yrs	Austria	4	<i>PPARGCIA</i>	rs8192678	AA (-) decreased fibre type 1 transformation	70-90% of Vo <sub>2peak</sub>	3 days/week 10 weeks	Candidate Gene
<b>Woods et al. (26)2001</b>	N= 108	No percentage mentioned	Age 18.9 ±0.4yrs	Caucasian	17	<i>ACE</i>	rs1799752	ACE I/D (2)	Aerobic Submaximal training at 75%	11 weeks	Candidate gene
<b>Yoo et al 2016 (27)</b>	N= 123	Males and Females	Age 30-60yrs	Korea	12 18 2 3 6 2 2	<i>AMN1</i> <i>CDH2</i> <i>ASB3</i> <i>SRGAP3</i> <i>UST</i> <i>PUM2</i> <i>KCNH7</i>	rs11051548 rs2542729 rs1451462 rs13060995 rs6570913 rs11096663 rs12613181	(+) VO <sub>2</sub> max (+) VO <sub>2</sub> max	HIIT 60%-84% of VO <sub>2max</sub>	9 weeks	GWAS
<b>Yu et al. 2014 (28)</b>	N= 360	Males (50%) and Females	Age 18-40yrs	China	19	<i>APOE</i>	E2, E3, E4	E2/E3 (+) VO <sub>2max</sub> E3/E4 (+) VO <sub>2max</sub>	Aerobic 60%-85%	6 months	Candidate gene
<b>Zarebska et al 2014 (29)</b>	N=66	Females only	Age 19-24yrs	Caucasian Poland	11	<i>GSTP1</i>	rs1695	G (+) VO <sub>2max</sub> and VEmax	Aerobic training	12 weeks	Candidate gene

									50% to 70% of HRmax		
<b>Zhou et al. 2006 (30)</b>	N=102	Males Only	18.8 ± 0.9yrs	China	19	<i>CKMM</i>	rs1803285	AG (-) RE	Distance running program 95-105% of VT	18 weeks	Candidate Gene

Table 3-5. Gene variants associated with resistance trainability.

Author, Date	Sample Size	Sex (% Males)	Age	Ancestry/ Country of origin/ ethnicity	Chromosome	Gene	Variant	Genotype and training response (+/-/0)	Intervention	Duration	Type of study
<b>Ash (2) (31)</b>	N=602	Males and Females	Age 18-40yrs	FAMuSS study: Predominantly European-American Ancestry	5	<i>NR3C1</i>	<i>rs10482614</i> <i>rs10482616</i> <i>rs4634384</i>	Females: rs4634384 T (+) Hypertrophy  Males: rs10482616 GG (+) MVC rs10482614 AA (+) MVC	Upper arm, Unilateral resistance program	12 weeks	Candidate Gene
<b>Charbonneau (2008) (32)</b>	N=243	Males =35.3% and Females	Age 50-85yrs	U.S.A. Caucasian	17	<i>ACE</i>	<i>rs1799752</i>	Females: ACE (2) Males: ACE (2)	Knee Extension unilateral resistance program	10 weeks 3days/weeks	Candidate Gene
<b>Clarkson (2005) (33)</b>	N=602	Males =41% And Females	Age 18-40yrs	FAMuSS study: Predominantly European-American Ancestry	11	<i>ACTN3</i>	<i>rs1815739</i>	Females: ACTN3 XX (+) Maximal dynamic strength (1RM). Males: ACTN3 (2)	Upper arm, Unilateral resistance program	12 weeks	Candidate Gene
<b>Delmonico (2007) (34)</b>	N=157	Males=45.2% And Females	Age=50-85yrs	Caucasian USA	11	<i>ACTN3</i>	<i>rs1815739</i>	Females: ACTN3 RR (+) PP Males: ACTN3 (2)	Knee Extension unilateral resistance program	3days/week 10 weeks	Candidate Gene
<b>Erskine (2012) (35)</b>	N=51	Males: 100%	Age 20.3±3.1yrs	Caucasian UK	8	<i>PTK2</i>	<i>rs7843014</i> <i>rs7460</i>	rs7843014 AA (+) Strength (MVC) rs7460 TT (+) Strength (MVC)	Knee Extension unilateral resistance program	3days/week 9 weeks	Candidate Gene
<b>Erskine (2013) (36)</b>	N=51	Males: 100%	Age 20.3±3.1yrs	Caucasian UK	17 11	<i>ACE</i> <i>ACTN3</i>	<i>rs1799752</i> <i>rs1815739</i>	ACE (2) ACTN3 (2)	Knee Extension unilateral resistance program	3days/week 9 weeks	Candidate Gene
<b>Folland (2000) (37)</b>	N=33	Males: 100%	Age 18-30yrs	UK	17	<i>ACE</i>	<i>rs4646994</i>	Isometric training: ACE DD/ID (+) Isometric strength (MVC) Dynamic training: ACE DD/ID (2)	Isometric Training	3days/week 9 weeks	Candidate Gene

									Dynamic training		
<b>Giaccaglia (2006) (38)</b>	N=213	Males and Females	Age>60yrs	Predominantly Males and Females of European-American Ancestry	17	<i>ACE</i>	<i>rs4646994</i>	ACE DD (+) strength (MVC)	Light resistance training	3days/week 18 months	Candidate Gene
<b>Harmon (2010) (39)</b>	N=874	Male 41.1%	Age 18-40yrs	FAMuSS study: Predominantly European-American Ancestry	17 3	<i>CCL2</i> <i>CCR2</i>	<i>CCL2</i> ( <i>rs17652343</i> ), ( <i>rs1860189</i> ), ( <i>rs3917878</i> ), ( <i>rs2857654</i> ), ( <i>rs1024611</i> ), ( <i>rs1024610</i> ), ( <i>rs3760396</i> ), ( <i>rs2857656</i> ), ( <i>rs2857657</i> ), ( <i>rs4586</i> ), ( <i>rs13900</i> )  <i>CCR2</i> ( <i>rs17141010</i> ), ( <i>rs768539</i> ), ( <i>rs3918358</i> ), ( <i>rs1799864</i> ), ( <i>rs1799865</i> ).	Females: CCL2 (2) and CCR2 (2)  Males: CCL2 T ( <i>rs1024610</i> ) (+) Maximal Isometric strength (MVC)  Males and Females CCR2 (AA) <i>rs3918358</i> and (TT) <i>rs1799865</i> (+) Isometric strength (MVC)	Upper arm, Unilateral resistance program	2 days/week 12 weeks	Candidate Gene
<b>He (2019) (40)</b>	N=40	(Females only)	Age 53-66yrs	Chinese, Beijing	17	<i>ACE</i>	<i>rs4646994</i>	ACE DD (+) Maximal Isometric strength (MVC), muscle hypertrophy and grip strength	Whole body resistance training	3 days/week 8 weeks	Candidate Gene
<b>Hong (2014) (41)</b>	N=83	100%	Age 22.6 ± 1.4 yrs	South Korean	11	<i>CNTF</i>	<i>rs1800169</i>	CNTF G/A (2)	Resistance training of the upper extremities	3 days/week 8 weeks	Candidate Gene
<b>Jamshidi et al (2002) (42)</b>	N=144	Males only	19.6 (2.4) yrs	UK	6	<i>PPARA</i>	<i>rs425778</i>	C (+) LV mass	Upper and lower body training program	10 weeks	Candidate Gene
<b>Jones (2006) (43)</b>	Study 1, N=28. Study 2 N=39	100%	18-20 yrs	Caucasian UK	17	(Power-related polygenic)	<i>ACE D</i> ( <i>rs1799752</i> ) <i>ACTN3</i> ( <i>rs1815739</i> )	Power genotype (+) Power (CMJ) after high intensity resistance training but not low intensity resistance training.	Low intensity (~30% of 1 RM and high	8 weeks of high or low	Polygenic Score

					11	<i>risk score</i>	<i>ADRB2 C (rs1042714)</i> <i>AGT C (rs699)</i> <i>IL-6 G/C (rs1800795)</i> <i>PPARA C (rs4253778)</i> <i>TRHR G (rs8192676)</i> <i>VDR A (rs1544410)</i>		repetitions) and high-intensity (~70% of 1 RM and low repetitions) resistance training	resistance training 1 to 2 days per week	
<b>Keogh (2015) (44)</b>	N=58	Not percentage mentioned	Age 69.8 ± 5.3	New Zealand (European ancestry)	17	<i>ACE</i> <i>UCP2</i>	<i>rs4646994</i> <i>rs7109266</i>	ACE ID (2) UCP2 GG (+) Lower body strength (8ft Up and Go time)	Resistance training light to moderate intensity	2days/week, 12 weeks	Candidate Gene
<b>Kostek (2005) (45)</b>	N=67	Males=47.7%	50-85yrs	U.S.A Caucasian	12	<i>IGF1</i>	<i>IGF1 192</i>	IGF1 192/192 + 192/- (+) dynamic (1RM) muscle strength	Unilateral resistance program	10 weeks 3days/wk	Candidate Gene
<b>Li (2014) (46)</b>	N=94	100%	Age 18-22years	Han Chinese	2	<i>MTSN</i>	<i>rs1805086</i> <i>rs1805065</i>	MTSN KR (+) Hypertrophy in Biceps and Quadriceps MTSN AT + TT (+) Hypertrophy in Biceps	Arm and Leg resistance training	3-4 days/wk 8 weeks	Candidate Gene
<b>Pereira (2013) (47)</b>	N=139	(Females only)	Age 65.5 (8.2)	Portugal, Caucasian	17 11	<i>ACE</i> <i>ACTN3</i>	<i>rs1799752</i> <i>rs1815739</i>	ACE D/D (+) maximal dynamic strength 1RM, power (CMJ), functional capacity (STS)  ACTN3 RR (+) maximal dynamic strength (1RM), power (CMJ), functional capacity (STS)	High-speed power training	12 weeks 3days/week	Candidate Gene
<b>Pescatello (2006) (48)</b>	N=631	Males=42%	Age 18-40yrs	FAMuSS study: Predominantly European-American Ancestry	17	<i>ACE</i>	<i>rs4646994</i>	Trained Arm Post Intervention: ACE II/ID (+) Maximal Isometric strength (MVC)  Untrained Arm Post Intervention: ACE DD/ID (+) maximal dynamic strength (1RM), muscle size (CSA of Type II fibres).	Upper arm, Unilateral resistance program	12 weeks, 2days/week	Candidate Gene
<b>Pistilli (2008) (49)</b>	N= 748	Males (40.2%) Females	18-40yrs	Caucasian	10	<i>IL15RA</i>	<i>rs2296135</i>	<i>rs2296135</i> CC (+) MVC	RT program	12 weeks 2 day/week	Candidate gene

<b>Reichman (2004) (50)</b>	N= 153	Males 49.6% Females	Aged 18-31 years	Predominantly European-American Ancestry	10	<i>IL15RA</i>	<i>rs3136617</i> <i>rs3136618</i> <i>rs2296135</i>	rs3136617 C (+) muscle hypertrophy rs2296135 C (+) muscle hypertrophy	Whole body resistance training @75% of 1RM	10 weeks, 3days/week	Candidate Gene
<b>Sprouse (2014) (51)</b>	N= 874	Males= 50%	Age: 18-40 years	FAMuSS study: Predominantly European-American Ancestry	8	<i>SLC30A8</i>	<i>rs13266634</i>	Females: SCL30A8 (2) Males: SCL30A8(2)	Upper arm, Unilateral resistance program	Acute and 12-week Intervention	Candidate Gene
<b>Thomis (2004) (52)</b>	N=57	100%	22.4 (3.7) yrs	Flemish Brabant, Belgium	17  2	<i>ACE</i>  <i>MTSN</i>	<i>rs4646994</i>  <i>rs1805086</i> <i>rs1805065</i>	ACE (I/D) (2) strength, isometric and concentric torque or arm muscle cross-sectional area  MTSN: Unable to be determined	High resistance training program	10 weeks, 3days/week	Candidate Gene
<b>Walsh (2009) (53)</b>	N=745	Males 40%	Age 18-40yrs	FAMuSS study: Predominantly European-American Ancestry	11	<i>CNTF</i>	<i>rs1800169</i>	Females: CNTF GG (+) isometric (MVC) and dynamic (1RM) muscle strength  Males: CNTF (2)	Upper arm, Unilateral resistance program	12 weeks, 2 days/wk	Candidate Gene
<b>Walsh (2012) (54)</b>	N=560	Males and Females No percentage mentioned	Age 18-40yrs	FAMuSS study: Predominantly European-American Ancestry	1	<i>LEP</i>  <i>LEPR</i>	<i>rs2167270</i>  <i>rs1137100</i> <i>rs1137101</i> <i>rs1805096</i> <i>rs8179183</i>	LEP (GG/GA) rs2167270 (+) Muscle hypertrophy  LEPR (2)	Upper arm, Unilateral resistance program	12 weeks, 2 days/wk	Candidate Gene

**Table 3.6.** Robust SNPs associated with aerobic or resistance trainability.

Aerobic Trainability			Resistance trainability		
<i>SNP</i>	Nearest Gene	Beneficial allele	<i>SNP</i>	Nearest Gene	Beneficial allele
rs6552828	<i>ACSL1</i>	G	rs4646994*	<i>ACE</i>	D
rs699	<i>AGT</i>	T	rs1799752*	<i>ACE</i>	D
rs6090314	<i>BIRC</i>	A	rs1815739	<i>ACTN3</i>	R
rs12580476	<i>C12orf36</i>	TBC	rs2296135	<i>IL15 RA</i>	C
rs884736	<i>CAMTA1</i>	G	rs4253778	<i>PPARA</i>	C
rs353625	<i>CD44</i>	TBC			
rs1956197	<i>DAAMI</i>	G			
rs17117533	<i>NDN</i>	A			
rs8192678	<i>PPARGC1A</i>	G			
rs10921078	<i>RGS18</i>	A			
rs7531957	<i>RYR2</i>	TBC			
rs11715829	<i>ZIC4</i>	G			

\*Linkage Disequilibrium above 80 % according to ensemble LD calculator.

### 3.1.2 Aerobic Trainability

Twin and family studies indicate that ~22–57% of aerobic fitness variability between individuals can be explained by genetics and therefore plays an important role in the range of aerobic phenotypes observed in a population (1). Here, we briefly describe some of the robust SNPs that have been associated with aerobic trainability, which means they were replicated in at least 2 independent cohorts and were shown to have functional relevance.

A bioinformatic analysis study conducted by Ghosh *et al.* found that the greatest number of SNPs were annotated to the PPAR signalling pathway suggesting its importance in  $VO_{2max}$  trainability (2). As such, the most widely studied genes within this pathway are the peroxisome proliferator-activated receptors (*PPARA*, *PPARG*, and *PPARD*) and their transcriptional coactivators (*PPARGC1A* and *PPARGC1B*). These genes have been linked to multiple aerobic phenotypes, including muscle morphology, aerobic capacity and endurance performance (3, 4). *PPARD* is expressed predominantly in adipocytes and skeletal muscle

where it promotes fatty acid oxidation (5). In the HERITAGE family study, the rs2016520 SNP located in *PPARD* was associated with  $VO_{2max}$  and maximal power output after a 20 week endurance training intervention in African-Americans, but not in Caucasians (6). *In vitro* and animal studies show that the minor allele (C allele) in this SNP (rs2016520) results in higher *PPARD* transcriptional activity, which in turn promotes lipid accumulation and alters normal regulation of lipid uptake and storage (5, 7, 8). In a European cohort it was shown that the *PPARD* rs2267668 SNP was associated with  $VO_{2peak}$  and anaerobic threshold after a 9-month lifestyle intervention (9). They then confirmed that in human primary cell lines that those carrying the minor allele at rs2267668 (G allele) were associated with lower mitochondrial activity, demonstrating a potential functional effect (9). Taken together, the *PPARD* locus may play a role in aerobic trainability, but larger cohorts of different ancestries and more in depth functional studies to determine causal SNP are needed to confirm this.

The transcriptional co-activator *PPARGC1A* interacts with *PPARD* and regulates mitochondrial biogenesis, angiogenesis, lipolysis and adipogenesis (10). Four candidate gene studies, predominantly in men, found consistent associations of rs8192678 within *PPARGC1A* and aerobic capacity in Europeans (9, 11-13). While in the Han Chinese cohort another nearby SNP (rs6821591) was associated with  $VO_{2max}$  specifically, the G allele was associated with increased  $VO_{2max}$  compared to those carrying the A allele (14). Work conducted in a Han Chinese cohort found that the *PPARGC1A* rs6821591 SNP had functional significance as gene expression was altered; this was dependent on genotype (A v G allele), with the G allele displaying increased PGC-1 $\alpha$  gene expression (15). Overexpression of PGC-1 $\alpha$  in an animal model showed increased Type I fibres in muscles that are normally Type II fibre-dense and this induced increases in resistance to fatigue, inferring increased aerobic capacity (16). These population-specific results indicate that it is the *PPARGC1A* locus itself, rather than individual SNPs located within that locus, may be important for trainability (14, 17).

Currently 26 SNPs associated with  $VO_{2max}$  trainability were identified in a GWAS and were validated in 2 separate cohorts (detailed in **Table 2**) (18). They accounted for 49% of  $VO_{2max}$  trainability and were able to classify responders and non-responders (18, 19). Whether these SNPs are directly involved in gene function or regulation of genes is the next step to validate these findings. The most robust is the SNP rs6552828 located near the *ACSL1* gene, which was the strongest predictor (~6%) of aerobic trainability ( $VO_{2max}$ ) (18). It has subsequently been validated in a bioinformatics pathway analysis and found to be strongly correlated to the aerobic electron transport chain phenotype and the PPAR signalling pathway, providing a robust candidate gene in  $VO_{2max}$  trainability (2). *ACSL1* regulates lipid metabolism by facilitating the transport of long chain fatty acids into the mitochondria and is an essential step in fatty acid oxidation (20). Timmons *et al.* integrated RNA profiles with genetic variants and found the following genes *CD44*, and *DAAMI*, also discovered in the Bouchard *et al.* GWAS, were associated with gene expression changes (21). Gene expression of *CD44* was up-regulated in response to endurance training (21) and was strongly associated with phenotypic terms associated with aerobic exercise, such as cardiovascular physiological processes, muscle contraction, physical fitness and aerobic electron transport chain (2). This indicates that this gene and any alterations to its function (i.e. via SNPs) may play an important role in aerobic trainability. While these genes certainly provide robustness, there are still limitations in determining the causality of these particular SNPs in the molecular mechanisms affecting aerobic trainability.

Many candidate gene and GWAS studies have been conducted and this chapter highlights the large collection of candidate genes that have been associated with aerobic trainability. Only 12 SNPs have been robustly associated with aerobic trainability (**Table 3**), meaning that they have been validated in at least 2 independent cohorts and were shown to have some functional

relevance. Subsequent studies should focus on understanding the functional role of the SNPs that have been replicated, as this chapter highlights the lack of understanding of the molecular mechanism and limits our understanding of aerobic trainability.

### 3.1.3 Resistance Trainability

Muscular strength and power show a heritability estimated around 52% (22). Skeletal muscle strength is defined as the force produced by muscle contraction. A variety of measures have been investigated, including muscle strength, maximal voluntary contraction (MVC), 1 repetition maximum (1RM) and handgrip strength. While the production of skeletal muscle power is defined as how much force can be produced and the velocity at which it is produced, the production of power can be measured at the by undertaking tests such as Wingate's, counter movement jumps (CMJ) and vertical jumps.

The *ACE I/D* and *ACTN3 R/X* SNPs are two of the most extensively studied gene loci. We have chosen not to discuss *ACTN3* here as it has recently been reviewed in detail by Del Coso et al. (24) and instead focus on the *ACE I/D* SNP. The *ACE* gene encodes the angiotensin-converting enzyme that is a central component of the renin-angiotensin-system (25). The *ACE I/D* results in either an insertion (26) or deletion (26) of a 287-basepair region in intron 16 of the gene (27) and can alter the levels of ACE in the blood (27). It has recently been shown that polymorphism can manipulate the activity of the C- and N-terminal domain in the enzyme (28). Further, exercise can decrease enzyme activity in the C-terminal domain and increase the activity in the N-terminal domain, which results in improved blood flow and proliferation of red blood cells (28). The I allele is assumed to confer enhanced endurance performance while the D allele is thought to confer increased muscle power and strength (29). The D allele was consistently shown across 6 separate candidate gene studies to be associated with greater gains

in strength after resistance training, and this was consistent across sex and age (30-35). While the literature is consistent regarding muscular strength, the association with muscular power is less convincing (30, 36-38). The D allele in *ACE* was associated with CMJ in older females after a 12-week power training program (33) and in young males after a high intensity training program (39). However, it was the I allele in *ACE* that was associated with a higher baseline VJ at baseline in males and females (37). Another two studies did not find any association between the *ACE* I/D and skeletal muscle power at baseline or in response to resistance training (36, 38). *ACE* provides a robust candidate gene for explaining variation in muscular strength but not muscular power, suggesting that this gene loci may only explain some of the inter-individual resistance variability dependent on type of resistance exercise.

Many of the candidate genes in resistance trainability came from a large multi-centre trial (FAMuSS) which aimed to identify nonsynonymous SNPs with functional effects on muscle power and strength (40). These include: *Glucocorticoid receptor (NR3C1)* (41), *alpha-actinin 3 (ACTN3)* (42), *Chemokine (C-C motif) ligand 2 (CCL2)* (43), *Chemokine (C-C motif) ligand 2 Receptor (CCR2)* (43), *ACE* (35), *Solute carrier family 30 (zinc transporter), member eight gene (SLC30A8)* (44), *Leptin (LEP)* and *Leptin receptor (LEPR)* (45). The FAMuSS study was conducted in young (18-40 years old) males (N=247) and females (N=355) of predominantly European-American ancestry. Participants underwent a 12-week unilateral resistance program consisting of upper arm exercises in the non-dominant arm (35). Only *IL-15RA*, *ACTN3* and *ACE* from this series of studies were replicated in separate cohorts and have functional relevance. In the *IL-15RA* locus the rs2296135 SNP was associated gains in muscular strength and replicated in two different studies in European ancestry cohorts (46, 47). When the gene *IL-15RA* is knocked down in an animal model it alters the contractile properties and fatigability in skeletal muscle fibres (48). While the locus is important, it is not yet clear which SNPs is responsible for altering the function of *IL-15RA* protein. Although SNPs within

*CCL2*, *CCR2* and *CNTF* have not been replicated, they interestingly showed sex-specific associations with muscle strength. *CTNF* polymorphisms were associated with strength gains only in females (49), which was subsequently confirmed in a South Korean cohort (50). SNPs in *CCL2* and *CCR2* were associated with strength gains in males only (43). This indicates potential sex-specific differences in the genetic architecture of complex traits and should be incorporated into study design (51, 52). In addition, *PTK2*, *CNTF*, *IL-6*, *PPARA* and *VDR* candidate genes have been replicated with functional relevance (39, 53).

In total 5 SNPs (**Table 3**) were robustly associated with resistance variability. While there is a plethora of candidate gene studies, no GWAS have been conducted that specifically focuses on resistance trainability.

### **3.1.4 Functional Validation**

We have identified 12 SNPs and 5 SNPs that are robustly associated with variance in aerobic and resistance trainability respectively. The next steps are to a) identify the causal SNP, b) annotate the causal SNP to the correct gene and then c) to establish the functional relevance of the gene (19). The overall evidence from literature connecting causal genes to trainability is relatively low (2). If we hope to identify the causal variants or genes it is vital that we begin to integrate ‘omic’ technologies, from genome and epigenome, to transcriptome, to proteome and metabolome, which can capture a complete picture of complex human traits such as aerobic and resistance trainability (54, 55).

There have been attempts to associate molecular pathways or ‘molecular phenotypes’ with physiological phenotypes of aerobic and resistance trainability (56-58). Sarzynski et al. applied this systems biology approach by combining the 21 SNP identified in a GWAS from

the HERITAGE study cohort (Table 2) (18, 59) and examined the joint contributions of these SNPs to exercise response (19). This approach identified potential pathways in calcium signalling, energy sensing and partitioning, mitochondrial biogenesis, angiogenesis, immune functions, and regulation of autophagy and apoptosis, which can be investigated more closely (19). Another integrative approach is expression quantitative trait loci (eQTLs) analysis, which leverages gene loci identified from GWAS and integrates them with gene expression data to identify differential gene expression levels, and uncover the ‘molecular phenotype’ that leads to these variations in exercise response (60, 61). Willems *et al.* identified the rs6565586 SNP in *ACTG1* as a strong candidate gene in inter-individual variability in the resistance-related phenotype (hand grip strength) and correlated this with a lower expression of mRNA in skeletal muscle. *ACTG1* encodes Actin Gamma 1 and is involved in the structure and function of skeletal muscle fibres. Interestingly, in a knockout mouse model, animals displayed overt muscle weakness (62). This type of analysis presented an ideal candidate gene to begin understanding the molecular mechanisms in human skeletal muscle.

The type of follow-up experiment will depend on the location of SNP within the gene. For SNPs within coding regions, ideally experiments are performed to study the effect of the SNP has on protein structure and function. For SNPs in non-coding regions it more difficult to determine, as they may not directly affect a gene but alter/regulate transcription factors and mediate alterations in genes this way (54). However, with the introduction of the large epigenetic database ENCODE (Encyclopaedia of DNA elements) we can now identify the transcription factor association, chromatin structure and histone modification of target genes (63), and more recently enhancers providing candidate gene targets for follow up analysis (64). With the discovery of CRISPR Cas-9 genome-editing tool in 2012 (65), this has paved the way for establishing causality of SNPs and the functional effects of them. This has been successfully used for establishing causal genes implicated in insulin resistance, whereby they were able to

determine the causal effect of 12 candidate genes that had previously been identified in a GWAS (66). To date no experiments have been conducted using this gene-editing tool to establish the function and causality of candidate genes of trainability beyond association analysis.

There is still much work to do before personalised exercise prescription (both in a clinical and elite athlete setting) can be based on an individual's genetics. However, there are concerted efforts taking place to make this possible, such as the Athlome Project Consortium and the Gene SMART (Skeletal Muscle Response to Training), recently launched with the aim of uncovering the genetic variation underlying athletic performance, adaptation to exercise training, and exercise-related musculoskeletal injuries (67, 68). These, and other initiatives will allow for population-based approach to understand the role of genes and environmental factors contributing to the complex exercise response phenotype (69).

### 3.2 References

1. Zempo, H., et al., *Heritability estimates of muscle strength-related phenotypes: A systematic review and meta-analysis*. Scand J Med Sci Sports, 2017. **27**(12): p. 1537-1546.
2. Bouchard, C., et al., *The HERITAGE family study. Aims, design, and measurement protocol*. Med Sci Sports Exerc, 1995. **27**(5): p. 721-9.
3. Bouchard, C., et al., *Familial resemblance for VO<sub>2</sub>max in the sedentary state: the HERITAGE family study*. Med Sci Sports Exerc, 1998. **30**(2): p. 252-8.
4. Bouchard, C., et al., *Familial aggregation of VO<sub>2</sub>max response to exercise training: results from the HERITAGE Family Study*. J Appl Physiol (1985), 1999. **87**(3): p. 1003-8.
5. Bouchard, C., *Human adaptability may have a genetic basis*. ealth Risk Estimation, Risk Reduction and Health Promotion. , 1983: p. 463-476.
6. Bouchard, C., T. Rankinen, and J.A. Timmons, *Genomics and Genetics in the Biology of Adaptation to Exercise*. 2011.
7. Ahmetov, I., et al., *Genome-wide association study identifies three novel genetic markers associated with elite endurance performance*. Biol Sport, 2015. **32**(1): p. 3-9.
8. Leonska-Duniec, A., et al., *Leptin and Leptin Receptor Genes Are Associated With Obesity-Related Traits Changes in Response to Aerobic Training Program*. J Strength Cond Res, 2018. **32**(4): p. 1036-1044.
9. Miotto, P.M. and G.P. Holloway, *Exercise-induced reductions in mitochondrial ADP sensitivity contribute to the induction of gene expression and mitochondrial biogenesis through enhanced mitochondrial H<sub>2</sub>O<sub>2</sub> emission*. Mitochondrion, 2019. **46**: p. 116-122.
10. McKenzie, J.A., et al., *AKT1 G205T genotype influences obesity-related metabolic phenotypes and their responses to aerobic exercise training in older Caucasians*. Exp Physiol, 2011. **96**(3): p. 338-47.
11. Bouchard, C., et al., *Genomic predictors of the maximal O<sub>2</sub> uptake response to standardized exercise training programs*. J Appl Physiol (1985), 2011. **110**(5): p. 1160-70.
12. Soci, U.P.R., et al., *Exercise Training and Epigenetic Regulation: Multilevel Modification and Regulation of Gene Expression*. Adv Exp Med Biol, 2017. **1000**: p. 281-322.
13. Cagnin, S., F. Chemello, and I.I. Ahmetov, *Genes and response to aerobic training*, in *Sports, Exercise, and Nutritional Genomics*. 2019. p. 169-188.
14. Huffman, J.E., *Examining the current standards for genetic discovery and replication in the era of mega-biobanks*. Nature Communications, 2018. **9**(1): p. 5054.
15. Chanock, S.J., et al., *Replicating genotype–phenotype associations*. Nature, 2007. **447**(7145): p. 655-660.
16. Tam, V., et al., *Benefits and limitations of genome-wide association studies*. Nat Rev Genet, 2019. **20**(8): p. 467-484.
17. Alves, G.B., et al., *Influence of angiotensinogen and angiotensin-converting enzyme polymorphisms on cardiac hypertrophy and improvement on maximal aerobic capacity caused by exercise training*. Eur J Cardiovasc Prev Rehabil, 2009. **16**(4): p. 487-92.
18. Dionne, F.T., et al., *Mitochondrial DNA sequence polymorphism, VO<sub>2</sub>max, and response to endurance training*. Med Sci Sports Exerc, 1991. **23**(2): p. 177-85.

19. Hautala, A.J., et al., *Peroxisome proliferator-activated receptor- $\delta$  polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study*. American Journal of Physiology-Heart and Circulatory Physiology, 2007. **292**(5): p. H2498-H2505.
20. He, Z., et al., *NRF-1 genotypes and endurance exercise capacity in young Chinese men*. Br J Sports Med, 2008. **42**(5): p. 361-6.
21. He, Z., et al., *Polymorphisms in the HBB gene relate to individual cardiorespiratory adaptation in response to endurance training*. Br J Sports Med, 2006. **40**(12): p. 998-1002.
22. He, Z., et al., *NRF2 genotype improves endurance capacity in response to training*. Int J Sports Med, 2007. **28**(9): p. 717-21.
23. He, Z., et al., *Is there an association between PPARGC1A genotypes and endurance capacity in Chinese men?* Scand J Med Sci Sports, 2008. **18**(2): p. 195-204.
24. He, Z.-H., et al., *Are calcineurin genes associated with endurance phenotype traits?* European Journal of Applied Physiology, 2010. **109**(3): p. 359-369.
25. He, Z.H., et al., *Polymorphisms in the calcineurin genes are associated with the training responsiveness of cardiac phenotypes in Chinese young adults*. Eur J Appl Physiol, 2010. **110**(4): p. 761-7.
26. Leon, A.S., et al., *Association of apolipoprotein E polymorphism with blood lipids and maximal oxygen uptake in the sedentary state and after exercise training in the HERITAGE family study*. Metabolism, 2004. **53**(1): p. 108-16.
27. McPhee, J.S., et al., *HIF1A P582S gene association with endurance training responses in young women*. Eur J Appl Physiol, 2011. **111**(9): p. 2339-47.
28. Pickering, C., et al., *The magnitude of Yo-Yo test improvements following an aerobic training intervention are associated with total genotype score*. PLoS One, 2018. **13**(11): p. e0207597.
29. Prior, S., et al., *Sequence variation in hypoxia-inducible factor 1 (HIF1A): association with maximal oxygen consumption*. Physiol Genomics 15: 20–26, 2003., 2003. **15**: p. 20-26.
30. Prior, S.J., et al., *DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption*. Am J Physiol Heart Circ Physiol, 2006. **290**(5): p. H1848-55.
31. RANKINEN, T., et al., *The Na K ATPase 2 gene and trainability of cardiorespiratory endurance: the HERITAGE Family Study*. J. Appl. Physiol., 2000. **88**: p. 346–351.
32. Rankinen, T., et al., *AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study*. Am J Physiol Heart Circ Physiol, 2000. **279**: p. 368-374.
33. Rico-Sanz, J., et al., *Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family study*. Physiol Genomics 2003. **14**: p. 161–166.,
34. Ring-Dimitriou, S., et al., *Does Genetic Variation in PPARGC1A Affect Exercise-Induced Changes in Ventilatory Thresholds and Metabolic Syndrome?* Journal of Exercise Physiology Online, 2014. **17**(2): p. 1-18.
35. Rivera, M.A., et al., *Muscle-specific creatine kinase gene polymorphism and VO<sub>2</sub>max in the HERITAGE Family Study*. Med Sci Sports Exerc, 1997. **29**(10): p. 1311-7.
36. Sonna, L.A., et al., *Angiotensin-converting enzyme genotype and physical performance during US Army basic training*. J Appl Physiol (1985), 2001. **91**(3): p. 1355-63.

37. Stefan, N., et al., *Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention*. J Clin Endocrinol Metab, 2007. **92**(5): p. 1827-33.
38. Steinbacher, P., et al., *The single nucleotide polymorphism Gly482Ser in the PGC-1alpha gene impairs exercise-induced slow-twitch muscle fibre transformation in humans*. PLoS One, 2015. **10**(4): p. e0123881.
39. Woods, D., et al., *Endurance enhancement related to the human angiotensin I-converting enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training*. European Journal of Applied Physiology, 2001. **86**(3): p. 240-244.
40. Yoo, J., et al., *Genetic polymorphisms to predict gains in maximal O2 uptake and knee peak torque after a high intensity training program in humans*. Eur J Appl Physiol, 2016. **116**(5): p. 947-57.
41. Yu, B., et al., *Association of apolipoprotein E polymorphism with maximal oxygen uptake after exercise training: a study of Chinese young adult*. Lipids in Health and Disease, 2014. **13**(40).
42. Zarebska, A., et al., *THE GSTP1 c.313A>G POLYMORPHISM MODULATES THE CARDIORESPIRATORY RESPONSE TO AEROBIC TRAINING*. Biol Sport, 2014. **31**(4): p. 261-6.
43. Zhou, D.Q., et al., *Muscle-specific creatine kinase gene polymorphism and running economy responses to an 18-week 5000-m training programme*. Br J Sports Med, 2006. **40**(12): p. 988-91.
44. Ash, G.I., et al., *Glucocorticoid Receptor (NR3C1) Variants Associate with the Muscle Strength and Size Response to Resistance Training*. PLoS One, 2016. **11**(1): p. e0148112.
45. Charbonneau, D.E., et al., *ACE genotype and the muscle hypertrophic and strength responses to strength training*. Med Sci Sports Exerc, 2008. **40**(4): p. 677-83.
46. Clarkson, P.M., et al., *ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women*. J Appl Physiol (1985), 2005. **99**(1): p. 154-63.
47. Delmonico, M.J., et al., *Alpha-actinin-3 (ACTN3) R577X polymorphism influences knee extensor peak power response to strength training in older men and women*. J Gerontol A Biol Sci Med Sci, 2007. **62**(2): p. 206-12.
48. Erskine, R.M., et al., *Do PTK2 gene polymorphisms contribute to the interindividual variability in muscle strength and the response to resistance training? A preliminary report*. J Appl Physiol (1985), 2012. **112**(8): p. 1329-34.
49. Erskine, R.M., et al., *The individual and combined influence of ACE and ACTN3 genotypes on muscle phenotypes before and after strength training*. Scand J Med Sci Sports, 2014. **24**(4): p. 642-8.
50. Folland, J., et al., *Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload*. Exp Physiol, 2000. **85**(5): p. 575-9.
51. Giaccaglia, V., et al., *Interaction between angiotensin converting enzyme insertion/deletion genotype and exercise training on knee extensor strength in older individuals*. Int J Sports Med, 2008. **29**(1): p. 40-4.
52. Harmon, B.T., et al., *CCL2 and CCR2 variants are associated with skeletal muscle strength and change in strength with resistance training*. J Appl Physiol (1985), 2010. **109**(6): p. 1779-85.
53. He, L., et al., *Effects of 8 weeks of moderate-intensity resistance training on muscle changes in postmenopausal women with different angiotensin-converting enzyme insertion/deletion polymorphisms of interest*. Menopause, 2019. **26**(8): p. 899-905.

54. Hong, A.R., S.M. Hong, and Y.A. Shin, *Effects of resistance training on muscle strength, endurance, and motor unit according to ciliary neurotrophic factor polymorphism in male college students*. J Sports Sci Med, 2014. **13**(3): p. 680-8.
55. Jamshidi, Y., et al., *Peroxisome proliferator--activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension*. Circulation, 2002. **105**(8): p. 950-5.
56. Jones, N., et al., *A genetic-based algorithm for personalized resistance training*. Biol Sport, 2016. **33**(2): p. 117-26.
57. Keogh, J.W., et al., *ACE and UCP2 gene polymorphisms and their association with baseline and exercise-related changes in the functional performance of older adults*. PeerJ, 2015. **3**: p. e980.
58. Kostek, M.C., et al., *Muscle strength response to strength training is influenced by insulin-like growth factor 1 genotype in older adults*. J Appl Physiol (1985), 2005. **98**(6): p. 2147-54.
59. Li, X., et al., *The A55T and K153R polymorphisms of MSTN gene are associated with the strength training-induced muscle hypertrophy among Han Chinese men*. J Sports Sci, 2014. **32**(9): p. 883-91.
60. Pereira, A., et al., *ACE I/D and ACTN3 R/X polymorphisms as potential factors in modulating exercise-related phenotypes in older women in response to a muscle power training stimuli*. Age (Dordr), 2013. **35**(5): p. 1949-59.
61. Pescatello, L.S., et al., *ACE ID genotype and the muscle strength and size response to unilateral resistance training*. Med Sci Sports Exerc, 2006. **38**(6): p. 1074-81.
62. Pistilli, E.E., et al., *Interleukin-15 and interleukin-15R alpha SNPs and associations with muscle, bone, and predictors of the metabolic syndrome*. Cytokine, 2008. **43**(1): p. 45-53.
63. Riechman, S.E., et al., *Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses*. J Appl Physiol (1985), 2004. **97**(6): p. 2214-9.
64. Sprouse, C., et al., *SLC30A8 nonsynonymous variant is associated with recovery following exercise and skeletal muscle size and strength*. Diabetes, 2014. **63**(1): p. 363-8.
65. Thomis, M.A., et al., *Exploration of myostatin polymorphisms and the angiotensin-converting enzyme insertion/deletion genotype in responses of human muscle to strength training*. Eur J Appl Physiol, 2004. **92**(3): p. 267-74.
66. Walsh, S., et al., *CNTF 1357 G -> A polymorphism and the muscle strength response to resistance training*. J Appl Physiol (1985), 2009. **107**(4): p. 1235-40.
67. Walsh, S., et al., *Leptin and leptin receptor genetic variants associate with habitual physical activity and the arm body composition response to resistance training*. Gene, 2012. **510**(1): p. 66-70.
68. Zadro, J.R., et al., *The Beneficial Effects of Physical Activity: Is It Down to Your Genes? A Systematic Review and Meta-Analysis of Twin and Family Studies*. Sports Med Open, 2017. **3**(1): p. 4.
69. Ghosh, S., et al., *Integrative pathway analysis of a genome-wide association study of (V)O(2max) response to exercise training*. J Appl Physiol (1985), 2013. **115**(9): p. 1343-59.
70. Petr, M., et al., *The Role of Peroxisome Proliferator-Activated Receptors and Their Transcriptional Coactivators Gene Variations in Human Trainability: A Systematic Review*. Int J Mol Sci, 2018. **19**(5).

71. Franks, P.W., et al., *PGC-1alpha genotype modifies the association of volitional energy expenditure with [OV0312]O2max*. *Med Sci Sports Exerc*, 2003. **35**(12): p. 1998-2004.
72. Wang, Y.X., et al., *Regulation of muscle fiber type and running endurance by PPARdelta*. *PLoS Biol*, 2004. **2**(10): p. e294.
73. Skogsberg, J., et al., *Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men*. *Arterioscler Thromb Vasc Biol*, 2003. **23**(4): p. 637-43.
74. Karpe, F. and E.E. Ehrenborg, *PPARdelta in humans: genetic and pharmacological evidence for a significant metabolic function*. *Curr Opin Lipidol*, 2009. **20**(4): p. 333-6.
75. Franks, P.W., et al., *Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program*. *Diabetologia*, 2014. **57**(3): p. 485-90.
76. He, Z.H., et al., *PGC-related gene variants and elite endurance athletic status in a Chinese cohort: a functional study*. *Scand J Med Sci Sports*, 2015. **25**(2): p. 184-95.
77. Lin, J., et al., *Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres*. *Nature*, 2002. **418**(6899): p. 797-801.
78. Huang, T., Y. Shu, and Y.D. Cai, *Genetic differences among ethnic groups*. *BMC Genomics*, 2015. **16**: p. 1093.
79. Sarzynski, M.A., S. Ghosh, and C. Bouchard, *Genomic and transcriptomic predictors of response levels to endurance exercise training*. *J Physiol*, 2017. **595**(9): p. 2931-2939.
80. Lobo, S., B.M. Wiczer, and D.A. Bernlohr, *Functional analysis of long-chain acyl-CoA synthetase 1 in 3T3-L1 adipocytes*. *J Biol Chem*, 2009. **284**(27): p. 18347-56.
81. Timmons, J.A., et al., *Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans*. *J Appl Physiol* (1985), 2010. **108**(6): p. 1487-96.
82. Del Coso, J., et al., *More than a 'speed gene': ACTN3 R577X genotype, trainability, muscle damage, and the risk for injuries*. *Eur J Appl Physiol*, 2019. **119**(1): p. 49-60.
83. Sparks, M.A., et al., *Classical Renin-Angiotensin system in kidney physiology*. *Compr Physiol*, 2014. **4**(3): p. 1201-28.
84. Rigat, B., et al., *An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels*. *J Clin Invest*, 1990. **86**(4): p. 1343-6.
85. Alves, C.R., et al., *Aerobic exercise training differentially affects ACE C- and N-domain activities in humans: Interactions with ACE I/D polymorphism and association with vascular reactivity*. *J Renin Angiotensin Aldosterone Syst*, 2018. **19**(2): p. 1470320318761725.
86. Ma, F., et al., *The association of sport performance with ACE and ACTN3 genetic polymorphisms: a systematic review and meta-analysis*. *PLoS One*, 2013. **8**(1): p. e54685.
87. Gineviciene, V., et al., *Genetic variation of the human ACE and ACTN3 genes and their association with functional muscle properties in Lithuanian elite athletes*. *Medicina (Kaunas)*, 2011. **47**(5): p. 284-90.
88. Pescatello, L.S., et al., *Highlights from the functional single nucleotide polymorphisms associated with human muscle size and strength or FAMuSS study*. *Biomed Res Int*, 2013. **2013**: p. 643575.
89. Loro, E., S. Bisetto, and T.S. Khurana, *Mitochondrial ultrastructural adaptations in fast muscles of mice lacking IL15RA*. *J Cell Sci*, 2018. **131**(21).

90. Khramtsova, E.A., L.K. Davis, and B.E. Stranger, *The role of sex in the genomics of human complex traits*. Nat Rev Genet, 2019. **20**(3): p. 173-190.
91. Landen, S., et al., *Genetic and epigenetic sex-specific adaptations to endurance exercise*. Epigenetics, 2019: p. 1-13.
92. Chanoock, S.J., et al., *Replicating genotype–phenotype associations*. Nature, 2007. **447**: p. 655-660.
93. Karczewski, K.J. and M.P. Snyder, *Integrative omics for health and disease*. Nat Rev Genet, 2018. **19**(5): p. 299-310.
94. Sun, Y.V. and Y.J. Hu, *Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases*. Adv Genet, 2016. **93**: p. 147-90.
95. Battle, A., et al., *Genomic variation. Impact of regulatory variation from RNA to protein*. Science, 2015. **347**(6222): p. 664-7.
96. Veyrieras, J.B., et al., *High-resolution mapping of expression-QTLs yields insight into human gene regulation*. PLoS Genet, 2008. **4**(10): p. e1000214.
97. Taylor, D.L., et al., *Integrative analysis of gene expression, DNA methylation, physiological traits, and genetic variation in human skeletal muscle*. Proc Natl Acad Sci U S A, 2019. **116**(22): p. 10883-10888.
98. Nicolae, D.L., et al., *Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS*. PLoS Genet, 2010. **6**(4): p. e1000888.
99. Keildson, S., et al., *Expression of phosphofructokinase in skeletal muscle is influenced by genetic variation and associated with insulin sensitivity*. Diabetes, 2014. **63**(3): p. 1154-65.
100. Sonnemann, K.J., et al., *Cytoplasmic gamma-actin is not required for skeletal muscle development but its absence leads to a progressive myopathy*. Dev Cell, 2006. **11**(3): p. 387-97.
101. Dunham, I., et al., *An integrated encyclopedia of DNA elements in the human genome*. Nature, 2012. **489**(7414): p. 57-74.
102. Fishilevich, S., et al., *GeneHancer: genome-wide integration of enhancers and target genes in GeneCards*. Database (Oxford), 2017. **2017**.
103. Jinek, M., et al., *A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity*. Science, 2012. **337**(6096): p. 816-821.
104. Chen, Z., et al., *Functional Screening of Candidate Causal Genes for Insulin Resistance in Human Preadipocytes and Adipocytes*. Circ Res, 2019.
105. Wang, G., et al., *The Future of Genomic Research in Athletic Performance and Adaptation to Training*. Med Sport Sci, 2016. **61**: p. 55-67.
106. Yan, X., et al., *The gene SMART study: method, study design, and preliminary findings*. BMC Genomics, 2017. **18**(Suppl 8): p. 821.
107. Baliga, N.S., et al., *The State of Systems Genetics in 2017*. Cell Syst, 2017. **4**(1): p. 7-15.

## Chapter 4: Variability in physiological fitness and skeletal muscle mitochondria-related phenotypes in response to HIIT

This chapter is based on the following article currently under review in a peer-reviewed journal. Alvarez Romero, J., et al., Physiological and mitochondrial phenotypes in response to high intensity interval training in male and female skeletal muscle: The Gene SMART Study. *Medicine & Science in Sports & Exercise* 2022.



THE NEW WAY TO DO UNI

### OFFICE FOR RESEARCH TRAINING, QUALITY AND INTEGRITY

#### DECLARATION OF CO-AUTHORSHIP AND CO-CONTRIBUTION: PAPERS INCORPORATED IN THESIS


*This declaration is to be completed for each conjointly authored publication and placed at the beginning of the thesis chapter in which the publication appears.*

##### 1. PUBLICATION DETAILS (to be completed by the candidate)

Title of Paper/Journal/Book:	Physiological and mitochondrial phenotypes in response to high intensity interval training in male and female skeletal muscle: The Gene SMART study Submitted: under review		
Surname:	Alvarez Romero	First name:	Javier
Institute:	Institute for Health and Sport	Candidate's Contribution (%):	35
Status:	Accepted and in press: <input checked="" type="checkbox"/> Date: 13/12/2022		
	Published: <input type="checkbox"/> Date:		

##### 2. CANDIDATE DECLARATION

I declare that the publication above meets the requirements to be included in the thesis as outlined in the HDR Policy and related Procedures – [policy.vu.edu.au](http://policy.vu.edu.au).

 javier	Digitally signed by javier Date: 2023.01.09 18:04:20 +11'00'	1/10/2023
Signature		Date

##### 3. CO-AUTHOR(S) DECLARATION

In the case of the above publication, the following authors contributed to the work as follows:

The undersigned certify that:

1. They meet criteria for authorship in that they have participated in the conception, execution or interpretation of at least that part of the publication in their field of expertise;
2. They take public responsibility for their part of the publication, except for the responsible author who accepts overall responsibility for the publication;

PO Box 14428, Melbourne,  
Vic 8001, Australia  
+61 3 9919 6100

Victoria University ABN 83776954731  
CRICOS Provider No. 00124K (Melbourne),  
02475D (Sydney), RTO 3113



- 3. There are no other authors of the publication according to these criteria;
- 4. Potential conflicts of interest have been disclosed to a) granting bodies, b) the editor or publisher of journals or other publications, and c) the head of the responsible academic unit; and
- 5. The original data will be held for at least five years from the date indicated below and is stored at the following location(s):

Name(s) of Co-Author(s)	Contribution (%)	Nature of Contribution	Signature	Date
Patrice Jones	20%	Writing and editing the manuscript		10/01/2023
Danielle Hiam	15%	Data collection, writing and editing the manuscript		10/01/2023
Macsue Jacques	15%	Data collection, writing and editing the manuscript		31/01/2023
Shanie Landen	3%	Writing and editing the manuscript		27/01/2023
Andrew Garnham	2%	Data collection		25/1/2023
Gad Abraham	2%	Writing and editing the manuscript		4/2/2023
Nir Eynon	5%	Writing and editing the manuscript		4/2/2023

PO Box 14428, Melbourne,  
Vic 8001, Australia  
+61 3 99196100

Victoria University ABN 83776954731  
CRICOS Provider No. 00124K (Melbourne)  
02475D (Sydney), RTO 3113

## 4.1 Introduction

Significant inter-individual differences exist in both physiological and molecular responses to any given exercise training [1-3]. Considerable variability is observed in many physiological parameters [4], including maximal oxygen uptake ( $VO_{2max}$ ) [5, 6], resting heart rate [6], exercise heart rate [6], aerobic and anaerobic thresholds (LT) [6, 7], and muscle mass and strength [8, 9]. Molecular phenotypes such as resting muscle glycogen content, muscle enzyme activity [10], and mitochondrial function have also shown large variability [11].

Variability identified in exercise training studies stems from multiple sources, including technical and biological factors as well as different baseline levels between individuals [12]. This variability is minimised when a control period is included in the study design and compared to the intervention period [13, 14]. A control period refers to exposing the same individual to a pre-intervention period, in which data is collected before and after [13, 14]. This data can then be correlated against the baseline data (immediately before starting the intervention), ensuring no significant changes in the tested phenotype. Thus, we can conclude that any phenotypic alteration post-exercise is attributed to the exercise intervention and not due to day-to-day variability or technical error [12]. Previous studies have addressed the changes in molecular and physiological phenotypes after the intervention, e.g. the mean individual-difference in pre-post exercise responses [15]. In addition, multiple studies have compared exercise responses for the training group vs a control group [16]. However, it is unknown if these changes would remain when a control period is applied.

Skeletal muscle mitochondria are highly responsive to exercise [17], with improvements in quantity (content) and quality (structure and function) as typical outcomes of an exercise

intervention [18, 19]. Prior research has examined changes in individual mitochondrial markers in response to exercise [20-25]; however, examining a composite measure is crucial to assess mitochondrial health, as changes in mitochondrial content are a compensatory mechanism for changes in mitochondrial quality [26, 27]. Thus, mitochondrial health may reveal insights around mitochondrial adaptations in response to exercise. The mitochondrial health index (MHI) mathematically outperformed individual markers of mitochondrial function and content in relation to caregiver status [11]. This study confirmed that combining mitochondrial markers in leucocytes had higher effect size (0.63) than individual components of the mitochondrial energy production machinery ( $0.23 \pm 0.12$ ). Thus, we aim to validate these results in skeletal muscle. The MHI combines four measures of mitochondrial function and content into a composite measure that integrates nuclear and mitochondrial DNA encoded measurements. Mitochondrial function is represented by key respiratory chain enzymes activity, including succinate dehydrogenase (SDH) and cytochrome C oxidase (COX) [28]. Mitochondrial content is represented by ii) citrate synthase (CS) [29] activity and mitochondria (mtDNA) copy number [30].

The aim of this study was to identify changes in physiological and mitochondrial markers in relative large Australian adult cohort (n=112) following four weeks of high-intensity interval training (HIIT), relative to a four weeks of a control period.

## **4.2 Methods**


### **4.2.1 Participants**

This study was performed on participants from the Gene SMART (Skeletal Muscle Adaptive Response to Training) cohort. A detailed methodology of the Gene SMART study has been previously published [31]. Briefly, 92 healthy males and 20 females aged 18 to 45 years with a body mass index (BMI) of  $25.46 \pm 3.29 \text{ kg m}^2$  were recruited to complete a four weeks of HIIT intervention. The study was approved by the Human Ethics Committee at

Victoria University (HRE13-223, and HRE 21-122), and written consent was obtained from each participant. A detailed medical history was obtained by questionnaire. Participants were excluded from the study if they had definite or possible heart disease, chronic respiratory condition, musculoskeletal problems that would restrict cycling, uncontrolled endocrine and metabolic disorders, or diabetes requiring insulin or other therapies.

#### 4.2.2 Study design

The study design consisted of six steps (**Figure 1**): 1) screening and familiarisation, 2) baseline testing before control period, 3) control period, 4) end of control and baseline testing pre-exercise training intervention, 5) exercise intervention (HIIT), and 6) post-training testing. Throughout the study participants were asked to maintain their habitual dietary and physical activity patterns and refrain from strenuous exercise, caffeine, or alcohol consumption for at least 24 hours before the tests.



**Figure 4.1 Study design.** Abbreviations; graded exercise test (GXT), high-intensity interval training (HIIT), citrate synthase activity (CS), cytochrome c oxidase activity (COX), succinate dehydrogenase activity (SDH).

### 4.2.3 Graded-Exercise Tests (GXT) tests

Prior to commencing a four-week HIIT intervention, a subset of Gene SMART participants ( $n=29$ , 10 females and 19 males) completed a four weeks of a control phase, in which participants were not prescribed any training and were asked to continue with any regular exercise, diet, and sleep routine. Before commencing this control phase, a pre-control baseline assessment was completed involving two GXTs. Tests were performed on an electronically braked cycle ergometer (Lode-Excalibur sport, Groningen, the Netherlands) and consisted of 4-min stages separated by 30-sec rest periods until exhaustion.  $W_{\text{peak}}$  was determined from the GXTs as 105% of the maximum power reached in the last stage of the GXT [32]. The test started at 50 and 60 watts and increased by 25 or 30 watts in each subsequent stage for males and females respectively. When females were not able to get six stages in the first GXT, they started the tests at 25 watts. Capillary blood samples were taken at rest after each completed stage and immediately following exhaustion, and analysed by the YSI STAT plus system (Yellow Springs, Ohio, USA). LT was calculated by the modified DMAX method, which is determined by the point on the polynomial regression curve that yields the maximum perpendicular distance to the straight line connecting the first increase in lactate concentration above resting value and the final lactate point. When the difference between replicate GXT was less than 5%, the average of the two GXT tests were used to individualise exercise intensities; otherwise, the highest value was used. Following a 5-min rest, peak oxygen consumption ( $\text{VO}_{2\text{max}}$ ) was measured using a calibrated Quark CPTE metabolic system (COSMED, Rome, Italy). In this test, participants wore the COSMED face mask, and cycled for 3-min at a starting intensity of 50 or 60W (females and males, respectively) and then cycled at  $W_{\text{peak}}$  until exhaustion.

#### **4.2.4 Muscle biopsies**

During pre-control baseline testing, muscle samples were taken from the *vastus lateralis* by an experienced medical doctor. Following injection of a local anaesthetic (5 mL, 1% Xylocaine), incisions were made, and the biopsy needle was inserted. Muscle samples were collected with manual suction applied. Following collection, the samples (50–200 mg) were immediately blotted on filter paper to remove excess blood. The muscle was immediately snap frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$  for subsequent analyses.

#### **4.2.5 Dietary control (48h prior to muscle biopsies)**

Standardised meals were provided to participants for 48-hours before muscle and blood sampling. These diets were based on the Australian National Health and Medical Research Council NHMRC guidelines (15-20% protein, 50-55% carbohydrates, <30% fat and <10% of saturated fat) and adjusted for dietary restrictions and preferences. Participants were also asked to fast for a minimum of eight hours prior to the biopsy.

#### **4.2.6 Control period**

Following pre-control baseline testing, the defined subset of Gene SMART participants (n=29) completed a four-week control period, where no exercise interventions were conducted and participants were told to continue with their habitual day-to-day lifestyle for two weeks. Following this period, duplicate GXTs and a muscle biopsy were conducted following procedures defined above.

#### **4.2.7 Pre-HIIT baseline testing and HIIT intervention**

All participants (n=112) completed two GXTs and muscle sampling baseline assessments before beginning the HIIT intervention as described above. Participants then

commenced a four-week HIIT program, where they trained in the laboratory, under supervision, three times a week for four weeks. All training sessions were completed on an electronically braked cycle ergometer (Velotron, Racer Mate Inc, Seattle, USA) and were preceded by a 5-min warm-up at 50 W. Each session consisted of six to twelve 2-min intervals performed at different intensities ranging from 40 to 70% of ( $W_{\text{peak}} - \text{LT}$ ) above LT, and interspersed by 1-min recovery periods (work-to-rest ratio of 2:1). The number of intervals and the intensity were progressively increased to maintain progression. Testing and training sessions were interspersed over 48 hours to avoid overtraining. At the completion of the four weeks of HIIT, two post-intervention GXTs were performed and a further muscle sample was collected.

#### **4.2.8 Muscle derived mitochondrial health index (MHI)**

We present a comprehensive index of mitochondrial health that includes either changes in mitochondrial content as well as mitochondrial functional capacity (quality). Collected muscle samples were used to assess MHI, which was derived from separate analyses of succinate dehydrogenase (SDH), cytochrome c oxidase (COX), citrate synthase (CS) activity, and mitochondrial copy number (mtDNA) for each participant. SDH using a colorimetric SDH activity Assay kit (Abcam #228560) was measured according to the manufacturer's instructions. Samples were analysed in duplicate, and the absorbance was measured in kinetic mode at 600nm for 10-30min at 25°C. COX was assessed using a COX assay kit (Abcam, #ab239711). and manufacturer's instructions were followed The muscle lysate from the SDH analysis was used in the COX activity analysis. Samples were measured in triplicates and the plate was immediately read at a 500nm wavelength and continuously measured over a period of 30-45min. CS activity (mol/h/kg of protein) was measured in triplicates at 30°C and pH 7.5. Muscle samples were lysed in an ice-cold buffer ( $\text{KH}_2\text{PO}_4$  &  $\text{KHPO}_4$ ) using a TissueLyser II

(Qiagen). In all analyses described above if the coefficient of variance [33] was >10% for the duplicate or triplicate results, values were removed.

Mitochondrial copy number (mtDNA) was determined in quadruplicates using multiplex qPCR. This method allows for simultaneous amplification of a mitochondrial (ND1) and a nuclear amplicon (RNaseP, Thermofisher Scientific #4403328) to verify their relative abundance (Krishnan et al. 2007; Picard et al. 2018). The assay was run on a QuantStudio™ 7 Flex Real-Time PCR System. The average CV for mtDNA Cts was 1.02%. Data was manually curated, and cases where samples yielded a standard deviation > 0.3 were removed.

The sequences for the ND1 amplicon (IDT) are as follows:

Forward primer (300nM), 5'CCCTAAAACCCGCCACATCT3';

Reverse primer (300nM): 5'GAGCGATGGTGAGAGCTAAGGT3'; and

Probe (100nM): 5'FAMCCATCACCTCTACATCACCGCCC-TAMRA3'.

To calculate MHI [11], the following formula was used:

$$\left[ \frac{\text{Energy production capacity}}{\text{Mitochondrial content}} \right] = \left[ \frac{\text{Complex II (SDH)} + \text{Complex IV (COX)}}{\text{CS} + \text{mtCN}} \right] * 100$$

#### 4.2.9 Statistical analysis

Statistical analysis was performed using R version 4.1.0 [34] using a linear mixed model of the form:

$$\text{Outcome} = \text{Delta change} \sim \text{sex} + \text{age} + \text{timepoint} + (1|ID)$$


where the outcome variable was either the change in physiological measure of fitness ( $W_{\text{peak}}$  or LT or  $VO_{2\text{max}}$ ) or the mitochondrial markers (CS activity, mtCN, SDH, COX) and the

composite measure (MHI), the timepoint was a numeric variable (0 (PRE intervention) or 1 (post intervention)). The mixed model estimates whether there were changes in outcome at the group level after four weeks of control vs. intervention period. Pearson correlations between changes in physiological variables and mitochondrial makers were also formulated to investigate any associations between them.

### **4.3 Results**

#### **4.3.1 Changes in physiological and mitochondrial markers following a control period**


No significant changes were observed in any physiological measurements following the control period (**Figure 2**). Further, when examining changes between the end of the control phase and pre-HIIT baseline testing, there were also no differences in any of the physiological variables. For mitochondrial markers, when comparing changes across the end of control Vs HIIT baseline we did not observe changes in mtCN and MHI (**Supplementary fig. 1**); however, we observed changes in SDH, CS and COX (**Supplementary fig. 1**).



**Figure 4.2** Changes in physiological variables over four weeks of control and HIIT exercise periods. Box plots show the mean changes over four weeks of the control period and four weeks of HIIT for a) power peak, b) lactate threshold and c) VO<sub>2max</sub>. Asterisks represent p-value < 0.05 and ‘ns’ represents non-significant results. Abbreviations: Lactate threshold (LT), power peak (W<sub>peak</sub>), start of control period (CON), end of control period (ENDCON), start of HIIT intervention (PRE), and following HIIT intervention (4WP).

### 4.3.2 Changes in physiological variables following HIIT

Following four weeks of HIIT, W<sub>peak</sub> (p= 0.001, **Figure 2a**) and LT (p = 0.001, **Figure 2b**) was significantly increased, with no significant change found in VO<sub>2max</sub> (p < 0.05, **Figure 2c**).




**Figure 4.3** Changes in mitochondrial markers over four weeks of control and four weeks of high intensity interval training (HIIT). Box plots show the mean changes over four weeks of the control period and four weeks of HIIT for a) CS, b) SDH, c) COX, d) mtCN, and e) MHI. Asterisks represent p-value < 0.05 and “ns” represents non-significant results. Abbreviations: Citrate synthase activity (CS), cytochrome c oxidase activity (COX), succinate dehydrogenase activity (SDH), mitochondria copy number (mtCN), mitochondrial health index (MHI), start of control period (CON), end of control period (ENDCON), start of HIIT intervention (PRE), and following HIIT intervention (4WP).

### 4.3.3 Changes in mitochondrial markers following HIIT


We did not observe significant changes in the MHI following four weeks of HIIT (Figure 3e). When changes in mitochondrial markers were analysed separately, there was a significant increase in CS ( $p < 0.05$ , Figure 3a) and COX ( $p < 0.05$ , Figure 3c).

#### 4.3.4 Associations between changes in physiological and mitochondrial markers


We investigated whether there were associations between changes in the physiological and mitochondrial markers following four weeks of HIIT. Changes in LT were found to be positively correlated with changes in both CS ( $r = 0.2$ ,  $p = 0.014$ , **Figure 4a**) and COX ( $r = 0.19$ ,  $p = 0.019$ , **Figure 4b**) following four weeks of HIIT. Significant correlations were found between increased changes in  $VO_{2max}$  and increased changes in two mitochondrial markers, CS ( $r = 0.24$ ,  $p = 0.0025$ , **Figure 5a**) and SDH ( $r = 0.20$ ,  $p = 0.011$ , **Figure 5c**), following four weeks of HIIT. Finally, a significant correlation was found between increased changes in  $W_{peak}$  and changes in CS following four weeks of HIIT ( $r = 0.24$ ,  $p = 0.0024$ , **Figure 6a**). No significant associations were found between  $W_{peak}$  changes and changes in the other assessed mitochondrial markers **Figure 6b-e**.



**Figure 4.4** Correlations between changes in mitochondrial markers and changes in lactate threshold (LT) following four weeks of high intensity interval training (HIIT). Scatter plots of correlations between changes in lactate threshold and changes in A) CS, B) COX, C) SDH, D) mtCN and E) MHI following four weeks of HIIT. Abbreviations: lactate threshold (LT), citrate synthase activity (CS), cytochrome c oxidase activity (COX), succinate dehydrogenase (SDH), mitochondria copy number (mtCN), and mitochondrial health index (MHI).



**Figure 4.5** Correlations between changes in mitochondrial markers and changes in VO<sub>2max</sub> following four weeks of high intensity interval training (HIIT). Scatter plots of correlations between changes in maximal VO<sub>2max</sub> and changes in a) CS, b) COX, c) SDH, d) mtCN and e) MHI following four weeks of HIIT are shown. Abbreviations: maximal consumption capacity (VO<sub>2max</sub>), citrate synthase activity (CS), cytochrome c oxidase activity (COX), succinate dehydrogenase (SDH), mitochondria copy number (mtCN), and mitochondrial health index (MHI).



**Figure 4.6. Correlations between changes in mitochondrial markers and changes in peak power ( $W_{\text{peak}}$ ) following four weeks of high intensity interval training (HIIT).** Scatter plots of correlations between changes in  $W_{\text{peak}}$  and changes in a) CS, b) COX, c) SDH, d) mtCN and e) MHI following 4-weeks of HIIT are shown. Abbreviations: peak power ( $W_{\text{peak}}$ ), citrate synthase activity (CS), cytochrome c oxidase activity (COX), succinate dehydrogenase (SDH), mitochondria copy number (mtCN), and mitochondrial health index (MHI).

#### 4.4 Discussion

In a relatively large sample of males and females ( $n=112$ ) we have provided an extensive analysis of changes in physiological variables and mitochondrial markers following four weeks of control vs HIIT intervention. We report a significant increase in two physiological phenotypes, LT and  $W_{\text{peak}}$ , following four weeks of HIIT. This suggests that observed changes in physiological variables, LT and  $W_{\text{peak}}$ , were induced by the HIIT intervention and not due

to external factors. In addition, increases were observed in two mitochondrial markers, CS and COX, after four weeks of HIIT. We then integrated key mitochondrial measurements into MHI to detect broader mitochondrial responses after exercise. However, we did not observe changes in MHI after four weeks of the HIIT intervention. We found positive correlations between some physiological and molecular markers. Specifically, increases in LT were correlated with increases in CS and COX. This correlation suggests that training near the lactate threshold affects also mitochondrial markers, and affects them in an independent manner [35]. Increases in  $VO_{2max}$  were correlated with increases in CS and SDH. Thus, these results suggests that increases in mitochondrial skeletal muscle COX activity are not necessary for increases in  $VO_{2max}$ . Finally, increases in  $W_{peak}$  were correlated with an increase in CS activity following four weeks of HIIT. This correlation is supported for a previous HIIT study where CS was also increased [36]. In general, these correlations suggests that HIIT affects physiological measurements and mitochondrial enzymes independently and not in parallel, as suggested previously [37].

The most common method to investigate exercise response variability is to compare an intervention group with an independent/separate control group [16]. However, there are limitations to this approach as observed differences cannot be truly attributed to the exercise intervention alone, as they may be due to individual variability between the control and exercise group. [16]. We aimed to address this limitation by including a four week control period, followed by four weeks of HIIT in the same individuals to minimise *inter-individual* variability during the control phase and in response to a HIIT training intervention.

In line with prior studies, we observed changes in measures of mitochondrial content following HIIT [38]. Here, we examined the usefulness of measuring mitochondrial health via

a composite measure MHI in skeletal muscle, as it was previously reported to be useful in blood [11]. Following four weeks of HIIT, we did not observe significant changes in skeletal muscle MHI. This finding was unexpected, given that measures used to derive MHI, mitochondrial function and content, are shown to upregulated in skeletal muscle by exercise [20, 39]. When examining each mitochondrial measurements individually, we found an increase in CS activity and COX [40, 41]; however, we did not observe increases in either SDH or mtCN. This may be due to the length of the training intervention, as previous studies with a training period of 8 weeks found SDH activity increased more than 27% after an interval training intervention, and more than 20% increase after a continuous exercise intervention [42].

We did not observe changes in mtCN after four weeks of HIIT. Our findings are supported because mtCN is weakly correlated with mitochondrial function or mitochondrial content [43]. We observed significant increases in mitochondrial markers (CS, SDH and COX) when comparing changes across the end of control period vs HIIT baseline testing (**supplementary figure 4.1**). This finding could be because the analysis was performed separately (possible batch effect). Nevertheless, we addressed the potential impact for these outcomes, putting the timepoint and batch as covariables in our statistical model. In addition, we did not see changes in the CON period, suggesting that changes after the HIIT intervention are accurate and not due to day-to-day variability. It is also known that enzymatic activity varies considerably within subjects according to the intracellular enzyme state [44]. We also minimized the possible technical variability, removing any variance >10% in duplicate results.

In this study we noted that HIIT intervention consistently affects mitochondrial content and physiological markers. Increases in CS activity were consistently associated with increases in  $VO_{2max}$ , LT and  $W_{peak}$ . This finding is interesting given CS is recognised as a robust marker

for mitochondrial content [20, 38]. In addition, we found that increase in LT is associated with an increase in COX activity, with this finding plausible given COX is the primary site of cellular oxygen consumption and is essential for aerobic energy generation in the form of ATP [45]. In addition this finding is supported due to skeletal muscle mitochondrial adaptations being largely dependent on exercise intensity [46]. These findings are consistent with previous results when using CS or COX activity as biomarkers of the skeletal muscle oxidative adaptation to a training intervention and a relationship between changes in aerobic capacity [40, 41]. In addition, CS activity has been associated with mitochondrial content, and is shown to be influenced by the oxidation of substrates and complex IV [43]. These findings may explain the presented relationships between CS and COX and physiological measures of aerobic capacity ( $VO_{2max}$ , LT,  $W_{peak}$ ) Finally, we found a correlation between SDH and  $VO_{2max}$ . This is consistent with previous studies where increases in  $VO_{2max}$  were clearly correlated with increases in SDH in heart failure patients, healthy participants, and professional cyclists [47, 48].

A limitation of this study is that we found significant differences in mitochondrial markers when comparing CONEND vs PRE (supplementary figure 4.1), and although we conducted the analysis in separated batches that may explain this, we also considered that batch and time point are covariables and we cannot explore this further. Also, not all participants undertook the control period; hence, the number of participants in each analysis was different (29 for CON group and 112 for PRE).

#### **4.5 Conclusion**

We found significant changes in several physiological and mitochondrial variables following four weeks of HIIT. We also identified consistent positive correlations between

mitochondrial markers (CS, SDH, and COX) and physiological variables ( $VO_{2max}$ ,  $W_{peak}$ , LT). Including a control period in the same individuals that completed the HIIT intervention allowed us to perform a direct comparison of the physiological and mitochondrial measurements and we can conclude that changes are likely due to the HIIT intervention. This study design highlights the value of including a control period in exercise studies. Compensatory mechanisms may affect the variability across the mitochondrial variables as reported here with COX and CS. However, further studies are needed to establish such mechanisms in exercise responses.

## 4.6 References

1. Bouchard, C., *Human adaptability may have a genetic basis*. ealth Risk Estimation, Risk Reduction and Health Promotion. , 1983: p. 463-476.
2. Bouchard, C., *DNA Sequence Variations Contribute to Variability in Fitness and Trainability*. Med Sci Sports Exerc, 2019. **51**(8): p. 1781-1785.
3. Jacques, M., et al., *Mitochondrial respiration variability and simulations in human skeletal muscle: The Gene SMART study*. FASEB J, 2020. **34**(2): p. 2978-2986.
4. Mann, T.N., R.P. Lamberts, and M.I. Lambert, *High responders and low responders: factors associated with individual variation in response to standardized training*. Sports Med, 2014. **44**(8): p. 1113-24.
5. Kohrt, W.M., et al., *Effects of gender, age, and fitness level on response of VO<sub>2</sub>max to training in 60-71 yr olds*. J Appl Physiol (1985), 1991. **71**(5): p. 2004-11.
6. Scharhag-Rosenberger, F., et al., *Differences in adaptations to 1 year of aerobic endurance training: individual patterns of nonresponse*. Scand J Med Sci Sports, 2012. **22**(1): p. 113-8.
7. McPhee, J.S., et al., *Inter-individual variability in adaptation of the leg muscles following a standardised endurance training programme in young women*. Eur J Appl Physiol, 2010. **109**(6): p. 1111-8.
8. Ahtiainen, J.P., et al., *Heterogeneity in resistance training-induced muscle strength and mass responses in men and women of different ages*. Age (Dordr), 2016. **38**(1): p. 10.
9. Jones, N., et al., *A genetic-based algorithm for personalized resistance training*. Biol Sport, 2016. **33**(2): p. 117-26.
10. McPhee, J.S., et al., *Variability in the magnitude of response of metabolic enzymes reveals patterns of co-ordinated expression following endurance training in women*. Exp Physiol, 2011. **96**(7): p. 699-707.
11. Picard, M., et al., *A Mitochondrial Health Index Sensitive to Mood and Caregiving Stress*. 2018(1873-2402 (Electronic)).
12. Voisin, S., et al., *Statistical Considerations for Exercise Protocols Aimed at Measuring Trainability*. Exerc Sport Sci Rev, 2019. **47**(1): p. 37-45.
13. Senn, S., *Three things that every medical writer should know about statistics*. Write Stuff, 2009. **18**(3): p. 159-162.
14. Hecksteden, A., et al., *How to Construct, Conduct and Analyze an Exercise Training Study?* Frontiers in physiology, 2018. **9**: p. 1007-1007.
15. Hecksteden, A., et al., *Individual response to exercise training - a statistical perspective*. Journal of Applied Physiology, 2015. **118**(12): p. 1450-1459.
16. Ross, R., et al., *Precision exercise medicine: understanding exercise response variability*. British Journal of Sports Medicine, 2019. **53**(18): p. 1141-1153.
17. Cardinale, D.A., et al., *Reliability of maximal mitochondrial oxidative phosphorylation in permeabilized fibers from the vastus lateralis employing high-resolution respirometry*. Physiol Rep, 2018. **6**(4).
18. Vargas-Ortiz, K., V. Perez-Vazquez, and M.H. Macias-Cervantes, *Exercise and Sirtuins: A Way to Mitochondrial Health in Skeletal Muscle*. Int J Mol Sci, 2019. **20**(11).
19. Drake, J.C., R.J. Wilson, and Z. Yan, *Molecular mechanisms for mitochondrial adaptation to exercise training in skeletal muscle*. FASEB J, 2016. **30**(1): p. 13-22.
20. Holloszy, J., *Biochemical Adaptations in Muscle*. J. Biol. Chem, 1967: p. 2278-82.

21. Russell, A.P., et al., *Skeletal muscle mitochondria: a major player in exercise, health and disease*. *Biochim Biophys Acta*, 2014. **1840**(4): p. 1276-84.
22. Pilegaard, H., B. Saltin, and P.D. Neuffer, *Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle*. *J Physiol*, 2003. **546**(Pt 3): p. 851-8.
23. Axelrod, C.L., et al., *Exercise training remodels human skeletal muscle mitochondrial fission and fusion machinery towards a pro-elongation phenotype*. *Acta Physiol (Oxf)*, 2019. **225**(4): p. e13216.
24. Pagano, A.F., et al., *Autophagy and protein turnover signaling in slow-twitch muscle during exercise*. *Med Sci Sports Exerc*, 2014. **46**(7): p. 1314-25.
25. Nielsen, J., et al., *Plasticity in mitochondrial cristae density allows metabolic capacity modulation in human skeletal muscle*. *J Physiol*, 2017. **595**(9): p. 2839-2847.
26. Giordano, C., et al., *Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy*. *Brain*, 2013. **137**(2): p. 335-353.
27. Yu-Wai-Man, P., et al., *OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules*. *Human Molecular Genetics*, 2010. **19**(15): p. 3043-3052.
28. Spinazzi, M., et al., *Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells*. *Nature Protocols*, 2012. **7**(6): p. 1235-1246.
29. Larsen, S., et al., *Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects*. *The Journal of Physiology*, 2012. **590**(14): p. 3349-3360.
30. Picard, M., *Blood mitochondrial DNA copy number: What are we counting?* *Mitochondrion*, 2021. **60**: p. 1-11.
31. Yan, X., et al., *The gene SMART study: method, study design, and preliminary findings*. *BMC Genomics*, 2017. **18**(Suppl 8): p. 821.
32. Sawyer, B.J., et al., *Supra-Versus Submaximal Cycle Ergometer Verification of VO(2max) in Males and Females*. *Sports (Basel)*, 2020. **8**(12).
33. Fuchsberger, C., et al., *The genetic architecture of type 2 diabetes*. *Nature*, 2016. **536**(7614): p. 41-47.
34. Kuznetsova, A., P.B. Brockhoff, and R.H.B. Christensen, *lmerTest Package: Tests in Linear Mixed Effects Models*. *Journal of Statistical Software*, 2017. **82**(13): p. 1 - 26.
35. Evertsen, F., et al., *Effect of training on the activity of five muscle enzymes studied on elite cross-country skiers*. *Acta physiologica Scandinavica*, 1999. **167**(3): p. 247-257.
36. Chrøis, K.M., et al., *Mitochondrial adaptations to high intensity interval training in older females and males*. *European Journal of Sport Science*, 2020. **20**(1): p. 135-145.
37. Henriksson, J. and J.S. Reitman, *Time course of changes in human skeletal muscle succinate dehydrogenase and cytochrome oxidase activities and maximal oxygen uptake with physical activity and inactivity*. *Acta Physiol Scand*, 1977. **99**(1): p. 91-7.
38. MacInnis, M.J. and M.J. Gibala, *Physiological adaptations to interval training and the role of exercise intensity*. *The Journal of Physiology*, 2017. **595**(9): p. 2915-2930.
39. Wyckelsma, V.L., et al., *Preservation of skeletal muscle mitochondrial content in older adults: relationship between mitochondria, fibre type and high-intensity exercise training*. *J Physiol*, 2017. **595**(11): p. 3345-3359.
40. Vigelsø, A., N.B. Andersen, and F. Dela, *The relationship between skeletal muscle mitochondrial citrate synthase activity and whole body oxygen uptake adaptations in response to exercise training*. *Int J Physiol Pathophysiol Pharmacol*, 2014. **6**(2): p. 84-101.
41. Stepto, N.K., et al., *Short-Term Intensified Cycle Training Alters Acute and Chronic Responses of PGC1α and Cytochrome C Oxidase IV to Exercise in Human Skeletal Muscle*. *PLOS ONE*, 2012. **7**(12): p. e53080.

42. Henriksson, J. and J.S. Reitman, *Quantitative Measures of Enzyme Activities in Type I and Type II Muscle Fibres of Man after Training*. Acta Physiologica Scandinavica, 1976. **97**(3): p. 392-397.
43. Larsen, S., et al., *Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects*. J Physiol, 2012. **590**(14): p. 3349-60.
44. Prouteau, M. and R. Loewith, *Regulation of Cellular Metabolism through Phase Separation of Enzymes*. Biomolecules, 2018. **8**(4).
45. Timón-Gómez, A., et al., *Mitochondrial cytochrome c oxidase biogenesis: Recent developments*. Seminars in cell & developmental biology, 2018. **76**: p. 163-178.
46. MacInnis, M.J. and M.J. Gibala, *Physiological adaptations to interval training and the role of exercise intensity*. J Physiol, 2017. **595**(9): p. 2915-2930.
47. Bekedam, M.A., et al., *Maximum rate of oxygen consumption related to succinate dehydrogenase activity in skeletal muscle fibres of chronic heart failure patients and controls*. Clin Physiol Funct Imaging, 2003. **23**(6): p. 337-43.
48. van der Zwaard, S., et al., *Maximal oxygen uptake is proportional to muscle fiber oxidative capacity, from chronic heart failure patients to professional cyclists*. J Appl Physiol (1985), 2016. **121**(3): p. 636-45.

## **Chapter 5: Genetic Variants and its association with physiological and molecular phenotypes in skeletal muscle**

### **5.1 Introduction**

There is a wide variability across individuals in response to the same exercise intervention [1]. Post-exercise intervention variability in fitness phenotypes is well known, for example, maximal oxygen consumption ( $VO_{2max}$ ) [2-11], lactate threshold [12] [9, 10] and power peak ( $W_{peak}$ ) [3, 13]. Variability is also seen with molecular traits such as mitochondrial functional markers [14]. The factors that drive this inter-individual variability in exercise responses remain largely unclear, however there is strong evidence that a genetic component contributes to this variability [15]. Genetic background plays an important role in sporting potential, with physiological and molecular traits such as  $VO_{2max}$  and mitochondrial markers known to be polygenic traits which are influenced by several genetic variants [16-19]. Many studies focus on a limited number of genes, which individually may contribute only small effects, and explain only a small proportion of overall variability. However, the polygenic nature of these traits implies there may be benefit investigating the combined effect of multiple genetic variants to establish the overall influence of genetics on exercise responses at both a physiological and molecular level.

Genetic variants identified in GWAS studies may be combined into a polygenic risk score that captures an individual's total genetic tendency for a specific trait, with the use of polygenic risk scores used initially in clinical research for disease and risk prediction [20]. Polygenic scores may also be used in the context of fitness, by using genetic variants identified through several GWAS studies for fitness traits such as  $VO_{2max}$  [21], heart rate and recovery of autonomic nervous system [22]. However, only one study has explored creating a polygenic

score in this context [23], albeit considering only one fitness trait,  $VO_{2max}$ , and no other physiological or underpinning molecular fitness phenotypes.

In examining the role of genetics in exercise responses it should be considered that someone's baseline fitness level (before an exercise intervention is implemented) is a key factor that influences their degree of response to that intervention. For example, it has been reported that the degree of change in phenotypes, such as  $VO_{2max}$  [24, 25] and strength [26], following exercise interventions is dependent on the initial fitness levels of the individual, prior to the intervention. For example, has been reported that individuals with lower  $VO_{2max}$  at baseline have the highest increases in it after the intervention [27]. In addition, changes in  $VO_{2max}$  following resistance training is dependent of the individual's  $VO_{2max}$  baseline levels [28]. Noting this, the vast majority of the literature in this area explores how genetic variants may predict response to exercise training [29] with little known around how they may predict baselines fitness levels, which reflects long-life and cumulative exposures to exercise.


In this study we therefore assessed the association between exercise polygenic scores, derived from genetic variants identified in Chapter 3 of this thesis, and physiological and mitochondrial markers at baseline and following a four-week high intensity interval training (HIIT) intervention.

## **5.2 Methods:**

### **5.2.1 Participants and study design**

This chapter utilises data collected for the Gene SMART study cohort, which has been described in detail previously in Chapter 3 and in a prior publication [30].

Briefly, the Gene SMART cohort study is a controlled exercise study involving a 4-week HIIT intervention, with familiarisation and baseline assessments completed before this intervention and a further study assessment conducted after it (**Figure 5.1**). This chapter reports on data gathered from 96 males and 20 females (18-45 years, BMI:  $25.46 \pm 3.29 \text{ kg m}^2$ ) who completed this study. This study was approved by the Humans Ethics Research Committee at Victoria University (HRE13-223 and HRE 21-122), and we obtained a written consent form from each participant.



**Figure 5.1.** Study design

## 5.2.2 Familiarization study visit

Prior to completing the 4-week HIIT intervention, participants completed a familiarisation exercise session that consisted of one graded exercise test (GXT). Physiological measurements (lactate threshold, peak aerobic power and VO<sub>2max</sub>) were taken during this familiarisation GXT and then used to set the initial intensity for the following baseline GXTs.

### 5.2.3 Baseline testing

Following a familiarisation session, all participants then completed two baseline GXTs. On a separate examination day, a muscle biopsy and blood sample were also taken. This was preceded by a 48-hour standardised diet, following procedures described in Chapter 4.

### 5.2.4 Exercise intervention (HIIT) and post-intervention testing

Following baseline visits, participants trained three times/week under supervision for four weeks. Each session consisted of six to twelve 2-min intervals performed at different intensities ranging from 40 to 70% of ( $W_{peak} - LT$ ) above LT and interspersed by 1-min recovery periods (work-to-rest ratio of 2:1). The number of intervals and the intensity were progressively increased to maintain progression. Testing and training sessions were at intervals of 48-hours to avoid overtraining. Following 4 weeks of HIIT, participants completed post-intervention study assessments, comprised of two GXTs and collection of a muscle and blood sample, as at baseline.

### 5.2.5 Mitochondrial measures

Analyses of mitochondrial measures succinate dehydrogenase (SDH), cytochrome C oxidase (COX), citrate synthase (CS), and mitochondria copy number (mtDNA) were performed using muscle samples collected at baseline and following the 4-week HIIT intervention, following methods described previously in Chapter 4. Values for these measures were used to derive the mitochondrial health index (MHI) using the following formula:

$$\left[ \frac{\text{Energy production capacity}}{\text{Mitochondrial content}} \right] = \left[ \frac{\text{Complex II (SDH)} + \text{Complex IV (COX)}}{\text{CS} + \text{mtCN}} \right] * 100$$

### 5.2.6 DNA extraction and genotyping

Genomic DNA was extracted from 350ul of blood samples using the MagSep Blood gDNA kit (Eppendorf, Germany), using the epMotion M5073 automated pipetting system (Eppendorf, Germany) and reversible absorption of nucleic acids to paramagnetic beads as per manufacturer instructions.

Isolated DNA samples (~200ng) were then genotyped using the Illumina Genome-Wide Genotyping array-24 Version 3.0 Beadchip following the illumine Infinium HTS assay (GGTNM00263). Quality assessment of the samples was performed by QuantiFluor at the Australian Genome Research Facility, Melbourne, Australia, with samples removed if they showed any deficiency in staining, extension, hybridization, stringency, non-specific binding or non-polymorphic controls. All samples from this project met the Illumina expectations of <0.3 for Log SD.

### 5.2.7 Exercise Polygenic Score

Genotype data generated using the Illumina Genome-Wide Genotyping array-24 Version 3.0 Beadchip was used to derive additive exercise polygenic scores, using the list of robust SNPs linked to exercise responses outlined in Chapter 3. Two exercise polygenic scores were created, with the first comprised of seven SNPs linked to changes aerobic fitness, and the second comprised of these seven SNPs plus two linked to resistant training (**Table 5.1**). Three SNPs not covered by the array were replaced by SNPs in high linkage disequilibrium (LD): 1) rs6090314 with rs6090327 (pairwise  $r^2= 1$ ), 2) rs884736 with rs11120796 (pairwise  $r^2=0.98$ ), and 3) rs1956197 with rs12891759 (pairwise  $r^2= 1$ ). Several SNPs identified in Chapter 3 were omitted from the polygenic scores due to their beneficial allele being unknown or the genotyping array not covering this SNP or their close proxies: ACE rs4646994, rs1799752, rs4340, and rs13447447; IL15RA rs2296135; C12orf36 rs12580476; CD44 rs353625; NDN rs17117533; RYR2; rs7531957; and ZIC4 rs11715829. The remaining included SNPs were summed to generate additive polygenic scores, with participants scoring a 1 for each beneficial allele they carried. For example, the G allele for the rs6552828 (A/G) SNP was identified to be beneficial to aerobic fitness in Chapter 3, with individuals who carry two copies of this G allele

scoring 2 towards their exercise polygenic score, with a heterozygous genotype corresponding to a score of 1 and a 0-score representing no copies of the G allele.

**Table 5.1** Lists of SNPs used to generate exercise polygenic scores.

Exercise Polygenic Score 1 (EPS1)			Exercise Polygenic Score 2 (EPS2)	
<i>Gene Name</i>	<i>Variant</i>	<i>Beneficial allele</i>	<i>Variant</i>	<i>Beneficial allele</i>
ACSL1	rs6552828	G	rs6552828	G
AGT	rs699	A	rs699	A
BIRC	rs6090327 <sup>1</sup>	G	rs6090327 <sup>1</sup>	G
DAAMI	rs12891759 <sup>2</sup>	G	rs12891759 <sup>2</sup>	G
PPARGC1A	rs8192678	G	rs8192678	G
CAMTA1	rs11120796 <sup>3</sup>	G	rs11120796 <sup>3</sup>	G
RGS18	rs10921078	A	rs10921078	A
PPARA			rs4253778	G
ACTN3			rs1815739	G

1: replaces rs6090314, 2: replaces rs1956197, 3: replaces rs884736

### 5.2.8 Statistical analysis

Data analyses were conducted using R software version 4.0.2 [31] (packages: *dplyr* [32] *readxl* [33], *mice* [34], and *miceadd* [34, 35]). Descriptive statistics were generated to describe cohort characteristics and allele frequencies; continuous data included means and standard error (SE), and categorical data included counts (n), frequencies (%). Data missing at random was imputed using multiple imputations using the *mice* package [34], and results were pooled from all imputed iterations for models with the *miceadds* package [35]. Findings derived from the unimputed dataset are also reported. Linear regression was used to assess relationships between exercise polygenic scores and physiological and mitochondrial variables, with relationships between individual SNPs and outcome variables also explored. All models were corrected for age and sex, with models assessing changes in outcome variables over 4 weeks of HIIT also adjusting for baseline levels of that variable. Post-hoc comparisons were used to investigate pairwise significance between genotypes. The level of significance was set

at  $\alpha=0.00028$  based on the Bonferroni method adjustment for multiple (176 overall models) testing [36].

## 5.3 Results

### 5.3.1 Cohort phenotypes before and after HIIT.

The mean age of the cohort was 31.6 years and had mean exercise polygenic scores of 4.8 (out of possible 14) for EPS1 and 8.4 for EPS2 (out of possible 18). Fitness phenotypes were on average higher following 4-weeks of HIIT, compared to baseline;  $VO_{2max}$  (47.6 (SD 8.6) vs. 46.6 (SD 8.8)), LT (2.6 (SD 0.7) vs. 2.4 (SD 0.7) ) and  $W_{peak}$  (3.7 (SD (0.8) vs 3.5 (SD 0.8)), however this increase was only significant ( $p<0.05$ ) for LT and  $W_{peak}$ . In addition, there were significant increases in mitochondrial markers, CS (13.6 (SD 6.3)vs 14.6 (SD 6.7)) ( $p<0.05$ ) and COX (1.9 (SD 1.3) vs 2.1 (SD 1.6)) ( $p<0.05$ ), after 4-weeks of HIIT. No significant changes were found in  $VO_{2max}$ , SDH, mtCN and MHI after 4-weeks of HIIT (Table 5.2).

**Table 5.2** Cohort phenotypes before and after HIIT.

	<b>Baseline</b> <i>Mean (SD)</i>	<b>After 4-weeks of HIIT</b> <i>Mean (SD)</i>	<b>Change <math>\Delta</math></b> <i>Mean (SD)</i>
Age	31.6 (8.1)	-	-
EPS1	4.8 (1.8)	-	-
EPS2	8.4 (2.1)	-	-
$VO_{2max}$	46.6 (8.8)	47.6 (8.6)	1.4 (4.3)
LT	2.4 (0.7)	2.6 (0.7)	<b>0.2 (0.2)*</b>
$W_{Peak}$	3.5 (0.8)	3.7 (0.8)	<b>0.2 (0.2)*</b>
CS	13.6 (6.3)	14.6 (6.7)	<b>1.0 (3.0)*</b>
SDH	85.0 (69.9)	78.9 (55)	13.0 (45.5)
COX	1.9 (1.3)	2.1 (1.6)	<b>0.2 (1.6)*</b>
mtCN	12664.9 (21085.5)	10456.8 (6534.4)	-5022.8 (28870.0)
MHI	166.3 (703.4)	-189 (1236)	-192.3 (1142.7)

(\* ) represents significant differences between baseline and 4 weeks measures. Abbreviations: Exercise polygenic score 1 and 2 (EPS1 and EPS2 respectively), maximal oxygen uptake ( $VO_{2max}$ ), lactate threshold [12], power peak ( $W_{peak}$ ) citrate synthase (CS), succinate dehydrogenase (SDH), cytochrome oxidase (COX), mitochondria copy number (mtCN), and mitochondrial health index (MHI).

### 5.3.2. Allele frequency distribution in the Gene SMART cohort

The distribution of examined SNPs (rs6552828, rs699, rs6090327, rs12891759, rs8192678, rs11120796, rs10921078, rs4253778, and rs1815739) are outlined in **Table 5.3**. Genotype frequencies were consistent with Hardy-Weinberg Equilibrium ([38], P-value>0.05) for all SNPs except for rs8192678 (P=0.04).

**Table 5.3** Allele distribution in cohort.

Variant	N (%)	Beneficial allele	HWE (P-value)
<b>rs6552828</b>		G	
AA	17 (17.3)		0.56 (0.44)
AG	52 (53.1)		
GG	29 (29.6)		
<b>rs699</b>		T	
CC	18 (18.3)		0.12 (0.72)
CT	50 (51.1)		
TT	30 (30.6)		
<b>rs6090327</b>		A	
AA	66 (67.3)		0.44 (0.50)
AG	30 (30.6)		
GG	2 (2.1)		
<b>rs12891759</b>		G	
AA	67 (68.3)		0.31 (0.57)
AG	29 (29.6)		
GG	2 (2.1)		
<b>rs8192678</b>		G	
AA	17 (17.3)		3.92 (0.04)
AG	36 (36.7)		
GG	45 (46)		
<b>rs11120796</b>		G	
AA	16 (16.3)		0.42 (0.51)
AG	51 (52)		
GG	31 (31.7)		
<b>rs10921078</b>		A	
GG	61 (62.2)		1.43 (0.23)
AG	30 (30.6)		
AA	7 (7.2)		
<b>rs4253778</b>		C	
GG	6 (6.1)		1.42 (0.23)
GC	28 (28.5)		
CC	64 (65.3)		
<b>rs1815739</b>		C	
TT	6 (6.1)		1.42 (0.23)
TC	28 (28.5)		
CC	64 (65.3)		

Abbreviations: HWE; Hardy-Weinberg Equilibrium

### 5.3.3 Associations between exercise polygenic scores and physiological and mitochondrial phenotypes.

No associations were found between exercise polygenic scores (both EPS1 and EPS2) and physiological and mitochondrial phenotypes either before or after 4-weeks of HIIT in the Gene SMART cohort (**Table 5.4**). These results did not change when models were run on unimputed data (**Appendix, Supplementary Table 5.1**).

**Table 5.4** Associations between Exercise Polygenic Scores and physiological and mitochondrial phenotypes.

Outcome	EPS1			EPS2		
	Estimate	SE	P value	Estimate	SE	P value
VO <sub>2</sub> MAX BL	-0.53	0.52	0.31	-0.55	0.44	0.22
VO <sub>2</sub> MAX 4W-Δ	-0.29	-1.08	0.28	-0.21	0.23	0.36
W <sub>peak</sub> BL	-0.04	0.04	0.33	-0.05	0.04	0.18
W <sub>peak</sub> 4W-Δ	-0.00	0.01	0.90	0.0004	0.01	0.96
LT BL	-0.03	0.03	0.34	-0.04	0.03	0.15
LT 4W-Δ	0.003	0.01	0.81	0.002	0.01	0.83
CS BL	-0.18	0.33	0.58	-0.24	0.28	0.38
CS 4W-Δ	0.05	0.20	0.78	0.11	0.19	0.56
COX BL	0.08	0.08	0.29	0.02	0.07	0.70
COX 4W-Δ	0.008	0.08	0.92	0.03	0.07	0.57
mtCN BL	-1080.94	1029.95	0.29	-760.67	884.37	0.39
mtCN 4W-Δ	-314.24	0.04	0.51	-1.01	0.04	0
SDH BL	1.19	4.52	0.79	-1.31	3.90	0.73
SDH 4W-Δ	1.73	3.51	0.62	0.25	3.06	0.93
MHI BL	535.96	4534.74	0.90	-620.25	3879.86	0.87
MHI 4W-Δ	-55.70	0.78	0.48	-70.97	0.76	0.35

Each line represents a separate model, with EPS1 and EPS2 also examined separately. All models were corrected for age and sex, with models exploring change over 4 weeks also adjusting for baseline levels of the appropriate outcome variable. Abbreviations: SE: standard error, BL: baseline, 4W-Δ: change over 4 weeks, EPS1 and EPS2: exercise polygenic score 1 and 2 respectively, VO<sub>2</sub>max: maximal oxygen uptake, LT: lactate threshold, W<sub>peak</sub>: power peak, CS: citrate synthase, SDH: succinate dehydrogenase, COX: cytochrome oxidase, MCN: mitochondria copy number, and MHI: mitochondrial health index.

### 5.3.4 Associations between individual SNPs and physiological variables

Given no associations were found between composite exercise polygenic scores and physiological phenotypes, potential associations between individual SNPs in these scores and these phenotypes were further explored. No significant differences were found between SNP genotypes and VO<sub>2</sub>max, LT and W<sub>peak</sub> measures at baseline and following 4-weeks of HIIT

(Table 5.5). These results did not change when models were run on unimputed data (Appendix, Supplementary Table 5.2).

**Table 5.5** Least square means estimates by genotype for physiological phenotypes before and following HIIT.

Variant ( <i>Gene</i> )	Least square means (SE) <sup>1</sup>		
<b>rs6552828 (<i>ACSL1</i>)</b>	<b><i>AA</i></b>	<b><i>AG</i></b>	<b><i>GG</i></b>
VO <sub>2</sub> MAX (mL/kg/min) BL	43.9 (2.31)	46.1 (1.36)	45.3 (1.85)
VO <sub>2</sub> MAX(mL/kg/min) 4W-Δ	2.01 (1.29)	1.01 (0.69)	0.71 (0.94)
Wpeak (W/kg) BL	3.40 (0.22)	3.43 (0.12)	3.35 (0.17)
Wpeak (W/kg) 4W-Δ	0.24 (0.05)	0.15 (0.03)	0.27 (0.04)
LT (W/kg) BL	2.37 (0.17)	2.33 (0.10)	2.29 (0.14)
LT (W/kg) 4W-Δ	0.28 (0.07)	0.23 (0.04)	0.29 (0.07)
<b>rs699 (<i>AGT</i>)</b>	<b><i>CC</i></b>	<b><i>CT</i></b>	<b><i>TT</i></b>
VO <sub>2</sub> MAX(mL/kg/min) BL	48.4 (2.22)	44.8 (1.38)	44.9 (1.76)
VO <sub>2</sub> MAX (mL/kg/min) 4W-Δ	1.08 (1.16)	1.72 (0.67)	0.09 (0.97)
Wpeak (W/kg) BL	3.51 (0.21)	3.39 (0.13)	3.37 (0.16)
Wpeak (W/kg) 4W-Δ	0.19 (0.05)	0.20 (0.03)	0.19 (0.04)
LT (W/kg) BL	2.43 (0.17)	2.31 (0.10)	2.30 (0.13)
LT (W/kg) 4W-Δ	0.24 (0.07)	0.25 (0.04)	0.25 (0.06)
<b>rs6090327 (<i>BIRC</i>)</b>	<b><i>GG</i></b>	<b><i>AG</i></b>	<b><i>AA</i></b>
VO <sub>2</sub> MAX (mL/kg/min) BL	45.9 (1.25)	44.7 (1.80)	41.1(6.39)
VO <sub>2</sub> MAX (mL/kg/min) 4W-Δ	0.95 (0.63)	1.28 (0.87)	5.81 (2.98)
Wpeak (W/kg) BL	3.40 (0.11)	3.44 (0.16)	3.23 (0.59)
Wpeak (W/kg) 4W-Δ	0.20 (0.03)	0.19 (0.04)	0.13 (0.14)
LT (W/kg) BL	2.32 (0.09)	2.37 (0.13)	2.06 (0.48)
LT (W/kg) 4W-Δ	0.25 (0.04)	0.26 (0.05)	0.20 (0.19)
<b>rs12891759 (<i>DAAMI</i>)</b>	<b><i>AA</i></b>	<b><i>AG</i></b>	<b><i>GG</i></b>
VO <sub>2</sub> MAX (mL/kg/min) BL	45.4 (1.28)	45.8 (1.73)	37.0 (6.26)
VO <sub>2</sub> MAX (mL/kg/min) 4W-Δ	1.27 (0.66)	0.85 (0.87)	-1.44 (3.66)
Wpeak (W/kg) BL	3.39 (0.12)	3.45 (0.16)	2.73 (0.58)
Wpeak (W/kg) 4W-Δ	0.18 (0.03)	0.22 (0.04)	0.17 (0.20)
LT (W/kg) BL	2.33 (0.09)	2.34 (0.13)	1.92 (0.47)
LT (W/kg) 4W-Δ	0.25 (0.04)	0.26 (0.05)	0.21 (0.26)
<b>rs8192678 (<i>PPARGC1A</i>)</b>	<b><i>AA</i></b>	<b><i>AG</i></b>	<b><i>GG</i></b>
VO <sub>2</sub> MAX (mL/kg/min) BL	48.0 (2.39)	44.9 (1.59)	45.3 (1.44)
VO <sub>2</sub> MAX(mL/kg/min) 4W-Δ	1.03 (1.24)	1.56 (0.79)	0.79 (0.73)
Wpeak (W/kg) BL	3.72 (0.22)	3.39 (0.14)	3.34 (0.13)
Wpeak (W/kg) 4W-Δ	0.21 (0.06)	0.19 (0.03)	0.19 (0.03)
LT (W/kg) BL	2.58 (0.18)	2.30 (0.12)	2.29 (0.10)
LT (W/kg) 4W-Δ	0.34 (0.07)	0.26 (0.05)	0.22 (0.05)
<b>rs11120796 (<i>CAMTA1</i>)</b>	<b><i>AA</i></b>	<b><i>AG</i></b>	<b><i>GG</i></b>
VO <sub>2</sub> MAX (mL/kg/min) BL	47.8 (2.43)	44.4 (1.39)	46.1 (1.68)
VO <sub>2</sub> MAX (mL/kg/min) 4W-Δ	2.06 (1.28)	1.00 (0.72)	0.94 (0.86)
Wpeak (W/kg) BL	3.64 (0.22)	3.37 (0.13)	3.37 (0.15)
Wpeak (W/kg) 4W-Δ	0.18 (0.06)	0.20 (0.03)	0.19 (0.04)
LT (W/kg) BL	2.48 (0.19)	2.32 (0.10)	2.28 (0.12)
LT (W/kg) 4W-Δ	0.22 (0.08)	0.23 (0.04)	0.30 (0.05)
<b>rs10921078 (<i>RGS18</i>)</b>	<b><i>GG</i></b>	<b><i>AG</i></b>	<b><i>AA</i></b>
VO <sub>2</sub> MAX(mL/kg/min) BL	45.4 (1.34)	45.3 (1.74)	46.6 (3.39)
VO <sub>2</sub> MAX(mL/kg/min) 4W-Δ	1.07 (0.68)	1.48 (0.86)	0.02 (1.88)

Wpeak (W/kg) BL	3.38 (0.12)	3.39 (0.16)	3.63 (0.31)
Wpeak (W/kg) 4W-Δ	0.20 (0.03)	0.21 (0.04)	0.07 (0.09)
LT (W/kg) BL	2.30 (0.10)	2.34 (0.13)	2.51 (0.25)
LT (W/kg) 4W-Δ	0.25 (0.04)	0.28 (0.05)	0.17 (0.14)
<b>rs4253778 (PPARA)</b>	<b>GG</b>	<b>GC</b>	<b>CC</b>
VO <sub>2</sub> MAX (mL/kg/min)BL	47.1 (4.03)	46.5 (1.74)	44.9 (1.31)
VO <sub>2</sub> MAX (mL/kg/min)4W-Δ	1.78 (2.16)	0.57 (0.84)	1.36 (0.68)
Wpeak (W/kg) BL	3.47 (0.37)	3.57 (0.16)	3.32 (0.12)
Wpeak (W/kg) 4W-Δ	0.22 (0.13)	0.18 (0.04)	0.20 (0.03)
LT (W/kg) BL	2.35 (0.29)	2.52 (0.13)	2.23 (0.09)
LT (W/kg) 4W-Δ	0.26 (0.19)	0.19 (0.05)	0.28 (0.04)
<b>rs1815739 (ACTN3)</b>	<b>TT</b>	<b>TC</b>	<b>CC</b>
VO <sub>2</sub> MAX (mL/kg/min)BL	47.1 (4.03)	46.5 (1.74)	44.9 (1.31)
VO <sub>2</sub> MAX (mL/kg/min)4W-Δ	1.78 (2.16)	0.57 (0.84)	1.36 (0.68)
Wpeak (W/kg) BL	3.47 (0.37)	3.57 (0.16)	3.32 (0.12)
Wpeak (W/kg) 4W-Δ	0.22 (0.13)	0.18 (0.04)	0.20 (0.03)
LT (W/kg) BL	2.35 (0.29)	2.52 (0.13)	2.23 (0.09)
LT (W/kg) 4W-Δ	0.25 (0.19)	0.19 (0.05)	0.28 (0.04)

All models were adjusted for sex, age, and baseline levels of appropriate phenotype (for models on 4W-Δ outcomes only) and performed on imputed data. Values within the same row that are bolded and denoted with different letters represent significant differences. (<0.05). Abbreviations: SE: standard error, BL: baseline, 4W-Δ: change over 4 weeks, VO<sub>2</sub>max: maximal oxygen uptake, LT: lactate threshold, Wpeak: power peak

### 5.3.5 Associations between individual SNPs and mitochondrial variables

Potential associations between individual SNPs and mitochondrial variables were also explored. A significant association between baseline mtCN and the rs8192678 SNP was found ( $p=0.02$ ), with individuals with the AA genotype having significantly higher mtCN levels on average (10579 (SE: 4912)) compared to individuals with AG (9631 (SE: 3137)) or GG (9762 (SE: 2813)) genotypes (**Supplementary Table 5.3**). We did not observe any further significant associations and mitochondrial phenotypes when models were performed using imputed data (**Supplementary Table 5.3**). However, when potential associations between individual SNPs and mitochondrial variables were examined in non-imputed data, several additional significant associations were found (**Table 5.6**).

Firstly, an association was found between baseline mtCN and the rs8192678 SNP ( $P=0.02$ ), as shown in imputed data, with a further relationship between change mtCN

following 4 weeks of HIIT and the rs6090327 ( $P = < 0.01$  add). For the rs6090327 variant, the AG genotype was associated with significantly greater decreases in mtCN following 4 weeks of HIIT (mean -10783 (SE: 1667)) when compared to the GG genotype (mean -3060 (SE: 1120), **Table 5.6**). A further association was found between change in CS following 4 weeks of HIIT and the rs699 variant ( $p=0.03$ ). The greatest mean change was seen with the CC genotype (1.85 (SE: 0.76)) compared to CT (0.06 (SE: 0.47)) and TT genotypes (0.37 (SE: 0.61), **Table 5.6**).

Significant associations were also observed between change in SDH after 4-weeks of HIIT and rs6090327 ( $p=0.03$ ) and rs12891759 ( $p=0.03$ ) variants (**Table 5.6**). The AG genotype for rs6090327 was associated with significant increases in SDH following HIIT (mean increase 38.85 (SE: 14.98)), with decreases observed on average for GG (-0.03 (SE: 9.24)) and AA (-31.91 (SE: 44.7)) genotypes. Relationships were further found between baseline MHI and three genetic variants: rs4253778, rs10921078 and rs1815739. For rs4253778, MHI was significantly higher in individuals with GG genotype (mean 1452 (SE: 686)), when compared to the CC and GC (mean -153 (SE: 172)) genotype (**Table 5.6**). Similarly, the GG genotype for rs10921078 was related to the highest MHI at baseline (mean 245.1 (SE: 146)) when compared to the AG genotype (mean -312.7 (SE: 219)) for this variant. Further, for variant rs1815739, MHI was significantly higher in individuals with the CC genotype (mean 1452 (SE: 686)), when compared to the TC genotype (mean -153 (SE: 172), **Table 5.6**). No further associations were found between SNPs and mitochondrial markers at baseline or after 4-weeks of HIIT.

**Table 5.6** Least square means estimates for mitochondria phenotypes before and after the HIIT intervention, by genotype (non-imputed data)

Variant (gene)	Least square means (SE) <sup>1</sup>		
	AA	AG	GG
rs6552828 (ACSL1)			
CS (mol/kg/protein) BL	11.0 (1.57)	11.4 (0.86)	10.5 (1.15)
CS (mol/kg/protein) 4W-Δ	1.25 (0.81)	0.13 (0.45)	0.88 (0.65)
COX (mol/kg/protein) BL	1.70 (0.37)	1.60 (0.20)	2.04 (0.27)

COX(mol/kg/protein) 4W-Δ	0.47 (0.49)	-0.15 (0.30)	0.23 (0.40)
mtCN BL	14342 (7286)	10018 (3998)	16817 (5607)
mtCN 4W-Δ	-5721 (2633)	-4782 (1492)	-6126 (2556)
SDH (mol/kg/mg tissue) BL	59.9 (20.4)	75.7 (13.3)	71.3 (17.8)
SDH(mol/kg/mg tissue)4WΔ	8.08 (16.6)	8.22 (11.7)	12.00 (17.1)
MHI BL	-309 (290)	-16.6 (164)	181 (247)
MHI 4W-Δ	-228 (247)	-169 (210)	-205 (397)
<b>rs699 (AGT)</b>	<b>CC</b>	<b>CT</b>	<b>TT</b>
CS (mol/kg/protein) BL	11.4 (1.43)	11.4 (0.87)	10.3 (1.13)
CS (mol/kg/protein) 4W-Δ	<b>1.85 (0.76)<sup>a</sup></b>	<b>0.06 (0.47)<sup>b</sup></b>	<b>0.37 (0.61)<sup>b</sup></b>
COX (mol/kg/protein) BL	1.49 (0.35)	1.90 (0.21)	1.58 (0.27)
COX(mol/kg/protein) 4W-Δ	0.23 (0.50)	0.32 (0.29)	-0.51 (0.40)
mtCN BL	8515 (7313)	14820 (3784)	8196 (6122)
mtCN 4W-Δ	-6719 (2645)	-5858 (1383)	-1712 (2460)
SDH(mol/kg/mg tissue) BL	67.2 (20.0)	78.0 (13.4)	60.8 (17.8)
SDH(mol/kg/mg tissue)4WΔ	-8.42 (16.7)	5.61 (12.6)	28.31 (13.7)
MHI BL	102 (289)	164 (161)	-185 (273)
MHI 4W-Δ	-250.6 (307)	-41.4 (185)	-444.3 (337)
<b>rs6090327 (BIRC)</b>	<b>GG</b>	<b>AG</b>	<b>AA</b>
CS(mol/kg/protein) BL	11.6 (0.76)	9.51 (1.71)	10.6 (3.85)
CS (mol/kg/protein) 4W-Δ	0.49 (0.42)	0.39 (0.67)	0.22 (2.69)
COX (mol/kg/protein) BL	1.72 (0.18)	1.85 (0.27)	-0.28 (1.26)
COX(mol/kg/protein) 4W-Δ	0.09 (0.27)	0.05 (0.37)	-
mtCN BL	10539 (3556)	18680 (5635)	7844 (16101)
mtCN 4W-Δ	<b>-3060 (1120)<sup>a</sup></b>	<b>-10783 (1667)<sup>b</sup></b>	<b>3600 (5464)<sup>b</sup></b>
SDH(mol/kg/mg tissue) BL	73.4 (11.7)	71.1 (18.5)	18.3 (50.9)
SDH(mol/kg/mg tissue)4WΔ	<b>-0.03 (9.24)<sup>a</sup></b>	<b>38.85 (14.98)<sup>b</sup></b>	<b>-31.91(44.7)<sup>b</sup></b>
MHI BL	-27.7 (135)	454.8 (244)	1100.5 (689)
MHI 4W-Δ	-204 (147)	-172 (288)	-
<b>rs12891759 (DAAMI)</b>	<b>AA</b>	<b>AG</b>	<b>GG</b>
CS (mol/kg/protein) BL	11.17 (0.82)	11.09 (1.088)	6.82 (3.83)
CS (mol/kg/protein) 4W-Δ	0.41 (0.45)	0.57 (0.59)	0.51 (2.75)
COX (mol/kg/protein) BL	1.65 (0.19)	1.91 (0.26)	-
COX(mol/kg/protein) 4W-Δ	-0.11 (0.27)	0.45 (0.37)	-
mtCN BL	14461 (3750)	8529 (5659)	2118 (15807)
mtCN 4W-Δ	-5896 (1319)	-2654 (2211)	-18002 (6383)
SDH(mol/kg/mg tissue) BL	71.4 (11.7)	70.9 (18.3)	-
SDH(mol/kg/mg tissue)4WΔ	<b>-0.23 (9.05)<sup>a</sup></b>	<b>36.02 (14.66)<sup>b</sup></b>	-
MHI BL	85.3 (149)	108.3 (252)	-
MHI 4W-Δ	-252.8 (140)	79.6 (370)	-
<b>rs8192678 (PPARGCIA)</b>	<b>AA</b>	<b>AG</b>	<b>GG</b>
CS (mol/kg/protein) BL	10.0 (1.48)	10.6 (0.99)	11.8 (0.92)
CS (mol/kg/protein) 4W-Δ	0.66 (0.81)	0.33 (0.56)	0.52 (0.50)
COX (mol/kg/protein) BL	1.52 (0.41)	1.79 (0.24)	1.74 (0.21)
COX(mol/kg/protein) 4W-Δ	-0.10 (0.58)	-0.31 (0.35)	0.37 (0.30)
mtCN BL	<b>27286 (6618)<sup>a</sup></b>	<b>9869 (4679)<sup>b</sup></b>	<b>10033 (4106)<sup>b</sup></b>
mtCN 4W-Δ	-2828 (3149)	-6747 (1825)	-4645 (1657)
SDH(mol/kg/mg tissue) BL	59.1 (21.9)	88.2 (15.4)	62.2 (13.5)
SDH(mol/kg/mg tissue)4WΔ	6.16 (19.4)	16.64 (13.5)	0.09 (10.1)
MHI BL	459.0 (302)	40.1 (198)	30.4 (177)
MHI 4W-Δ	1949 (1221)	-338 (232)	-385 (153)
<b>rs11120796 (CAMTA1)</b>	<b>AA</b>	<b>AG</b>	<b>GG</b>
CS (mol/kg/protein) BL	11.0 (1.60)	10.9 (0.87)	11.5 (1.08)
CS(mol/kg/protein) 4W-Δ	-0.82 (0.87)	0.88 (0.47)	0.24 (0.58)

COX (mol/kg/protein) BL	1.97 (0.39)	1.75 (0.21)	1.64 (0.25)
COX (mol/kg/protein) 4W-Δ	-0.53 (0.63)	0.35 (0.29)	-0.15 (0.36)
mtCN BL	12556 (7442)	13531 (4030)	10414 (5372)
mtCN 4W-Δ	-3023 (3030)	-5289 (1450)	-6217 (2224)
SDH(mol/kg/mg tissue) BL	86.9 (25.4)	63.3 (13.3)	78.9 (15.5)
SDH(mol/kg/mg tissue)4WΔ	40.55 (24.7)	7.72 (11.7)	4.87 (12.8)
MHI BL	92.7 (344)	175.3 (163)	-72.5 (217)
MHI 4W-Δ	-211 (425)	-352 (143)	120 (203)
<b>rs10921078 (RGS18)</b>	<b>GG</b>	<b>AG</b>	<b>AA</b>
CS (mol/kg/protein) BL	11.64 (0.82)	10.50 (1.10)	8.82 (2.21)
CS (mol/kg/protein) 4W-Δ	0.33 (0.45)	0.43 (0.60)	1.86 (1.21)
COX(mol/kg/protein) BL	1.66 (0.20)	1.64 (0.25)	2.61 (0.47)
COX(mol/kg/protein) 4W-Δ	0.15 (0.29)	0.07 (0.38)	-0.50 (0.91)
mtCN BL	15059 (4009)	8688 (4733)	12286 (11212)
mtCN 4W-Δ	-4831 (1441)	-5717 (2045)	-7638 (4946)
SDH (mol/kg/mg tissue) BL	66.1 (12.3)	68.4 (18.0)	110.2 (28.5)
SDH(mol/kg/mg tissue)4WΔ	8.88 (10.9)	13.19 (16.8)	-6.68 (34.2)
MHI BL	<b>245.1 (146)<sup>a</sup></b>	<b>-312.7 (219)<sup>b</sup></b>	<b>86.2 (396)<sup>b</sup></b>
MHI 4W-Δ	-279.4 (133)	90.5 (260)	-
<b>rs4253778 (PPARA)</b>	<b>GC</b>	<b>GC</b>	<b>CC</b>
CS (mol/kg/protein) BL	14.9 (2.50)	11.8 (1.09)	10.6 (0.82)
CS (mol/kg/protein) 4W-Δ	-0.81 (1.39)	0.61 (0.59)	0.49 (0.47)
COX (mol/kg/protein) BL	2.62 (0.67)	1.90 (0.25)	1.62 (0.19)
COX (mol/kg/protein) 4W-Δ	-0.57 (1.11)	-0.28 (0.34)	0.36 (0.28)
mtCN BL	15667 (15708)	8169 (5069)	14905 (3934)
mtCN 4W-Δ	-2026 (6958)	-4773 (2255)	-5568 (1499)
SDH(mol/kg/mg tissue) BL	52.3 (33.8)	82.8 (15.4)	64.3 (13.2)
SDH(mol/kg/mg tissue)4WΔ	13.68 (27.5)	23.53 (13.1)	-3.82 (11.9)
MHI BL	<b>1452 (686)<sup>a</sup></b>	<b>-153 (172)<sup>b</sup></b>	<b>293 (167)<sup>b</sup></b>
MHI 4W-Δ	-93.4 (179)	-368.6 (251)	-
<b>rs1815739 (ACTN3)</b>	<b>TT</b>	<b>TC</b>	<b>CC</b>
CS (mol/kg/protein) BL	14.9 (2.50)	11.8 (1.09)	10.6 (0.82)
CS (mol/kg/protein) 4W-Δ	-0.81 (1.39)	0.61 (0.59)	0.49 (0.47)
COX (mol/kg/protein) BL	2.62 (0.67)	1.90 (0.25)	1.62 (0.19)
COX (mol/kg/protein) 4W-Δ	-0.57 (1.11)	-0.34 (0.34)	0.36 (0.28)
mtCN BL	15667 (15708)	8169 (5069)	14905 (3934)
mtCN 4W-Δ	-2026 (6958)	-4773 (2255)	-5568 (1499)
SDH(mol/kg/mg tissue) BL	52.3 (33.8)	82.8 (15.4)	64.3 (13.2)
SDH(mol/kg/mg tissue)4WΔ	13.68 (27.5)	23.53 (13.1)	-3.82 (11.9)
MHI BL	<b>1452 (686)<sup>a</sup></b>	<b>-153 (172)<sup>b</sup></b>	<b>293 (167)<sup>b</sup></b>
MHI 4W-Δ	-93.4 (179)	-368.6 (251)	-

All models were adjusted for sex, age, and baseline levels of appropriate phenotype (for models on 4W-Δ outcomes only) and performed on the non-imputed dataset. Values within the same row that are bonded and denoted with different letters represent significant differences. (<0.05). Data is missing in cases where no outcome data was available for individuals with particular genotypes. Abbreviations: SE: standard error, BL: baseline, 4W-Δ: change over 4 weeks, VO<sub>2</sub>max: maximal oxygen uptake, LT: lactate threshold, Wpeak: power peak, (CS) citrate synthase, (COX) Cytochrome C oxidase, (mtCN) mitochondrial copy number, (SDH) succinate dehydrogenase, (MHI) mitochondrial health index.

## 5. 4 Discussion

This study investigated the relationships between exercise polygenic scores and physiological and mitochondrial markers before and after 4-weeks of HIIT. The examined polygenic scores were derived from robust genetic variants linked to exercise responses (Chapter 3), with relationships between these individual genetic variants and physiological and mitochondrial markers also explored. The present study comprehensively looked at this in a tightly controlled exercise study cohort. This study found no associations between derived exercise polygenic scores and physiological and mitochondrial markers before or after 4-weeks of HIIT. However, several associations were found between individual genetic variants (rs699, rs8192678, rs6090327, rs12891759, rs10921078, rs4253778 and rs1815739) and baseline and post-4-week HIIT measures of mitochondrial function (SDH and MHI) and mitochondrial content.

Previous efforts to detect the genetic influence in exercise responses have had limited success [39]. In our study, a lack of association between exercise polygenic scores and physiological and mitochondrial phenotypes may be due to four weeks not being enough time to detect the influence of genetics on changes in physiological and mitochondrial phenotypes. We further observed no associations between exercise polygenic scores and baseline fitness levels, which may be explained by a small and likely underpowered sample set, or a different set of genes underpinning lifelong fitness traits. In addition, exercise responses are modulated by many genes with small and different effect sizes, thus, the proposed exercise polygenic score has equal SNPs effect sizes for the studied phenotypes. While our interventional study was done in the general population with different fitness levels, cross-sectional studies have reported a genetic influence on physiological exercise responses in elite athletes [40, 41]. Other

studies including intervention have reported a genetic influence after 20 weeks of continuous exercise in sedentary individuals [21, 42] vs the 4 weeks of HIIT intervention proposed in this study. Although we condensed in the EPS a group of genetic variants robustly associated with exercise responses, the relationship between genes and fitness traits remain inconclusive, given that those findings are derived from varied cohorts (e.g. varied ethnicities, elite and sedentary populations) of small samples sizes, contributing to a large heterogeneity across studies [39]. In addition, the baseline heterogeneity in our study could be considered as limitation as the impact of the HIIT intervention on individuals who were already trained differ within our cohort. However, this heterogeneity is also an advantage as the findings of this study are applicable to the general population. As highlighted in Chapter 3, no single study has exceeded 900 participants, which makes all the genetics studies gravely underpowered. We could not overcome this limitation with 116 individuals involved in our study. This is one of the major reasons for the large body of contradictory results reported in exercise science literature [43]. We tried to overcome this limitation by including several genetic variants from different sources (candidate genes and GWAS) studies, but according to our results this was not achieved. Although previously demonstrated that exercise training is as polygenic trait, undoubtedly many genetic variants remain to be identified.

In the current study, seven genetic variants (rs8192678, rs699, rs6090327, rs12891759, rs4253778, rs1815739 and rs10921078) were associated with measures of either mitochondrial function (SDH and MHI) or mitochondrial content (CS and mtCN). Firstly, a significant association was found between rs8192678 with baseline mtCN levels and also with mtCN changes after 4 weeks of HIIT. The causality of this finding cannot be explored here. However, this finding is supported by previous studies relating this SNP to training-induced adaptations of clinical relevance, with increases in mitochondrial function and several cardiovascular

phenotypes [44]. It also has been consistently associated with an increased aerobic capacity in Europeans [45, 46]., However, these results were in contrast to a Chinese cohort [47] where no increases were detected after 18-weeks of training for GG allele carriers. Significant associations were found between rs699 and change in CS following 4 weeks of HIIT, rs12891759 and change in SDH after HIIT, and between rs6090327 and changes in both mtCN and SDH after HIIT. The rs699 variant (also known as M235T) is located at amino acid 235 in the angiotensinogen (*AGT*) gene, which encodes pre-angiotensin. It is associated with elite power as it upregulates angiotensinogen II and increases serum *AGT* concentrations [48], which acts as a growth factor in skeletal muscle and thus promotes hypertrophy, power or speed [48, 49]. In the present study, the rs699 genetic variant was associated with citrate synthase activity in skeletal muscle, which has not been previously reported. This finding may be explained by the mitochondrial function of the *AGT*, with previous studies demonstrating that the stimulation of angiotensin receptors enhances mitochondrial biogenesis and increases mitochondrial content markers [50].

This study further reports an association between rs12891759 and increases in SDH after HIIT for the G allele carriers, which has not been previously reported. In this study, we replaced the rs12891759 genetic variant with one in high LD with the rs1956197 (pairwise  $r^2=1$ ), which has been linked to increases in  $VO_{2max}$  in other studies [51], however this relationship was not reported here. The rs6090327 variant was further linked to decrease SDH after HIIT for the AA genotype carriers. It also was also linked to increase mtCN in this cohort for the AA genotype carriers, with this variant located in the *BIRC* gene linked to apoptosis and mitochondrial signalling pathways [52, 53]. rs6090327 is in high LD with exercise-related rs6090314, and acted as a proxy for this SNP in the current study given it was covered by the genotyping array used. rs6090314 has been associated with increases in  $VO_{2max}$  after 20-weeks

of continuous exercise [21]; however, it was not related to this phenotype in the current study, likely due to a shorter exercise intervention. Nevertheless, it was linked to changes in SDH and mtCN after 4-weeks of HIIT, suggesting this genetic variant is a prominent candidate gene for future molecular pathways studies in exercise responses.

Three genetic variants (rs4253778, rs1815739 and rs10921078) were associated with an increased MHI for the TT genotype. Interestingly, none of the three SNPs were linked to individual mitochondria (CS, SDH, mtCN and COX) in the current study, highlighting the potential value of examining a composite measure of mitochondrial function and content, and subsequently considering the combined effect of a single genetic variant gene on multiple mitochondrial markers.

rs4253778 is located in the intron of the *PPARA* gene and appears to influence gene expression by disrupting mRNAs site and consequently altering encoded PPAR $\alpha$  proteins [54]. The observed relationship between this variant and MHI is supported by a prior study linking the C allele of rs4253778 to the downregulation of mitochondrial enzymes [55]. rs1815739 and rs10921078 variants were also associated with MHI in the current study. The rs1815739 variant is located in the gene that codes for alpha-actinin-3 (ACTN3), which has been related to many aspects of exercise responses (especially speed and power [56]) as well as mitochondrial content [57]. In a prior study, a variant in high LD with rs10921078, rs17581162 (pairwise  $r^2 = 0.84$ ), was found to be associated with increases in  $VO_{2max}$  [21]; however, it has not been previously linked to markers of mitochondrial function or content. No relationships were found between SNPs and physiological variables ( $VO_{2max}$ , LT and  $W_{peak}$ ), with this likely due to the 4-week HIIT intervention having limited effect on these measures, with a significant but small change only reported for LT.

This study has several limitations that should be considered when interpreting findings. Firstly, we investigated a relatively small sample size, with limited power and the ability to capture small genetic effects, even when combined into polygenic scores. Further, the cohort examined was predominately Caucasian, with the generalisability of our findings therefore limited. However, the study design had strengths in using repeated GTXs and controlled diets to reduce variability in physiological and mitochondrial phenotypes. Also, the study derived a mitochondrial health index for all individuals, to assess the effects of genetics on a composite measure of mitochondrial function and content. Models also adjusted for sex, age and baseline measures of outcome where appropriate.

## **5.5 Conclusion**

In conclusion, we found no association between exercise polygenic score and physiological and mitochondrial phenotypes. However, several associations between individual SNPs (rs8192678, rs699, rs6090327, rs12891759, rs4253778, rs1815739 and rs10921078) and mitochondrial markers (CS, SDH, mtCN and MHI) were found, which have not been reported previously. Further investigations combining cohorts to improve sample size, paired with validation and functional experiments, are needed to improve understanding of the links between genetics and fitness.

## 5.6 References

1. Bonafiglia, J.T., et al., An appraisal of the SDIR as an estimate of true individual differences in training responsiveness in parallel-arm exercise randomized controlled trials. *Physiological Reports*, 2019. 7(14): p. e14163.
2. Hautala, A.J., et al., *Individual differences in the responses to endurance and resistance training*. *Eur J Appl Physiol*, 2006. 96(5): p. 535-42.
3. Volllaard, N.B., et al., *Systematic analysis of adaptations in aerobic capacity and submaximal energy metabolism provides a unique insight into determinants of human aerobic performance*. *J Appl Physiol* (1985), 2009. 106(5): p. 1479-86.
4. Sisson, S.B., et al., *Volume of exercise and fitness nonresponse in sedentary, postmenopausal women*. *Med Sci Sports Exerc*, 2009. 41(3): p. 539-45.
5. Astorino, T.A. and M.M. Schubert, *Individual responses to completion of short-term and chronic interval training: a retrospective study*. *PLoS One*, 2014. 9(5): p. e97638.
6. Wolpern, A.E., et al., *Is a threshold-based model a superior method to the relative percent concept for establishing individual exercise intensity? a randomized controlled trial*. *BMC Sports Sci Med Rehabil*, 2015. 7: p. 16.
7. Ross, R., L. de Lannoy, and P.J. Stotz, *Separate Effects of Intensity and Amount of Exercise on Interindividual Cardiorespiratory Fitness Response*. *Mayo Clin Proc*, 2015. 90(11): p. 1506-14.
8. Raleigh, J.P., et al., *The impact of work-matched interval training on  $\dot{V}O_{2peak}$  and  $\dot{V}O_2$  kinetics: diminishing returns with increasing intensity*. *Appl Physiol Nutr Metab*, 2016. 41(7): p. 706-13.
9. Gurd, B.J., et al., *Incidence of nonresponse and individual patterns of response following sprint interval training*. *Appl Physiol Nutr Metab*, 2016. 41(3): p. 229-34.
10. Bonafiglia, J.T., et al., *Inter-Individual Variability in the Adaptive Responses to Endurance and Sprint Interval Training: A Randomized Crossover Study*. *PLOS ONE*, 2016. 11(12): p. e0167790.
11. Montero, D. and C. Lundby, *Refuting the myth of non-response to exercise training: 'non-responders' do respond to higher dose of training*. *J Physiol*, 2017. 595(11): p. 3377-3387.
12. Giordano, C., et al., *Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy*. *Brain*, 2013. 137(2): p. 335-353.
13. Da, Y., et al., *Mixed Model Methods for Genomic Prediction and Variance Component Estimation of Additive and Dominance Effects Using SNP Markers*. *PLOS ONE*, 2014. 9(1): p. e87666.
14. Jacques, M., et al., *Individual physiological and mitochondrial responses during 12 weeks of intensified exercise*. *Physiological Reports*, 2021. 9(15): p. e14962.
15. Ross, R., et al., *Precision exercise medicine: understanding exercise response variability*. *British Journal of Sports Medicine*, 2019. 53(18): p. 1141-1153.
16. Bouchard, C., T. Rankinen, and J.A. Timmons, *Genomics and Genetics in the Biology of Adaptation to Exercise*, in *Comprehensive Physiology*. 2011. p. 1603-1648.
17. Fowler, K., et al., *Genetic variation for total fitness in *Drosophila melanogaster**. *Proc Biol Sci*, 1997. 264(1379): p. 191-9.
18. Moreira, J.D., et al., *Gaining Insight into Mitochondrial Genetic Variation and Downstream Pathophysiology: What Can *i*(PSCs) Do?* *Genes*, 2021. 12(11): p. 1668.
19. Drake, J.C., R.J. Wilson, and Z. Yan, *Molecular mechanisms for mitochondrial adaptation to exercise training in skeletal muscle*. *FASEB journal : official Publication of the Federation of American Societies for Experimental Biology*, 2016. 30(1): p. 13-22.

20. Lewis, C.M. and E. Vassos, *Polygenic risk scores: from research tools to clinical instruments*. *Genome Medicine*, 2020. 12(1): p. 44.
21. Bouchard, C., et al., *Genomic predictors of the maximal O<sub>2</sub> uptake response to standardized exercise training programs*. *Journal of applied physiology (Bethesda, Md. : 1985)*, 2011. 110(5): p. 1160-1170.
22. Ramírez, J., et al., *Thirty loci identified for heart rate response to exercise and recovery implicate autonomic nervous system*. *Nature Communications*, 2018. 9(1): p. 1947.
23. Bouchard, C., *Genomic predictors of trainability*. *Exp Physiol*, 2012. 97(3): p. 347-52.
24. McCARTHY, J.P., et al., *Compatibility of adaptive responses with combining strength and endurance training*. *Medicine & Science in Sports & Exercise*, 1995. 27(3): p. 429-436.
25. Stone, M.H., et al., *Cardiovascular responses to short-term olympic style weight-training in young men*. *Can J Appl Sport Sci*, 1983. 8(3): p. 134-9.
26. Hu, M., et al., *Effects of strength training on work capacity and parasympathetic heart rate modulation during exercise in physically inactive men*. *Int J Sports Med*, 2009. 30(10): p. 719-24.
27. Daniels, J.T., R.A. Yarbrough, and C. Foster, *Changes in VO<sub>2</sub> max and running performance with training*. *Eur J Appl Physiol Occup Physiol*, 1978. 39(4): p. 249-54.
28. Ozaki, H., et al., *Resistance training induced increase in VO<sub>2</sub>max in young and older subjects*. *European Review of Aging and Physical Activity*, 2013. 10(2): p. 107-116.
29. Chung, H.C., et al., *Do exercise-associated genes explain phenotypic variance in the three components of fitness? a systematic review & meta-analysis*. *PLOS ONE*, 2021. 16(10): p. e0249501.
30. Yan, X., et al., *The gene SMART study: method, study design, and preliminary findings*. *BMC Genomics*, 2017. 18(Suppl 8): p. 821.
31. Team, R.C. *A language and environment for statistical computing* 2017; Available from: <https://www.R-project.org/>.
32. Wickham, H. and R. Francois. *A Grammar of Data Manipulation*. *R Packag. version 0.4.2*. 2015; Available from: <https://CRAN.R-project.org/package=dplyr>.
33. Wickham, H. and J. Bryan. *readxl: Read Excel files*. *R package version 1.3.1*. 2019; Available from: <https://CRAN.R-project.org/package=readxl>
34. van Buuren, S. and K. Groothuis-Oudshoorn, *mice: Multivariate Imputation by Chained Equations in R*. *Journal of Statistical Software*, 2011. 45(3): p. 1 - 67.
35. Robitzsch, A., S. Grund, and T. Henke. *miceadds: Some additional multiple imputation functions, especially for mice*. *R package version 2.8-24*. 2017; Available from: <https://CRAN.R-project.org/package=miceadds>
36. Bland, J.M. and D.G. Altman, *Multiple significance tests: the Bonferroni method*. *Bmj*, 1995. 310(6973): p. 170.
37. Juster RP, et al., *Social inequalities and the road to allostatic load: From vulnerability to resilience*. 3rd ed, ed. C. D. 2016, Developmental Psychopathology: Cambridge Press.
38. Fagerberg, L., et al., *Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics*. *Molecular & Cellular Proteomics* 2014. 13(2): p. 397-406.
39. Wang, Z., et al., *Genome-wide association analyses of physical activity and sedentary behavior provide insights into underlying mechanisms and roles in disease prevention*. *Nature Genetics*, 2022. 54(9): p. 1332-1344.

40. Drozdovska, S.B., et al., *The association of gene polymorphisms with athlete status in ukrainians*. Biol Sport, 2013. 30(3): p. 163-7.
41. Ahmetov, II, et al., *SOD2 gene polymorphism and muscle damage markers in elite athletes*. Free Radic Res, 2014. 48(8): p. 948-55.
42. Ghosh, S., et al., *Integrative pathway analysis of a genome-wide association study of  $\dot{V}o_{2max}$  response to exercise training*. Journal of Applied Physiology, 2013. 115(9): p. 1343-1359.
43. Loos, R.J., et al., *Advances in exercise, fitness, and performance genomics in 2014*. Med Sci Sports Exerc, 2015. 47(6): p. 1105-12.
44. Yvert, T., et al., *PPARGC1A rs8192678 and NRF1 rs6949152 Polymorphisms Are Associated with Muscle Fiber Composition in Women*. Genes (Basel), 2020. 11(9).
45. Stefan, N., et al., *Genetic Variations in PPARGC1A Determine Mitochondrial Function and Change in Aerobic Physical Fitness and Insulin Sensitivity using Lifestyle Intervention*. The Journal of Clinical Endocrinology & Metabolism, 2007. 92(5): p. 1827-1833.
46. Ring-Dimitriou, S., et al., *Does Genetic Variation in PPARGC1A Affect Exercise-Induced Changes in Ventilatory Thresholds and Metabolic Syndrome?* JEPonline, 2014. 17: p. 1-18.
47. He, Z., et al., *Is there an association between PPARGC1A genotypes and endurance capacity in Chinese men?* Scandinavian Journal of Medicine & Science in Sports, 2008. 18(2): p. 195-204.
48. Zarębska, A., et al., *Association of rs699 (M235T) polymorphism in the AGT gene with power but not endurance athlete status*. J Strength Cond Res, 2013. 27(10): p. 2898-903.
49. Ruiz, J.R., et al., *Can we identify a power-oriented polygenic profile?* J Appl Physiol (1985), 2010. 108(3): p. 561-6.
50. Escobales, N., R.E. Nuñez, and S. Javadov, *Mitochondrial angiotensin receptors and cardioprotective pathways*. American Journal of Physiology-Heart and Circulatory Physiology, 2019. 316(6): p. H1426-H1438.
51. Bouchard, C., et al., *Genomic predictors of the maximal  $O_2$  uptake response to standardized exercise training programs*. J Appl Physiol (1985), 2011. 110(5): p. 1160-70.
52. Ren, J., et al., *The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development*. Proc Natl Acad Sci U S A, 2005. 102(3): p. 565-70.
53. Gyrd-Hansen, M. and P. Meier, *IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer*. Nat Rev Cancer, 2010. 10(8): p. 561-74.
54. Ahmetov, II, et al., *PPARalpha gene variation and physical performance in Russian athletes*. Eur J Appl Physiol, 2006. 97(1): p. 103-8.
55. Barger, P.M., et al., *Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth*. J Clin Invest, 2000. 105(12): p. 1723-30.
56. Del Coso, J., et al., *More than a 'speed gene': ACTN3 R577X genotype, trainability, muscle damage, and the risk for injuries*. European Journal of Applied Physiology, 2019. 119(1): p. 49-60.
57. Galeandro, V., et al., *ACTN3/ACE genotypes and mitochondrial genome in professional soccer players performance*. Journal of biological regulators and homeostatic agents, 2017. 31(1): p. 207-213.

## **Chapter 6: General discussion, contribution to knowledge, limitations, and future research**

### **6.1 General discussion**

Regular exercise is crucial for good health and healthy ageing, with physical inactivity associated with many chronic diseases [1, 2]. The benefits provided by exercise stem from skeletal muscle adaptations in response to exercise, which subsequently influence other tissues at a whole-body level. However, our understanding of molecular and physiological phenotypes that may explain or underpin these exercise adaptations and the factors that influence these adaptations, such as genetics, is still in its infancy [3]. Advancing our understanding in these areas may provide new avenues to use exercise interventions to further support our health and combat chronic diseases.

The overarching aim of this thesis was to investigate the influence of robust genetic variants using the Exercise Polygenic Score (EPS) in mitochondrial and physiological response to exercise phenotypes after four weeks of High Intensity Interval Training (HIIT) in the Gene SMART study. Chapter 1 provided an overview of this thesis. Chapter 2 then outlined the relevant background literature for this project, including the concept of trainability and the key biological elements (e.g., genetics, mitochondria), as well as methodological and statistical factors that influence trainability. Following this, the aim of this thesis was addressed over three experimental chapters (Chapters 3-5). Firstly, in Chapter 3, prior studies exploring links between genetic variants and fitness variables were systematically reviewed to identify genetic variants robustly linked to exercise responses. In Chapter 4, we examined changes and correlations between physiological and mitochondrial markers in response to 4 weeks of HIIT in the Australian Gene SMART cohort (n=116). Finally, in Chapter 5, we brought together the genetic variants identified in Chapter 3 and data from the Gene SMART study to create exercise polygenic scores, which were then assessed against baseline and HIIT changes in physiological

and mitochondrial markers to explore how they may be used to predict trainability. In this Chapter (Chapter 6), the key findings of these experimental chapters will be discussed, as well as strengths, limitations, and potential future directions of this work.

*I. Which genetic variants are most robustly and consistently linked to exercise responses? (Chapter 3)*

Multiple studies have identified a plethora of genetic variants associated with exercise responses [4]. However, it remains unclear which genetic variants are key drivers in trainability, with the majority of genetic variants previously associated with exercise based on findings in a single cohort, or residing within genes with unclear functional relevance to exercise [5]. Evidence of findings between replicated in other independent cohorts and/or functional relevance of the identified genetic variants is important, as a large limitation of genetic studies, -- which sometimes examine 1000s of SNPs -- is the risk of false positives, where genetic variants are falsely associated with traits. In Chapter 3, we screened and summarised the genetic variants associated with either resistance or aerobic trainability in at least two independent cohorts, and reviewed where these SNPs were located as well as the biological factors influenced by these loci. We identified 12 and 5 genetic variants robustly associated with aerobic or resistance trainability, respectively. The use of thorough selection criteria ensured that these SNPs held a true association with exercise responses. The identified genetic variants resided in genes within pathways related to multiple trainability phenotypes. For example, the genetic variant rs4253778 (annotated to peroxisome proliferator-activated receptor *PPARA*) and rs8192678 (annotated to peroxisome proliferator transcriptional coactivator *PPARGC1A*) are linked to muscle morphology, aerobic capacity, endurance performance and mitochondrial biogenesis [6]. In addition, the rs6552828 genetic variant located near the *ACSL1* is reported to be strongly correlated to the aerobic electron transport

chain as well as to the transport of fatty acids into the mitochondria [7]. Moreover, rs353625 (annotated to the *CD44* gene) and rs1956197 (annotated to *DAAMI* gene) were associated with up-regulated gene expression in response to endurance training [8]. Genetic variants annotated to the ACE gene (rs4646994, rs1799752, rs4340 and the rs13447447) are reported to be associated with improved blood flow and proliferation of red blood cells [9]. Also, rs1815739 (annotated to the *ACTN3* gene) is reported to be associated to muscle strength [10]. These findings highlighted key genetic variants and biological pathways influencing trainability and provided direction for genetic variants to be explored in the Gene SMART cohort (Chapter 5).

*II. Are physiological and skeletal muscle mitochondria adaptations seen after 4-weeks of HIIT, relative to a 4-week untrained control period? (Chapter 4).*

In Chapter 4, the response of multiple physiological and mitochondrial markers following four weeks of high-intensity interval training (HIIT), relative to four weeks of an untrained control period, was assessed. This study assessed the value of using a composite measure of mitochondrial content and quality, the mitochondrial health index (MHI). The MHI had previously been used with great success in leucocytes [11], but had not yet been explored in skeletal muscle in the context of exercise and neither had its potential relationships with changes in physiological variables.

In Chapter 4 we showed significant increases in physiological variables ( $W_{\text{peak}}$  and LT) as well as increases in mitochondrial markers (CS and COX) after 4 weeks of HIIT. However, changes in the MHI were not seen, and significant increases were also seen in CS and COX during the untrained control period. Our findings were unexpected given that mitochondrial function and content are upregulated in skeletal muscle by exercise [12, 13]. This, may in part, be explained by the length of the HIIT intervention potentially being too short, with prior studies showing effects of 6-8 weeks [13, 14]; or it may be due to a batch effect, given muscle

samples from different time points were analysed separately. Chapter 4 also reports positive correlations found between changes in CS activity following 4-weeks of HIIT and  $VO_{2max}$ , LT, and  $W_{peak}$ . These findings are supported by similar studies that show HIIT interventions lead to changes in mitochondrial and physiological phenotypes [15, 16]. Correlation findings are also, in part, supported by a study by Guillen et al. [17], where increase of CS activity in skeletal muscle mitochondria as well as increase in  $VO_{2max}$  were reported after 12 weeks of sprint interval training in sedentary males. Prior studies also suggests a relationship between lactate production and defects in mitochondrial function in individuals with Huntington's Disease [18]. Finally, data from Chapter 4 revealed the importance of using a control untrained period to more robustly detect true changes in response to exercise.

III. *Which physiological phenotypes and mitochondrial markers are associated with Exercise Polygenic Score (EPS)? (Chapter 5)*

Previous studies have reported a genetic influence in exercise responses in general populations, elite athletes, and disease-specific groups [19-22]. The limitations of prior studies have been in investigating the association between single genetic variants, which have small effect sizes on fitness phenotypes. In this thesis, a combined genetic score (exercise polygenic score) was devised from several genetic variants shown to be robustly linked to exercise responses (Chapter 3), with relationships between this score and physiological and mitochondrial variables prior to and following a 4-week HIIT intervention then examined. Prior to this thesis, no studies had examined the association between genetic variants and fitness markers before an exercise intervention (i.e., at baseline).

We found no significant associations between the devised exercise polygenic scores and mitochondrial and physiological markers before and after 4-weeks of HIIT. When examining for potential relationships between mitochondrial and physiological markers and the individual

SNPs making up the exercise polygenic scores, no association were shown between the latter and the physiological variables, with limited associations found between the SNPs and the mitochondrial markers. Reasons for these findings may be that four weeks of HIIT might be a relative short training intervention to detect the genetic influence in exercise, specifically for our moderately-active cohort. Furthermore, although a handful of studies have reported that multiple genetic variants are associated with exercise responses [7, 23, 24], these studies have either bigger cohorts or the exercise intervention was longer than the 4 weeks proposed in the present study. Based on this, it appears this work may have been underpowered to be able to associate genotypes with phenotypes.

However, several associations were found between individual genetic variants and responses in muscle function and mitochondrial content before and after 4-weeks of HIIT. For example, we detected associations between the rs4253778 and rs1815739 with the MHI at baseline, with this supported by prior literature that found an association between rs4253778 and mitochondrial enzymes [25] and between rs1815739 and mitochondrial content [26]. We report several associations between SNPs (rs10921078, rs6090314, rs699, rs8192678) and mitochondrial markers, which have not been reported previously. However, many of these SNPs have been linked to physiological outcomes, such as changes in  $VO_{2max}$  after 20 weeks of continuous exercise (SNP: rs6090314) [7], power in elite athletes (rs699) [27] and aerobic capacity in women (SNP: rs8192678) [28]. This data suggests these genetic variants influence these exercise phenotypes by altering mitochondrial functioning, with relationships between fitness physiological and mitochondrial measures supported by correlations reported between several physiological measures and CS in Chapter 3.

## **6.2 Contribution to Knowledge**

This thesis contributes to the existing body of knowledge by compiling a list of robust genetic variants associated with exercise. We leveraged this list to create and assess the usefulness of using an exercise polygenic score to predict exercise responses. Although this investigation had limited findings, likely due to a limited sample size, this list of SNPs and our approach may provide important direction for future investigations exploring the role of genetics in trainability in larger cohorts. Further studies may use this list of SNPs to refine their genetic targets, and increase their ability to capture genetic effects through the use of polygenic scores.

This thesis sought to provide new understanding of the exercise adaptations in skeletal muscle as well as skeletal muscle mitochondria, with robust genetic variants involved in these molecular and physiological adaptations. It presents new evidence of relationships and potential interplay between genetic and mitochondrial factors and changes in physiological traits during exercise. In addition, this work shows the value of using an untrained exercise period in exercise trials to minimise variability in human studies. This study design may provide direction for further investigations, and will increase the field's ability to identify true responses to exercise interventions, which may be overlooked or currently under/over-estimated.

## **6.3 Strengths**

Strengths of this thesis include the use of a systematic approach to defining robust SNPs linked to exercise responses and further devise exercise polygenic scores to be explored in later parts of the thesis. Further, the Gene SMART (Chapter 4-5) is a well-controlled cohort study, which utilised uncontrolled training periods, repeated exercise tests, and controlled diets and muscle analyses to minimise variability in data. For example, we performed the muscle biopsies consistently at the same time of the day to mitigate changes in circadian cycles. In

addition, our experiments at the mitochondrial level were conducted using pieces of the same biopsy, as intra-biopsy variability is substantial [29] and may affect analysis. This tight-controlled study was suitable to detect physiological and mitochondrial phenotypes changes after the intervention.

#### **6.4 Limitations**

A limitation of this study is the small number of participants and the length of the intervention in the Gene SMART study (n= 116). Whilst as a cohort size this is quite substantial for an exercise study, it is likely to be underpowered to detect small effect sizes, such as the effect of genetic variants on phenotypes, or changes in physiological and mitochondrial markers over a 4-week exercise period. Although we adjusted our model for multiple testing and many variables were included, we were not able find significant results when comparing genotypes with phenotypes. Further, while we identified significant changes in physiological and mitochondrial markers, a larger cohort is needed to identify the genetic influence in exercise responses. A further limitation of this work is that not all Gene SMART participants undertook the control untrained period. Further, although we included a control period before intervention and we provided a 48-hour diet before biopsies, we could not control participants' lifestyle (diet, sleep, physical activity and many others) which may impact the effect of the intervention, especially on mitochondrial analysis. Further limitations are mitochondrial analyses being performed in different batches, and therefore a risk of batch effect in the data. In addition, this Gene SMART study cohort is predominately Caucasian, which means that our results are less applicable to other ethnic cohorts.

#### **6.5 Future research**

There remains several knowledge gaps and questions around what underpins variability in exercise responses. There are discordant or inconclusive findings across studies, with the vast majority of findings for associations between genetic variants and exercise responses

based on one study [30]. Further independent studies are needed to validate findings linking genetic variants to fitness traits, to provide a clearer picture around the contribution of genetics to exercise. It is likely that future work will need to explore combining and collating genetic data from multiple global cohorts to increase statistical power and the generalisability and robustness of findings. Many prior studies in this field focus on physiological changes seen with exercise, and neglect to explore potentially underpinning changes in mitochondria or broader effects on wider tissues. As mitochondrial health is an important regulator of cellular function across different tissues, further work is needed exploring the influence of exercise interventions not only in skeletal muscle mitochondria, but also in other tissues. This work may provide insights into how exercise supports healthy ageing and prevents chronic diseases [31], by identifying mechanisms that influence exercise adaptations across tissues and uncovering molecular targets to guide disease prevention interventions and treatment.

To develop further insights in the mechanisms that may link genetic and molecular processes to exercise responses, future studies should include other “omics” layers such as methylome, transcriptome, and metabolome. Integrating omic data from skeletal muscle will provide a more comprehensive and improved understanding of exercise adaptations, as genetic composition alone does not determine fitness phenotype, and changes in many of these omic are more responsive to external factors such as exercise [32].


## 6.6 References

1. Booth, F.W., C.K. Roberts, and M.J. Laye, *Lack of exercise is a major cause of chronic diseases*. *Compr Physiol*, 2012. **2**(2): p. 1143-211.
2. Guthold, R., et al., *Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants*. *The Lancet Global Health*, 2018. **6**(10): p. e1077-e1086.
3. Han, J., D. Neuffer, and H. Pilegaard, *Exercise physiology: future opportunities and challenges*. *Pflügers Archiv - European Journal of Physiology*, 2019. **471**(3): p. 381-381.
4. Bouchard, C., T. Rankinen, and J.A. Timmons, *Genomics and genetics in the biology of adaptation to exercise*. *Compr Physiol*, 2011. **1**(3): p. 1603-48.
5. Cagnin, S., F. Chemello, and I. Ahmetov, *Genes and response to aerobic training*. 2019. p. 169-188.
6. Alvarez-Romero, J., et al., *Mapping Robust Genetic Variants Associated with Exercise Responses*. *Int J Sports Med*, 2020. **42**(01): p. 3-18.
7. Bouchard, C., et al., *Genomic predictors of the maximal O<sub>2</sub> uptake response to standardized exercise training programs*. *J Appl Physiol (1985)*, 2011. **110**(5): p. 1160-70.
8. Ghosh, S., et al., *Integrative pathway analysis of a genome-wide association study of (V)O<sub>2</sub>max response to exercise training*. *J Appl Physiol (1985)*, 2013. **115**(9): p. 1343-59.
9. Alves, C.R., et al., *Aerobic exercise training differentially affects ACE C-and N-domain activities in humans: Interactions with ACE I/D polymorphism and association with vascular reactivity*. *Journal of the Renin-Angiotensin-Aldosterone System*, 2018. **19**(2): p. 1470320318761725.
10. Pistilli, E.E., et al., *Interleukin-15 and interleukin-15R $\alpha$  SNPs and associations with muscle, bone, and predictors of the metabolic syndrome*. *Cytokine*, 2008. **43**(1): p. 45-53.
11. Picard, M., et al., *A Mitochondrial Health Index Sensitive to Mood and Caregiving Stress*. 2018(1873-2402 (Electronic)).
12. Wyckelsma, V.L., et al., *Preservation of skeletal muscle mitochondrial content in older adults: relationship between mitochondria, fibre type and high-intensity exercise training*. *J Physiol*, 2017. **595**(11): p. 3345-3359.
13. Holloszy, J., *Biochemical Adaptations in Muscle*. *J. Biol. Chem*, 1967: p. 2278-82.
14. Henriksson, J. and J.S. Reitman, *Quantitative Measures of Enzyme Activities in Type I and Type II Muscle Fibres of Man after Training*. *Acta Physiologica Scandinavica*, 1976. **97**(3): p. 392-397.
15. Stepto, N.K., et al., *Short-Term Intensified Cycle Training Alters Acute and Chronic Responses of PGC1 $\alpha$  and Cytochrome C Oxidase IV to Exercise in Human Skeletal Muscle*. *PLOS ONE*, 2012. **7**(12): p. e53080.
16. Robinson, M.M., et al., *Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans*. *Cell Metabolism*, 2017. **25**(3): p. 581-592.
17. Gillen, J.B., et al., *Twelve Weeks of Sprint Interval Training Improves Indices of Cardiometabolic Health Similar to Traditional Endurance Training despite a Five-Fold Lower Exercise Volume and Time Commitment*. *PLoS One*, 2016. **11**(4): p. e0154075.

18. Ciammola, A., et al., *Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease*. *Movement Disorders*, 2011. **26**(1): p. 130-137.
19. Bouchard, C., et al., *Genomic predictors of the maximal O<sub>2</sub> uptake response to standardized exercise training programs*. *Journal of applied physiology (Bethesda, Md. : 1985)*, 2011. **110**(5): p. 1160-1170.
20. Drozdovska, S.B., et al., *The association of gene polymorphisms with athlete status in ukrainians*. *Biol Sport*, 2013. **30**(3): p. 163-7.
21. Ahmetov, II, et al., *SOD2 gene polymorphism and muscle damage markers in elite athletes*. *Free Radic Res*, 2014. **48**(8): p. 948-55.
22. Ramírez, J., et al., *Thirty loci identified for heart rate response to exercise and recovery implicate autonomic nervous system*. *Nature Communications*, 2018. **9**(1): p. 1947.
23. He, Z., et al., *NRF-1 genotypes and endurance exercise capacity in young Chinese men*. *British Journal of Sports Medicine*, 2008. **42**(5): p. 361-366.
24. Yoo, J., et al., *Genetic polymorphisms to predict gains in maximal O<sub>2</sub> uptake and knee peak torque after a high intensity training program in humans*. *Eur J Appl Physiol*, 2016. **116**(5): p. 947-57.
25. Barger, P.M., et al., *Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth*. *J Clin Invest*, 2000. **105**(12): p. 1723-30.
26. Galeandro, V., et al., *ACTN3/ACE genotypes and mitochondrial genome in professional soccer players performance*. *J Biol Regul Homeost Agents*, 2017. **31**(1): p. 207-213.
27. Zarebska, A., et al., *Association of rs699 (M235T) Polymorphism in the AGT Gene With Power but Not Endurance Athlete Status*. *The Journal of Strength & Conditioning Research*, 2013. **27**(10): p. 2898-2903.
28. Yvert, T., et al., *PPARGC1A rs8192678 and NRF1 rs6949152 Polymorphisms Are Associated with Muscle Fiber Composition in Women*. *Genes (Basel)*, 2020. **11**(9).
29. Islam, H., et al., *Repeatability of exercise-induced changes in mRNA expression and technical considerations for qPCR analysis in human skeletal muscle*. *Exp Physiol*, 2019. **104**(3): p. 407-420.
30. Sarzynski, M.A., S. Ghosh, and C. Bouchard, *Genomic and transcriptomic predictors of response levels to endurance exercise training*. *J Physiol*, 2017. **595**(9): p. 2931-2939.
31. McGee, S.L. and M. Hargreaves, *Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefit*. *Nature Reviews Endocrinology*, 2020. **16**(9): p. 495-505.
32. Chung, H.C., et al., *Do exercise-associated genes explain phenotypic variance in the three components of fitness? a systematic review & meta-analysis*. *PLOS ONE*, 2021. **16**(10): p. e0249501.


## Appendix: Supplementary figure and tables

### Supplementary figures



#### **Supplementary figure 4.1 Changes in mitochondrial markers over four weeks of control period.**

Box plots showing the mean changes over 4-weeks of the untrained control period for a) CS, b) SDH, c) COX, d) mtCN, and e) MHI. Abbreviations; citrate synthase activity (CS), cytochrome c oxidase activity (COX), succinate dehydrogenase activity (SDH), mitochondria copy number (mtCN), mitochondrial health index (MHI), start of control period (CON), and start of HIIT intervention (PRE). \* Represents p-value <0.05 and ns represents non-significant results.



**Supplementary figure 4.2 Changes in physiological variables over four weeks of control period.**

Box plots showing the mean changes over four weeks of the control period for a) power peak, b) lactate threshold and c) VO<sub>2max</sub> are shown. Abbreviations; lactate threshold (LT), power peak (W<sub>peak</sub>), start of control period (CON), and start of HIIT intervention (PRE), ns represents non-significant results.

**Supplementary Table 5.1** Associations between Exercise Polygenic Scores and physiological and mitochondrial phenotypes (non-imputed data)

Outcome	EPS1			EPS2		
	Estimate	SE	P value	Estimate	SE	P value
VO <sub>2</sub> MAX BL	-0.60	0.53	0.26	-0.65	0.46	0.16
VO <sub>2</sub> MAX 4W-Δ	-0.17	0.25	0.49	-0.15	0.22	0.50
Wpeak BL	-0.05	0.50	0.30	-0.06	0.04	0.14
Wpeak 4W-Δ	0.003	0.01	0.77	0.004	0.01	0.64
LT BL	-0.40	0.40	0.31	-0.05	0.03	0.11
LT 4W-Δ	0.007	0.01	0.59	0.004	0.01	0.70
CS BL	-0.32	0.33	0.33	-0.34	0.29	0.23
CS 4W-Δ	-0.34	0.29	0.23	0.11	0.16	0.46
COX BL	0.07	0.08	0.35	-0.0008	0.07	0.99
COX 4W-Δ	-0.01	0.12	0.88	0.04	0.11	0.68
mtCN BL	-2485.3	1773.83	0.16	-1707.3	1455	0.24
mtCN 4W-Δ	-0.06	0.07	0.38	-0.03	0.05	0.59
SDH BL	0.57	5.09	0.91	-3.13	4.48	0.48
SDH 4W-Δ	7.09	5.13	0.17	1.82	4.20	0.66
MHI BL	-85.6	76.8	0.27	-39.05	73.1	0.59
MHI 4W-Δ	142.5	0.01	0.38	4.4	0.01	0.79

Each line represents a separate model, with EPS1 and EPS2 also examined separately. All models were corrected for age and sex, with models exploring change over 4 weeks also adjusting for baseline levels of the appropriate outcome variable. Abbreviations: SE: standard error, BL: baseline, 4W-Δ: change over 4 weeks, EPS1 and EPS2: exercise polygenic score 1 and 2 respectively, VO<sub>2</sub>max: maximal oxygen uptake, LT: lactate threshold, Wpeak: power peak, CS: citrate synthase, SDH: succinate dehydrogenase, COX: cytochrome oxidase, MCN: mitochondria copy number, and MHI: mitochondrial health index.

**Supplementary Table 5.2** Least square means estimate for physiological variables before and after 4-weeks of HIIT intervention by each genotype (non-imputed data)

Variant	Least square means (SE) <sup>1</sup>		
	AA	AG	GG
<b>rs6552828</b>			
VO <sub>2</sub> MAX BL	43.1 (2.42)	46.1 (1.38)	45.2 (1.87)
VO <sub>2</sub> MAX 4W-Δ	1.09 (1.13)	1.10 (0.64)	1.03 (0.89)
Wpeak BL	3.33 (0.22)	3.43 (0.12)	3.34 (0.17)
Wpeak 4W-Δ	0.24 (0.04)	0.14 (0.02)	0.28 (0.03)
LT BL	2.32 (0.18)	2.33 (0.10)	2.28 (0.14)
LT 4W-Δ	0.32 (0.05)	0.23 (0.03)	0.315 (0.04)
<b>rs699</b>			
VO <sub>2</sub> MAX BL	48.6 (2.30)	44.7 (1.41)	44.6 (1.79)
VO <sub>2</sub> MAX 4W-Δ	0.57 (1.08)	1.72 (0.63)	0.04 (0.86)
Wpeak BL	3.48 (0.21)	3.38 (0.13)	3.34 (0.16)
Wpeak 4W-Δ	0.19 (0.05)	0.20 (0.03)	0.18 (0.04)
LT BL	2.41 (0.17)	2.30 (0.10)	2.28 (0.13)
LT 4W-Δ	0.25 (0.05)	0.27 (0.03)	0.29 (0.04)
<b>rs6090327</b>			
VO <sub>2</sub> MAX BL	45.7 (1.27)	44.7 (1.85)	41.1(6.47)
VO <sub>2</sub> MAX 4W-Δ	0.81 (0.58)	1.40 (0.83)	5.64 (2.80)
Wpeak BL	3.37 (0.11)	3.44 (0.17)	3.23 (0.60)
Wpeak 4W-Δ	0.19 (0.02)	0.20 (0.03)	0.11 (0.13)
LT BL	2.30 (0.09)	2.37 (0.13)	2.06 (0.48)
LT 4W-Δ	0.26 (0.03)	0.30 (0.04)	0.19 (0.14)
<b>rs12891759</b>			
VO <sub>2</sub> MAX BL	45.3 (1.32)	45.7 (1.75)	36.8 (6.33)

	VO <sub>2</sub> MAX 4W-Δ	1.26 (0.61)	0.78 (0.81)	-3.59 (3.94)
	Wpeak BL	3.38 (0.12)	3.44 (0.16)	2.71 (0.59)
	Wpeak 4W-Δ	0.18 (0.02)	0.23 (0.03)	0.20 (0.18)
	LT BL	2.31 (0.10)	2.33 (0.13)	1.90 (0.48)
	LT 4W-Δ	0.27 (0.03)	0.27 (0.04)	0.27 (0.21)
<b>rs8192678</b>		<b>AA</b>	<b>AG</b>	<b>GG</b>
	VO <sub>2</sub> MAX BL	48.0 (2.46)	44.8 (1.62)	45.2 (1.47)
	VO <sub>2</sub> MAX 4W-Δ	0.75 (1.10)	1.62 (0.74)	0.69 (0.70)
	Wpeak BL	3.71 (0.22)	3.37 (0.15)	3.32 (0.13)
	Wpeak 4W-Δ	0.24 (0.05)	0.20 (0.03)	0.19 (0.03)
	LT BL	2.57 (0.18)	2.29 (0.12)	2.28 (0.11)
	LT 4W-Δ	0.34 (0.05)	0.27 (0.03)	0.24 (0.03)
<b>rs11120796</b>		<b>AA</b>	<b>AG</b>	<b>GG</b>
	VO <sub>2</sub> MAX BL	48.1 (2.55)	44.3 (1.41)	46.0 (1.71)
	VO <sub>2</sub> MAX 4W-Δ	2.69 (1.22)	1.05 (0.65)	0.56 (0.79)
	Wpeak BL	3.65 (0.23)	3.35 (0.13)	3.35 (0.16)
	Wpeak 4W-Δ	0.19 (0.05)	0.20 (0.03)	0.19 (0.03)
	LT BL	2.50 (0.19)	2.31 (0.10)	2.25 (0.13)
	LT 4W-Δ	0.27 (0.06)	0.22 (0.03)	0.34 (0.04)
<b>rs10921078</b>		<b>GG</b>	<b>AG</b>	<b>AA</b>
	VO <sub>2</sub> MAX BL	45.3 (1.37)	45.2 (1.76)	46.5 (3.43)
	VO <sub>2</sub> MAX 4W-Δ	0.83 (0.63)	1.63 (0.82)	0.70 (1.77)
	Wpeak BL	3.36 (0.12)	3.38 (0.16)	3.62 (0.31)
	Wpeak 4W-Δ	0.20 (0.02)	0.21 (0.03)	0.06 (0.08)
	LT BL	2.28 (0.10)	2.34 (0.13)	2.50 (0.25)
	LT 4W-Δ	0.26 (0.03)	0.29 (0.04)	0.23 (0.09)
<b>rs4253778</b>		<b>TT</b>	<b>CT</b>	<b>CC</b>
	VO <sub>2</sub> MAX BL	46.8 (4.20)	46.4 (1.76)	44.8 (1.35)
	VO <sub>2</sub> MAX 4W-Δ	0.32 (2.02)	0.82 (0.80)	1.26 (0.63)
	Wpeak BL	3.40 (0.38)	3.57 (0.16)	3.29 (0.12)
	Wpeak 4W-Δ	0.18 (0.09)	0.19 (0.03)	0.19 (0.02)
	LT BL	2.29 (0.31)	2.51 (0.13)	2.21 (0.09)
	LT 4W-Δ	0.20 (0.10)	0.21 (0.04)	0.30 (0.03)
<b>rs1815739</b>		<b>TT</b>	<b>TC</b>	<b>CC</b>
	VO <sub>2</sub> MAX BL	46.8 (4.20)	46.4 (1.76)	44.8 (1.35)
	VO <sub>2</sub> MAX 4W-Δ	0.32 (2.02)	0.82 (0.80)	1.26 (0.63)
	Wpeak BL	3.40 (0.38)	3.57 (0.16)	3.29 (0.12)
	Wpeak 4W-Δ	0.18 (0.09)	0.19 (0.03)	0.19 (0.02)
	LT BL	2.29 (0.31)	2.51 (0.13)	2.21 (0.09)
	LT 4W-Δ	0.20 (0.10)	0.21 (0.04)	0.30 (0.03)

All models were adjusted for sex, age, and baseline levels of appropriate phenotype (for models on 4W-Δ outcomes only) and performed on non-imputed data. Values within the same row that are bolded and denoted with different letters represent significant differences. (<0.05). Abbreviations: SE: standard error, BL: baseline, 4W-Δ: change over 4 weeks, VO<sub>2</sub>max: maximal oxygen uptake, LT: lactate threshold, Wpeak: power peak

**Supplementary Table 5.3** Least square means estimates for mitochondria phenotypes before and after the HIIT intervention, by genotype (imputed data)

Variant	Least square means (SE) <sup>1</sup>		
<b>rs6552828</b>	<b>AA</b>	<b>AG</b>	<b>GG</b>
CS BL	11.7 (1.54)	11.4 (0.86)	11.0 (1.15)
CS 4W-Δ	0.64 (0.92)	0.17 (0.55)	0.74(0.71)
COX BL	1.67 (0.35)	1.62 (0.19)	2.04 (0.26)
COX 4W-Δ	0.28 (0.34)	-0.12 (0.20)	0.07 (0.28)
mtCN BL	11877 (4586)	9841 (2776)	13968 (3753)
mtCN 4W-Δ	-174 (2363)	-207 (1364)	-1073 (1945)
SDH BL	69.4 (22.2)	74.7 (11.3)	75.7 (15.4)
SDH 4W-Δ	-4.15 (14.58)	-1.35 (9.09)	2.13 (12.09)
MHI BL	-6544 (24509)	12914 (14535)	-4754 (18632)
MHI 4W-Δ	-8190 (352)	-8299 (225)	-8672 (386)
<b>rs699</b>	<b>CC</b>	<b>CT</b>	<b>TT</b>
CS BL	11.3 (1.47)	11.7 (0.88)	10.9 (1.14)
CS 4W-Δ	0.86 (0.98)	0.25 (0.54)	0.38 (0.77)
COX BL	1.51 (0.32)	1.86 (0.20)	1.65 (0.26)
COX 4W-Δ	0.08 (0.33)	0.18 (0.20)	-0.36 (0.25)
mtCN BL	8492 (4492)	13819 (2805)	8422 (3548)
mtCN 4W-Δ	-305 (2176)	-432 (1391)	-442 (1739)
SDH BL	69.6 (19.2)	77.2 (11.4)	70.7 (15.0)
SDH 4W-Δ	-16.32 (15.68)	0.03 (9.83)	6.24 (11.48)
MHI BL	-5570 (24058)	11961 (13986)	-1170 (20300)
MHI 4W-Δ	-8464 (470)	-8419 (252)	-8227 (283)
<b>rs6090327</b>	<b>GG</b>	<b>AG</b>	<b>AA</b>
CS BL	11.9 (0.79)	10.0 (1.13)	10.6 (3.93)
CS 4W-Δ	0.36 (0.49)	0.65 (0.79)	-1.24 (2.62)
COX BL	1.71 (0.17)	1.88 (0.26)	0.386 (1.01)
COX 4W-Δ	-0.01 (0.18)	0.07 (0.26)	-0.19 (1.10)
mtCN BL	10248 (2499)	14100 (3691)	9215 (12918)
mtCN 4W-Δ	695 (1397)	-3983 (1709)	7566 (5018)
SDH BL	77.0 (10.6)	69.0 (15.7)	21.6 (50.3)
SDH 4W-Δ	-1.90 (8.7)	2.13 (13.5)	-10.71 (45.9)
MHI BL	45.9 (12301)	-3957 (21910)	-2260 (64341)
MHI 4W-Δ			
<b>rs12891759</b>	<b>AA</b>	<b>AG</b>	<b>GG</b>
CS BL	11.49 (0.83)	11.31 (1.088)	7.37 (3.90)
CS 4W-Δ	0.40 (0.54)	0.39 (0.67)	1.05 (2.92)
COX BL	1.66 (0.18)	1.90 (0.25)	1.40 (1.13)
COX 4W-Δ	-0.09 (0.19)	0.2157 (0.26)	-0.57 (1.00)
mtCN BL	12807 (2587)	8292 (3509)	1985 (12655)
mtCN 4W-Δ	-183 (1396)	-669 (1781)	-6769 (6229)
SDH BL	74.9 (10.9)	72.3 (15.1)	60.1 (63.8)
SDH 4W-Δ	-4.96 (8.66)	8.03 (11.85)	-21.44 (48.07)
MHI BL	9265 (13487)	-3886 (18189)	-6533 (63318)
MHI 4W-Δ	-8390 (223)	-8357 (268)	-7461 (2180)
<b>rs8192678</b>	<b>AA</b>	<b>AG</b>	<b>GG</b>
CS BL	10.5 (1.51)	10.6 (1.007)	12.2 (0.91)
CS 4W-Δ	0.71 (0.92)	0.17 (0.64)	0.48 (0.57)
COX BL	1.45 (0.40)	1.78 (0.23)	1.77 (0.20)
COX 4W-Δ	-0.02 (0.37)	-0.22 (0.24)	0.18 (0.21)
mtCN BL	<b>22501 (4666)<sup>a</sup></b>	<b>9631 (3137)<sup>b</sup></b>	<b>9762 (2813)<sup>b</sup></b>
mtCN 4W-Δ	707 (2669)	-1132 (1597)	-130 (1375)
SDH BL	63.0 (19.7)	82.9 (13.7)	69.6 (12.3)
SDH 4W-Δ	-11.62 (16.0)	0.75 (10.3)	0.09 (10.1)

MHI BL	-6632 (23861)	-3684 (15917)	14281 (16057)
MHI 4W-Δ	-8195 (399)	-8364 (281)	-8415 (259)
<b>rs11120796</b>	<b>AA</b>	<b>AG</b>	<b>GG</b>
CS BL	11.3 (1.63)	11.1 (0.88)	11.8 (1.07)
CS 4W-Δ	0.64 (0.92)	0.17 (0.55)	0.74 (0.71)
COX BL	1.89 (0.38)	1.74 (0.20)	1.67 (0.24)
COX 4W-Δ	-0.23 (0.38)	0.11 (0.21)	-0.07 (0.253)
mtCN BL	10579 (4912)	12318 (2868)	9872 (3427)
mtCN 4W-Δ	-308 (2381)	-495 (1471)	-325 (1717)
SDH BL	77.2 (20.7)	69.3 (11.9)	79.6 (14.6)
SDH 4W-Δ	7.029 (18.27)	-0.687 (9.27)	-4.504 (10.91)
MHI BL	528 (31697)	11807 (14027)	-3893 (17389)
MHI 4W-Δ	-8216 (531)	-8405 (236)	-8373 (308)
<b>rs10921078</b>	<b>GG</b>	<b>AG</b>	<b>AA</b>
CS BL	11.81 (0.85)	10.89 (1.09)	9.88 (2.29)
CS 4W-Δ	0.27 (0.55)	0.39 (0.68)	1.61 (1.40)
COX BL	1.66 (0.19)	1.67 (0.24)	2.62 (0.47)
COX 4W-Δ	0.02 (0.19)	0.04 (0.25)	-0.31 (0.55)
mtCN BL	12402 (2666)	8622 (3511)	12142 (6935)
mtCN 4W-Δ	-586 (1313)	-384 (1738)	883 (3479)
SDH BL	70.7 (11.0)	72.5 (14.6)	105.3 (28.0)
SDH 4W-Δ	-1.12 (9.6)	2.52 (11.5)	-12.98 (24.4)
MHI BL	-7499 (38339)	-618 (21075)	8216 (13279)
MHI 4W-Δ	-8394 (237)	-8137 (278)	-9094 (525)
<b>rs4253778</b>	<b>TT</b>	<b>CT</b>	<b>CC</b>
CS BL	14.9 (2.51)	12.0 (1.095)	10.9 (0.83)
CS 4W-Δ	-0.73 (1.57)	0.65 (0.74)	0.35 (0.56)
COX BL	2.20 (0.62)	1.93 (0.25)	1.62 (0.19)
COX 4W-Δ	-0.30 (0.58)	-0.20 (0.25)	0.12 (0.19)
mtCN BL	10678 (7925)	8489 (3592)	12632 (2650)
mtCN 4W-Δ	-1059 (3516)	238 (1871)	-703 (1329)
SDH BL	66.0 (32.6)	83.0 (14.1)	69.8 (10.8)
SDH 4W-Δ	16.87 (28.73)	8.23 (11.12)	-6.59 (8.87)
MHI BL	-7499 (38339)	-618 (21075)	8216 (13279)
MHI 4W-Δ	-7974 (624)	-8164 (282)	-8490 (230)
<b>rs1815739</b>	<b>TT</b>	<b>TC</b>	<b>CC</b>
CS BL	14.9 (2.51)	12.0 (1.09)	10.9 (0.83)
CS 4W-Δ	-0.73 (1.57)	0.65 (0.74)	0.35 (0.56)
COX BL	2.20 (0.62)	1.93 (0.251)	1.62 (0.19)
COX 4W-Δ	-0.30 (0.58)	-0.20 (0.25)	0.12 (0.19)
mtCN BL	10678 (7925)	8489 (3592)	12632 (2650)
mtCN 4W-Δ	-1059 (3516)	238 (1871)	-703 (1329)
SDH BL	66.0 (32.6)	83.0 (14.1)	69.8 (10.8)
SDH 4W-Δ	16.87 (28.73)	8.23 (11.12)	-6.59 (-6.59)
MHI BL	-7499 (38339)	-618 (21075)	8216 (13279)
MHI 4W-Δ	-7974 (624)	-8164 (282)	-8490 (230)

All models were adjusted for sex, age, and baseline levels of appropriate phenotype (for models on 4W-Δ outcomes only) and performed on imputed data. Values within the same row that are bonded and denoted with different letters represent significant differences. (<0.05). Abbreviations: SE: standard error, BL: baseline, 4W-Δ: change over 4 weeks, VO<sub>2</sub>max: maximal oxygen uptake, LT: lactate threshold, Wpeak: power peak, (CS) citrate synthase, (COX) Cytochrome C oxidase, (mtCN) mitochondrial copy number, (SDH) succinate dehydrogenase, (MHI) mitochondrial health index.